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1 Summary 
DNA demethylation processes have been studied for many years and entered the 
focus of extensive research with the discovery of active demethylation mechanisms 
(He et al., 2011; Ito et al., 2011; Iyer et al., 2009; Kriaucionis and Heintz, 2009; 
Tahiliani et al., 2009). These processes contribute to the regulation of cell type-specific 
gene expression patterns and the dynamics of other epigenetic mechanisms (Wu and 
Zhang, 2014). The investigation of the different types of mechanisms and their role in 
different cell types or developmental stages is an important challenge to understand 
the complex regulatory processes in mammals. The data presented in this work 
allowed further insights into the active demethylation processes and contributed to the 
understanding of regulatory mechanisms in different hematopoietic cell types. Using an 
in vitro model system, representing the human mononuclear phagocyte system, we 
were able to characterize the active DNA demethylation mechanism in the absence of 
passive demethylation events. The data revealed that the targeted, locus-specific 
active DNA demethylation process is initiated by the modification of 5mC to 5hmC. 
Further experiments based on the knockdown of candidate enzymes identified TET2 
as the initiator of the active DNA demethylation process and as being responsible for 
the conversion of 5mC to 5hmC. Investigation of further possible players like TDG, 
MBD4, OGT, and HELLS gave first insights into a possible contribution to the process 
and so far the data indicated that none of the enzymes is involved in the first 
conversion step. Functional investigation of the demethylated regions in reporter gene 
assays linked the local binding of TFs like PU.1 and synchronous demethylation events 
to the activation of potential enhancer elements. The data demonstrated that their 
activation depended on the methylation level and that demethylation led to enhancer 
activation in a cell type-specific manner. Moreover the results indicated that the 
activation of cell type-specific enhancer elements requires a corresponding set of TF to 
open the regions, which may include the removal of 5mC in this process. 
 
The validation and adaption of a 5hmC-enrichment method to next generation 
sequencing allowed us to investigate the active demethylation processes on a 
genome-wide level. Using the Hydroxymethyl CollectorTM kit we assessed the global 
dynamics of DNA demethylation and its association with the key hematopoietic 
transcription factor PU.1 in differentiating monocytes. The global screen illustrated 
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dynamic patterns of 5hmC and confirmed its role as an intermediate of active 
demethylation events accompanying the transition into another cell type. Local binding 
of PU.1 at demethylated sites further supported the theory of a correlation between 
demethylation events and the recruitment of PU.1. However, active DNA demethylation 
events were not altogether dependent on PU.1 binding, since several regions 
accumulated 5hmC in the absence of this TF, indicating the involvement of other 
factors and thus a site-specific recruitment of PU.1. The data further hinted at a 
possible regulatory role of 5hmC as an epigenetic mark, actively recruiting or passively 
impeding other factors. Further gene ontology analyses confirmed the immunological 
background of the cells and presented genes involved in the immune response and 
inflammation to be associated with active demethylation processes and the local 
appearance of PU.1. Corresponding expression changes suggested an involvement of 
PU.1 in the regulation of transcriptional changes during monocyte differentiation. 
However, regions with increasing or stable 5hmC levels displayed transcriptional 
changes independent of demethylation or PU.1 and supported the involvement of other 
factors in their regulation as well as possible regulatory functions of 5hmC.  
A global screen of PU.1 distribution in differentiating monocytes illustrated dynamic 
PU.1 binding patterns upon the transition into another cell type and confirmed the 
association with demethylation events at subsets of PU.1 target regions. Comparing 
the 5hmC and PU.1 dynamics during monocyte differentiation we presented first 
evidence for a distinct chronology of PU.1 and demethylation events. In a subset of 
PU.1 target regions demethylation was present in monocytes but recruited PU.1 
primarily on the transition into a new cell type. It is still unclear, if PU.1 generally profits 
from the opening of demethylated regions or if it administrates various functions at 
different target regions. The localization of the PU.1 patterns to active, cell type-specific 
regulatory elements revealed distinct distribution dynamics during cell differentiation. 
PU.1 is mainly targeted to promoter and promoter-distal regulatory regions that are 
activated in a cell type-specific manner. The active nature of the regions supported an 
involvement of PU.1 in hematopoietic cell differentiation. PU.1 binding was associated 
with marginally dynamic, demethylated states and indicated a role for PU.1 in the 
maintenance of an active transcriptional state or its independent recruitment to 
demethylated regulatory regions. 
 
In summary the data presented in this work contributed to the understanding of the 
active DNA demethylation mechanism and revealed dynamic global association of 
demethylation events and PU.1 binding accompanying cell fate decisions in 
hematopoietic cells.
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2 Introduction to epigenetics 
 
In multicellular organisms embryonic development starts from one zygote and results in 
a complete organism with various lineages of distinct cell types. Although almost all of 
those cell types (with few exceptions) carry the same DNA sequence they adopt 
different functions, phenotypes and have diverse potential to mature into other cell 
types in response to a changing environment (Kohli and Zhang, 2013; Probst et al., 
2009). This diversity is created by changes to the epigenome, resulting in tissue-
specific gene expression patterns, which are established in the early embryo, 
maintained during cell divisions and adjusted upon developmental or environmental 
changes. The epigenome is defined as heritable changes in genome activity that are 
independent of changes in the DNA sequence (Probst et al., 2009; Russo, 1996) and 
represents a complex network of molecular mechanisms involved in genome 
regulation. Those epigenetic mechanisms mostly affect and reorganize the chromatin 
structure. Chromatin is a complex of DNA, histones and non-histone proteins which 
organizes DNA and regulates its accessibility (Margueron and Reinberg, 2010). Post-
translational modifications of histone tails, like methylation or acetylation, function as 
major epigenetic marks. They facilitate a dynamic regulation of the chromatin 
compaction and help to recruit TFs and other regulatory proteins (Laugesen and Helin, 
2014; Luger et al., 1997). Chromatin regulators are mostly organized in large protein 
complexes and act as “readers”, “writers” or “erasers” of the histone marks. While the 
latter two add or remove modifications from the histone tails, “readers” are able to 
recognize and interpret the histone marks and thus recruit other factors to the 
chromatin (Badeaux and Shi, 2013). Additionally, variants of the core histones (H2A, 
H2B, H3, and H4) contribute to flexible regulation of gene expression. They take over 
histone functions, but tend to be less stable and thus easier to remove or reposition via 
chromatin remodeling (Jin and Felsenfeld, 2007; Weber et al., 2014). Additionally 
histone variants keep genomic regions accessible and enable the binding of activating 
or repressive complexes and thus regulate transcription (Hu et al., 2013a; Weber et al., 
2014). Long non-coding RNAs (lncRNA) can function as epigenetic modulators, too. 
Among many features they are able to target activating and repressive chromatin 
modifying complexes (CMC) to the genome (Yang et al., 2014; Zhao et al., 2010) and 
regulate the DNA-binding activity of interacting TFs (Vance and Ponting, 2014). They 
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play an important role for organization and modification of chromatin structure and 
regulate gene expression programs (Vance and Ponting, 2014). The DNA itself carries 
another epigenetic mark, the 5-methylcytosine (5mC). This mark plays a central role in 
epigenetic genome regulation and is described more detailed in the following chapter. 
 
 
Figure 2.1: Epigenetic mechanisms of genome regulation 
Schematic overview of major mechanisms regulating the epigenome (Modified from (Dulac, 2010)) 
 
2.1 DNA methylation 
 
Methylation of the fifth position of cytosine is a key epigenetic modification and highly 
conserved in most plants, animals and fungi (Law and Jacobsen, 2010). In mammals 
DNA methylation occurs mainly at palindromic CG dinucleotide sequences (CpG) and 
is catalyzed by the de novo DNA methyltransferases DNMT3A and DNMT3B (Bird, 
2002). Other non-CpG DNA methylations like CpC, CpT and CpA have been reported 
in plants where they occur frequently (Law and Jacobsen, 2010). In mammals those 
events are rather rare and, so far, restricted to oocytes, embryonic stem cells (ESC) 
and brain cells (Lister et al., 2013; Lister et al., 2009; Shirane et al., 2013; Xie et al., 
2012). Although the overall abundance of CpGs is low in mammalian genomes (~28 
million in human), CpG methylation is distributed all over the genome and covers 60-
80% of all CpGs (Smith and Meissner, 2013). However, a small fraction of CpGs 
(<10%) is clustered together in CpG islands (CGI), which remain largely unmethylated 
(Wu and Zhang, 2014). 5mC is a heritable epigenetic mark and maintained through the 
cell cycle by the maintenance DNA methyltransferase 1 (DNMT1). The ubiquitin-like 
plant homeo-domain and RING finger domain 1 (UHRF1) recruits DNMT1 to hemi-
methylated DNA where it transfers a methyl group to the unmethylated cytosine 
(Bostick et al., 2007; Sharif et al., 2007). The stable inheritance of 5mC plays an 
important role in genomic imprinting, where the methylation pattern of the parental 
alleles are passed on to the daughter cells, and additionally in silencing of transposable 
elements, in order to maintain genome stability (Bird, 2002; Law and Jacobsen, 2010). 
DNA methylation is primarily associated with the suppression of gene expression and 
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exhibits its repressing effects by blocking the binding of transcription activators or by 
the recruitment of transcriptional repressors (Tate and Bird, 1993). Thus although 
some transcription factors favor methylated binding sites, many others, that activate 
gene expression upon binding to their binding motifs, fail to bind when their consensus 
binding sequences are methylated (Campanero et al., 2000; Rozenberg et al., 2008; 
Sunahori et al., 2009). Other proteins recognize and bind the 5mC mark. Among those 
readers are several members of the methyl-CpG-binding domain (MBD) family of 
proteins, which aid in transcription repression (Hendrich and Bird, 1998). They 
selectively bind 5mC and recruit repressive complexes with chromatin modifying 
components like histone deacetylases (HDAC) and histone methyltransferases 
(Robertson and Wolffe, 2000; Sarraf and Stancheva, 2004; Spruijt and Vermeulen, 
2014)  
A correct regulation of DNA methylation is an important feature for the prevention of 
malignant diseases. Many types of cancer show aberrant DNA methylation patterns 
and acquire a genome-wide hypomethylated state. The global loss of 5mC affects 
oncogenes, which are originally methylated and thus silenced, but become activated 
during cancer progression. Other genes, so called tumor suppressor genes, are 
generally located at non-methylated CGI and associated with tumor repression. Those 
regions are targets for aberrant DNA methylation, which occurs frequently in and 
contributes to cancer progression (Baylin and Jones, 2011; Jones and Baylin, 2002, 
2007). These mechanisms of 5mC-mediated transcriptional repression are crucial for 
the cell and add to a complex repertoire of repressive mechanisms to ensure correct 
development from zygote to the adult organism and to prevent tumorigenesis.  
 
2.2 DNA demethylation 
 
DNA methylation regulates gene expression in different ways leading to a silenced and 
repressed environment. To overcome and reverse repressive regulation and to open 
and activate silenced genes, DNA methylation can be removed in a process called 
DNA demethylation. In the past few years several distinct pathways have been 
discovered which can be global or restricted to specific loci and play important roles in 
different stages of cell differentiation. One distinctive feature of demethylation 
mechanisms is the dependence on cell proliferation and thus replication of DNA. In the 
passive DNA demethylation mechanism (PD), DNMT1 and UHRF1 are absent or 
impeded by modified 5mC and fail to methylate the nascent strand, resulting in the loss 
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of DNA methylation after a few rounds of replication. This mechanism plays an 
important role in zygote development where PD mainly, but not exclusively, contributes 
to demethylation processes in the paternal, and also in the maternal genome (Guo et 
al., 2014; Shen et al., 2014). 
In order to respond quickly to environmental and intrinsic signals, the cell uses active 
DNA demethylation mechanisms, which involve enzymatic activity and are in most 
cases independent of DNA replication (Kohli and Zhang, 2013). Active DNA 
demethylation mechanisms have been discovered in both plants and animals. The 
direct excision of 5mC by DNA glycosylases is mainly found in flowering plants, where 
DME (Demeter) and ROS1 (repressor of silencing 1) in combination with the BER 
(base excision repair) excise and remove 5mC (Zhu, 2009). In mammals, no 
orthologues of DME and ROS1 exist, but several studies support the idea that modified 
derivatives of 5mC are removed via BER in animals (Wu and Zhang, 2010). In 
zebrafish AID/APOBEC (activation-induced cytidine deaminase/ apolipoprotein B 
mRNA editing enzyme) deaminates 5mC which can be excised by methyl-CpG-binding 
domain protein 4 (MBD4), a member of the BER family of proteins (Rai et al., 2008). A 
similar process was also found in mammals, where deamination of 5mC leads to T:G 
mismatches, which are excised by thymine DNA glycosylase (TDG) or MBD4 and 
replaced by BER (Bhutani et al., 2010; Popp et al., 2010; Rai et al., 2008). Alternatively 
in mouse brain, AID/APOBEC deaminates 5hmC (5-hydroxymethylcytosine) to 5hmU 
(5-hydroxymethyluracil), which can be excised by the glycosylases TDG and single-
strand-selective monofunctional uracil-DNA glycosylase 1 (SMUG1) (Cortellino et al., 
2011; Guo et al., 2011). At the moment the significance of these processes in 
mammals is discussed controversially, since the affinity of AID/APOBEC to 5hmC and 
5mC in vitro is much lower than to C (cytosine) and the knockout of those enzymes did 
not show any developmental defects in mice (Muramatsu et al., 2000; Nabel et al., 
2012). Other pathways of active demethylation, which include the oxidation of 5mC to 
5hmC or further to 5fC (5-formylcytosine) and 5caC (5-carboxylcytosine), have been 
discovered. One example is the decarboxylation of 5caC to C, which has been 
demonstrated for mESC lysates, but did not reveal a possible candidate enzyme yet 
(Schiesser et al., 2012). Other reports suggest a dehydroxymethylation function of 
DNMT3A and DNMT3B under oxidizing conditions (Chen et al., 2012; Liutkeviciute et 
al., 2009). Those mechanisms have been identified in vitro but their biological 
relevance has yet to be determined. The best studied example of active demethylation 
mechanisms in mammals includes the active modification of 5mC followed by active 
removal of the modified cytosine in a BER mechanism (AM-AR) (Kohli and Zhang, 
2013). In the first steps TET (ten-eleven translocation) proteins convert 5mC to 5hmC 
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and further to 5fC and 5caC (He et al., 2011; Ito et al., 2011; Tahiliani et al., 2009). 
Those modifications can then be subsequently excised by TDG via BER (He et al., 
2011; Maiti and Drohat, 2011). It has been proposed that in some cases the 
intermediates can also be diluted in a replication-dependent manner, combining active 
modification and passive dilution (AM-PD) (Kohli and Zhang, 2013). The AM-PD 
pathway contributes to the early loss of 5mC in both parental genomes after fertilization 
of the zygote (Guo et al., 2014) whereas the AM-AR mechanism is abundant in many 
cell types (reviewed by Wu and Zhang, 2014).  
Both pathways require the initial conversion step, which is catalyzed by the TET 
proteins. Therefore the following section focusses on the important role of TET proteins 
in cellular processes. 
 
 
Figure 2.2: DNA demethylation pathways 
Schematic overview of possible pathways for DNA demethylation (modified from (Branco et al., 2012)) 
 
TET proteins 
All three mammalian members of the family of ten-eleven translocation proteins TET1, 
TET2, and TET3 are Fe2+- and 2-oxoglutarate-dependent dioxygenases which directly 
convert 5mC to 5hmC and further to 5fC and 5caC in the active demethylation process. 
All TET proteins share similar structural features, for example a c-terminal catalytic 
domain, containing a double-stranded β-helix fold and an adjacent cysteine-rich 
domain. Both domains can form a compact catalytic fold, which converts 5mC to 5hmC 
(Hu et al., 2013b). A conserved Cysteine-X-X-Cysteine (CXXC) zinc-finger domain is 
located at the n-terminus of TET1 and TET3. The CXXC domain facilitates DNA 
binding at unmodified, CpG-rich sequences and is a common feature of DNA binding 
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proteins like DNMT1. In TET proteins the CXXC regulates the stability of the proteins, 
but different functional properties have been reported. TET1 CXXC preferentially binds 
CpG sequences regardless of the modification status of the cytosine or, controversially, 
no DNA at all (Frauer et al., 2011; Xu et al., 2011; Zhang et al., 2010) and mutations of 
the domain don’t alter the expression or activity of TET1 (Ko et al., 2013). The CXXC 
domain of TET3 targets unmodified cytosines in both CpG and non-CpG context (Xu et 
al., 2012) and regulates protein levels and tethering to DNA (Ko et al., 2013). In the 
case of TET2, the CXXC domain has been separated in a chromosomal inversion 
event and now encodes for the IDAX (inhibition of the Dvl and axin complex) protein 
(Iyer et al., 2011; Iyer et al., 2009), which regulates TET2 turnover. ES cells depleted of 
TET2 failed to downregulate its protein levels and overexpression of IDAX in a myeloid 
cell line resulted in elevated TET2 and 5hmC levels (Ko et al., 2013). The CXXC 
domain of IDAX targets unmethylated CpGs at CGI and promoters, and plays an 
important role in the recruitment of TET2 to its target sites, which is significantly 
enriched at CpG-rich promoters (Chen et al., 2013; Deplus et al., 2013; Ko et al., 
2013)). A recent study reported a direct DNA-binding potential of TET2 via its cysteine-
rich domain. The interaction is sequence specific and shows substrate preference for 
5mC in a CpG context. Interestingly the binding is independent of the methyl-group and 
does not distinguish methylated or unmethylated CpGs, indicating an involvement of 
other TET-interacting proteins in the correct targeting of TET2 to effector regions (Hu et 
al., 2013b). Taken together TET2 binding to DNA is dependent on the presence or 
absence of specific targeting proteins (Pastor et al., 2013), and further investigation of 
possible candidate enzymes is needed to clarify the issue.  
The interaction of TET proteins with their target regions results in regulation of 
transcriptional activity, which is mostly associated with local demethylation events (see 
below) and may involve the recruitment of chromatin modifying complexes. Recent 
studies identified the O-linked β-D-N-acetylglucosamine (O-GlcNAc) transferase OGT 
to be one of the direct binding partners of TET proteins (Balasubramani and Rao, 
2013; Chen et al., 2013; Deplus et al., 2013; Vella et al., 2013). OGT catalyzes the 
addition of O-GlcNAc sugars to a variety of proteins in vivo, including chromatin-
modifying enzymes (Kreppel et al., 1997; Vosseller et al., 2002). It has been shown 
that the O-GlcNAcylation of H2B, which is associated with transcriptional activation, 
can be found at TET2 binding sites (Chen et al., 2013). Other interactions of OGT and 
TET proteins involve the recruitment of the Set1/COMPASS (complex associated with 
Set1) complex, which results in H3K4me3 deposition and thus activates transcription 
(Deplus et al., 2013). Those studies suggest an important role of TET proteins in 
transcriptional regulation, but whether it is of active or repressive nature depends on 
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the interaction partners. TET1 for example is highly abundant in murine ESC (mESC) 
and can be found at active, CpG-rich promoters and at repressed bivalent promoters in 
the same cell type. On the one hand, TET1 facilitates oxidation of 5mC to maintain an 
active state at promoters or distal-regulatory elements (Ficz et al., 2011; Shen et al., 
2013; Wu et al., 2011b). At poised genes, on the other hand, which are marked by 
bivalent chromatin modifications (H3K4me3 and H3K27me3) TET1 recruits the PRC2 
complex, associated with transcriptional repression (Wu and Zhang, 2011). Interaction 
of TET1 with other repressing complexes was detected for the MBD3/NuRD (methyl-
CpG binding domain protein 3/ nucleosome remodeling deacetylase) (Yildirim et al., 
2011) and SIN3A (SIN3 transcription regulator family member A) complex (Williams et 
al., 2011), but further insights into the selection of active or repressive interaction 
partners are needed to determine their importance for gene regulation (Wu and Zhang, 
2014). 
Several studies in the past years have pointed out a link between functional disruption 
of TET proteins and human malignancies. While TET1 and TET3 mutations are rare in 
hematological malignancies, over 700 TET2 mutations have been identified to be 
associated with leukemia (Abdel-Wahab et al., 2009; Euba et al., 2012; Liu et al., 2014; 
Weissmann et al., 2012). They mostly cause a loss-of-function of the protein and result 
in decreased 5hmC levels, for example in the bone marrow, as well as aberrant DNA 
methylation (Ko et al., 2010; Konstandin et al., 2011). Taken together these findings 
indicate an important role for TET2 as a tumor suppressor in the hematopoietic lineage 
(Delhommeau et al., 2009). This hypothesis is supported by several murine TET2 
knock-out models. Mice lacking TET2 are viable, fertile and develop a mostly normal 
phenotype, but acquire hematopoietic malignancies with age. Their disease state is 
associated with an increased number of myeloid and lymphoid progenitor cells that 
failed to differentiate. This phenotype resembles the human CMML (chronic 
myelomonocytic leukemia) and confirms the crucial role of TET2 in hematopoietic 
lineage commitment and differentiation (Li et al., 2011; Moran-Crusio et al., 2011; 
Quivoron et al., 2011). 
 
TDG 
The thymine-DNA glycosylase (TDG) is a member of the base excision repair system 
and has previously been linked to DNA demethylation processes in mammals. It 
recognizes and excises pyrimidine base T:G or U:G mismatches in a base-flipping 
mechanism and initiates the BER mechanism to restore the proper base (Cortazar et 
al., 2007; Neddermann and Jiricny, 1994). Two possible TDG-mediated pathways are 
initiated by the deamination of 5mC or 5hmC via AID/APOBEC. TDG is responsible for 
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subsequent removal of the resulting 5hmU and T, followed by base excision repair to 
restore C (Guo et al., 2011; Popp et al., 2010). It is also involved in the AM-AR 
demethylation process, where TDG is responsible for the removal of 5fC and 5caC 
modifications (He et al., 2011; Maiti and Drohat, 2011). In contrast to C, 5mC and 
5hmC the N-glycosidic bond of 5fC and 5caC is much weaker (Bennett et al., 2006) 
and allows an efficient removal of those modifications at low energy cost (Williams et 
al., 2012). Knockdown and catalytic mutation experiments revealed a crucial role for 
TDG in embryonic development. TDG-/- mice are lethal with distinct developmental 
defects in the embryo and show aberrant DNA methylation and decreased expression 
of developmental transcription factors (Cortazar et al., 2011; Cortellino et al., 2011). 
The association with activating histone modifiers like MLL1 (mixed-lineage leukemia 1) 
methyltransferase and p300/CBP (E1A binding protein p300/CREB-binding protein) at 
promoters was impaired upon TDG depletion, indicating an important role of TDG in 
the recruitment of transcriptional activators and chromatin maintenance (Cortazar et 
al., 2011; Tini et al., 2002). Subsequent studies in TDG-depleted mESC detected about 
10-fold elevated levels of 5fC and 5caC (He et al., 2011; Shen et al., 2013; Song et al., 
2013), which were enriched at inactive, poised promoters and regions of lineage-
specific TF binding. Accumulation of 5fC and 5caC was also found at promoter-distal 
regulatory elements associated with H3K4me1. The poised state of these enhancers 
suggested a role for 5fC and 5caC in enhancer priming (see chapter 2.2.1 and (Shen 
et al., 2013; Song et al., 2013). These findings indicate a role for the TET/TDG-
mediated active demethylation process at regulatory elements in the early 
development. Further investigation of demethylation processes at those elements is 
crucial for the complete understanding of cell type-specific regulation of gene 
expression. 
 
2.2.1 Genomic distribution of oxidized 5-
methylcytosines 
To interpret the function of active demethylation, a number of studies have mapped 
oxidized modifications of 5mC throughout the genomes of various cell types (Wu and 
Zhang, 2014) and detected the presence of intermediates of the TET/TDG-mediated 
DNA demethylation process at specific genomic elements.  
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Promoters and gene bodies 
Promoters are often associated with CpG islands and lack DNA methylation. DNMTs 
are blocked by the presence of active H3K4me3 and H3K27ac histone marks and the 
histone variant H2A.Z, which keep CGI promoters transcriptionally active (Ooi et al., 
2007; Wu and Zhang, 2014; Zilberman et al., 2008).  
In line with the lack of 5mC at mESC TSS, CpG-rich promoters are also devoid of 
5hmC, 5fC and 5caC, the modification products of 5mC. In contrast, promoters with 
low or intermediate CpG-density are enriched for 5hmC in mouse and human ESC 
(Pastor et al., 2011; Shen et al., 2013; Song et al., 2013; Szulwach et al., 2011; Yu et 
al., 2012). Among those, promoters of lineage-specific genes (mESC) carry a bivalent 
chromatin signature in (H3K4me3, H2K27me3). The accumulation of 5hmC, 5fC and 
5caC at those sites, indicates maintaining functions of TET/TDG-mediated 
demethylation at poised promoters. Similar enrichment of 5hmC, 5fC and 5caC at gene 
bodies further supports the significance of active demethylation events in mESC 
transcription regulation (Shen et al., 2013; Song et al., 2013). 
 
Enhancer 
 
Of all genomic locations 5hmC is most abundant at cis-regulatory elements, called 
enhancers (Stadler et al., 2011; Stroud et al., 2011; Szulwach et al., 2011; Yu et al., 
2012). These cis-acting, regulatory elements are ~200-500 bp in length, and marked by 
active chromatin marks H3K4me1 and H3K27ac in the active state (Shen et al., 2012; 
Spitz and Furlong, 2012). Enhancers establish long-range interactions with promoters 
and recruit activating TF to regulate gene expression. RNA polymerase II occupancy is 
another feature of active enhancers and leads to the transcription of enhancer RNAs 
(eRNA) (Natoli and Andrau, 2012). Several studies suggest that those eRNAs are 
important for the formation and stabilization of the promoter-enhancer-interaction, but 
controversial data exists (Hah et al., 2013; Lai et al., 2013; Li et al., 2013; Melo et al., 
2013).  
Active enhancers are occupied by a variety of common and cell type-specific TFs at 
proximal clusters of binding sites, which is associated with nucleosomal depletion, loss 
of DNA methylation and increased DNase hypersensitivity (He et al., 2010; Mito et al., 
2007; Schmidl et al., 2009; Song et al., 2011). In line with this observation 5hmC is 
absent from the binding site of TFs but enriched in the surrounding area, indicating a 
constant turnover of 5mC to keep those regions open (Lister et al., 2013; Yu et al., 
2012). TFs themselves recruit co-activator proteins which lack the ability to bind DNA 
and act as chromatin remodelers, histone modifiers or as mediator of long-range 
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crosstalk with the basal transcriptional machinery at the promoter (Borggrefe and Yue, 
2011; Calo and Wysocka, 2013; D'Alessio et al., 2009; Roeder, 2005; Weake and 
Workman, 2010). TF occupancy is increased at active and poised enhancers 
(Creyghton et al., 2010; Heinz et al., 2010). In ESC poised state enhancers are 
transcriptionally inactive, characterized by low nucleosome density and surrounded by 
bivalent histone marks H3K27me3 and H3K4me1 (Creyghton et al., 2010; Rada-
Iglesias et al., 2011). The poised state is similar to activated enhancer states and 
indicates a priming or pre-marking at those regions for rapid activation upon future cell-
fate decisions (Buecker and Wysocka, 2012). Association of poised enhancers with 
key developmental TF, like OGT4 in human ESC (hESC) supports this notion and 
suggests that they are important drivers of differentiation (Loh and Lim, 2010; Thomson 
et al., 2011).  
 
 
Figure 2.3: Hallmarks of active and poised enhancers 
Schematic overview of characteristic factors and chromatin at active and poised enhancers. (Modified from 
(Calo and Wysocka, 2013)) 
 
Accumulation of active demethylation intermediates, 5hmC and 5fC at poised and 
5caC preferentially at active enhancers further supported the involvement of TET/TDG-
mediated active demethylation processes at distal regulatory elements in mESC (see 
previous chapter and (Shen et al., 2013; Song et al., 2013). A recent study further 
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confirmed this hypothesis, showing that hypermethylation following a triple TET 
knockout in mESC mainly occurred at active and poised enhancer elements (Lu et al., 
2014). The authors demonstrated a direct link of TET/TDG-mediated demethylation at 
distal regulatory elements with the regulation of cell type-specific transcription to 
establish and mediate cell identity. 
 
2.3 The transcription factor PU.1 
 
Among the key transcription factors regulating gene expression patterns, PU.1 (PU box 
binding protein 1) is one of the most studied examples and plays a major role in 
hematopoiesis. It is responsible for the regulation and conduction of this multi-step 
process and controls lineage decisions and cell-fate of a variety of specialized blood 
cell types arising from one hematopoietic stem cell precursor (Arinobu et al., 2007; 
Back et al., 2005; Friedman, 2007; Singh et al., 1999). 
PU.1 is a member of the E26 transformation-specific (ETS) transcription factor family. 
Its functional structure consists of several distinct domains like an ETS domain next to 
a helix-turn-helix domain, which both facilitate binding to specific DNA sequence motifs 
(Kodandapani et al., 1996; Pio et al., 1996; Wei et al., 2010). PU.1 further contains an 
N-terminal acidic and a glutamine-rich domain for transcription activation and a PEST 
(peptide sequence rich in proline, glutamic acid, serine and threonine) domain which is 
involved in protein-protein-interactions. Due to its unique structural properties, PU.1 
belongs to a specialized group of transcription factors with pioneering characteristics 
(Zaret and Carroll, 2011). It has the particular ability to access and bind DNA in DNase 
I-inaccessible heterochromatin regions. In cooperation with chromatin remodeling and -
modifying interaction partners it facilitates repositioning of nucleosomes and opens 
chromatin structure to enable occupancy of other TF (Ghisletti et al., 2010; Pham et al., 
2013; Schonheit et al., 2013; Serandour et al., 2011). 
Together with other TF PU.1 is able to alter cell type-specific expression patterns 
(Ghisletti et al., 2010; Heinz et al., 2010; Pham et al., 2013). And different 
combinations of lineage-specific TFs at given cell states, determine the PU.1-
dependent regulation of the differentiation process in the hematopoietic lineage. For 
example, in concert with the transcription factor C/EBPα PU.1, guides differentiation of 
the myeloid lineage via alteration of the expression pattern towards myeloid-specific 
genes (Hohaus et al., 1995). The interactions can also be antagonistic, as was shown 
for the erythroid lineage-specific TF GATA-1. The specific interplay of these factors 
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determines the cell-fate of precursor cells and drives their commitment towards the 
myeloid or erythroid-megakaryocytic lineage (Zhang et al., 1999; Zhang et al., 2000). 
The ability of PU.1 to recruit and assembly chromatin or DNA modifying complexes 
indicates another important role in the regulation of gene expression. In cooperation 
with the histone acetyltransferases CBP and p300, PU.1 promotes active transcription 
(Bai et al., 2005; Yamamoto et al., 1999). Other reports have found repressive 
interaction partners of PU.1. In combination with the methyl CpG-binding protein 2 
(MeCP2) or with the DNA methyltransferases DNMT3A and 3B, PU.1 target sites are 
transcriptionally repressed (de la Rica et al., 2013; Imoto et al., 2010; Suzuki et al., 
2006). Studies in hematopoietic cell systems, which express PU.1 endogenously, have 
displayed controversial data regarding the involvement of PU.1 in DNA methylation 
changes during differentiation. Our group identified a general association of PU.1 
binding with local demethylation events in differentiating monocytes and macrophages 
(Pham et al., 2013). This finding is in line with work of de la Rica et al. who proposed 
that an interaction of PU.1 with TET2 regulates transcriptional activation in monocyte-
derived osteoclasts (de la Rica et al., 2013). Interestingly they also linked PU.1 to DNA 
methylation in cooperation with DNMT3B, which is opposite to our finding that PU.1 
binding is inversely correlated to 5mC appearance (Pham et al., 2013). Further 
investigation is needed to address this controversy. 
 
2.4 The mononuclear phagocyte system 
2.4.1 The mononuclear phagocyte system 
In the past years several cell systems in mammals have been discovered, isolated and 
recapitulated for in vitro studies. One intensively studied example is the mononuclear 
phagocyte system (MPS). It was initially defined by van Furth and Cohn in 1968, 
comprising a network of non-granulocytic, myeloid cells with extraordinary phenotypic 
plasticity (van Furth and Cohn, 1968), and it belongs to the hematopoietic lineage tree 
(Abbas et al., 2007). Peripheral blood-monocytes, the non-dividing progenitor cells of 
the MPS, give rise to a variety of cell types in vivo. Upon distinct stimuli they are able to 
differentiate into tissue macrophages, myeloid dendritic cells and osteoclasts 
(Geissmann et al., 2010; Hume, 2008). In this process PU.1 plays an important role. It 
regulates gene expression in myeloid cells, like macrophages or monocytes (De Kleer 
et al., 2014; Ghisletti et al., 2010) and is essential for DC development (Carotta et al., 
2010a). As a fundamental component of the adaptive and innate immune response, 
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the MPS is in charge of important stimulatory and regulatory functions as well as 
functions in tissue remodeling and homeostasis (Yona and Jung, 2010). It is involved in 
chronic inflammatory diseases like rheumatoid arthritis, inflammatory bowel disease, 
neurodegenerative disorders, and arteriosclerosis (Valledor et al., 2010). Although the 
MPS acts as a dynamically interacting network of cells with similar functional features, 
it comprises individual lineages with distinct roles as well as different origins and 
maintenance strategies (Jenkins and Hume, 2014).  
The unique differentiation steps of the MPS can be recapitulated in vitro using a 
system published by Sallusto and Lanzavecchia (Sallusto and Lanzavecchia, 1994). 
Upon stimulation with granulocyte-macrophage colony stimulating factor (GM-CSF) 
and IL-4 (interleukin 4), isolated peripheral blood-monocytes can be differentiated into 
immature dendritic cells (iDC) and further matured by adding toll-like receptor ligands, 
TNFα or LPS (De Smedt et al., 1996). However, in the presence of human AB-serum, 
isolated monocytes differentiate into macrophages after seven days of cell culture 
(Andreesen et al., 1983) (see Figure 3.1).  
 
 
Figure 2.4: Cell model of the MPS in vitro 
Schematic overview of differentiating monocytes in vitro. (Modified from (Klug et al., 2013)) 
 
One of the unique features of this in vitro system is the absence of proliferation during 
the differentiation of monocytes into iDC or MAK (Cheung and Hamilton, 1992; Clanchy 
et al., 2006; Finnin et al., 1999; Pickl et al., 1996; van Furth et al., 1979). Several 
proliferation assays confirmed, that the transition of one cell type into another occurs 
independent of any replication events (Klug et al., 2010). This cellular setting therefore 
represents an ideal model system to study molecular mechanisms involving enzymatic 
activity in the absence of DNA replication. 
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2.4.2 Monocytes 
Monocytes belong to the group of white blood cells or leukocytes and originate from 
hematopoietic precursor cells in the bone marrow (BM) (Abbas et al., 2007). They are 
defined as non-proliferative, circulating cells in the peripheral blood system (Hume, 
2006; van Furth et al., 1979) and represent 10% of peripheral leukocytes in human (4% 
in mice). Monocytes can be classified into three subpopulations by their distinctive 
expression of the lipopolysaccharide (LPS)-coreceptor CD14 and the Fcɣ III receptor 
CD16 (Passlick et al., 1989; Ziegler-Heitbrock et al., 2010). Around 90% of blood 
monocytes are referred to as “classical” monocytes due to their high expression of 
CD14 and lack of CD16 (CD14++CD16-). The other two subgroups are referred to as 
“non-classical” (CD14dimCD16+) and “intermediate” monocytes (CD14+CD16+). Each 
subgroup is characterized by differential gene-expression patterns, transcriptional 
regulation and specific functions (Schmidl et al., 2014; Zawada et al., 2011). 
In the MPS, monocytes constitute the most mobile and dynamic population (Yona and 
Jung, 2010). Via the bloodstream these myeloid precursor cells have access to all 
tissues in the body and supply local sites of immune response with effector cells of the 
MPS (Yona and Jung, 2010). To reach the inflamed areas they use chemokine and 
adhesion receptors in order to cross tissue barriers and produce cytokines to mediate 
local inflammatory reactions. In the current view monocytes in the blood stream 
represent a reservoir to maintain small subpopulations of the macrophage (MAK) and 
dendritic cell (DC) compartments (Geissmann et al., 2003; Randolph et al., 1998; 
Serbina and Pamer, 2006). In general both cell types originate from other precursor 
cells from the bone marrow or fetal tissues (Ginhoux et al., 2010; Yona et al., 2013). 
However, in certain settings and under inflammatory conditions, monocytes are able to 
differentiate into MAK and DCs (Ingersoll et al., 2011; Serbina et al., 2008; Shi and 
Pamer, 2011). In mice, for example, dendritic cells in the mucosal epithelium, called 
Langerhans’ cells originate from bone marrow precursors, but can be derived from 
LY6Chi monocytes in an inflammatory milieu (Iijima et al., 2007). Each new study adds 
more details to the classification of immune cells, but makes it difficult to clearly define 
the borders of their definition. A subset splenic DC, called Tip-DCs (TNFα and iNOS 
expressing DCs) are derived from MO (Serbina et al., 2003) in mice. But according to 
recent characterizations of their phenotype, they represent activated effector 
monocytes rather than dendritic cells (Mildner et al., 2013). 
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2.4.3 Macrophages 
 
Macrophages are stationary, phagocytotic cells residing in a variety of lymphoid and 
non-lymphoid tissues, like microglia in the brain (Mildner et al., 2007), alveolar MAK 
(Sawyer et al., 1982; Tarling et al., 1987), splenic white pulp and metallophilic MAK 
(Wijffels et al., 1994), and Kupffer cells in the liver (Crofton et al., 1978). Tissue 
macrophages are important effector cells of the immune system. Their broad spectrum 
of receptors is important for pathogen-specific phagocytosis and they are able to 
regulate and maintain the inflammatory response via inflammatory cytokines. In 
addition, macrophages have various functions in tissue homeostasis. They produce 
growth factors for tissue remodeling and repair after injury and are responsible for the 
elimination of apoptotic cells (Gilroy et al., 2004; Gordon, 2002, 2007; Lawrence et al., 
2002). Macrophages are derived from different origins. Although monocytes can 
differentiate into MAK in vitro they are not the main source of MAK in vivo. Most tissue 
macrophages, like microglia (Ginhoux et al., 2010; Schulz et al., 2012), alveolar MAK 
(Guilliams et al., 2013) or Kupffer cells (Schulz et al., 2012), originate from fetal 
precursors and are replenished by local proliferation. Monocyte-derived macrophages 
are mainly inflammatory MAK, which stem from peripheral blood monocytes infiltrating 
the inflamed tissue (Ingersoll et al., 2011; Shi and Pamer, 2011). Interestingly several 
studies detected additional MO-derived MAK sub-populations in a variety of other 
tissues, like liver, kidney, and peritoneal cavity (Ginhoux et al., 2009; Goldszmid et al., 
2012). And intestinal macrophages, in the lamina propria, are completely replenished 
from monocytes originating from BM or fetal precursors (Varol et al., 2009). These 
findings suggest that, independent of infection, several subsets of tissue MAK are 
permanently replenished from monocytes in the steady state (Jenkins and Hume, 
2014). The majority of these observations have been obtained from murine systems 
and still await confirmation in the human setting. Although both organisms share 
similarities in their hematopoietic organization (Tavian and Peault, 2005) humans have 
different life spans than rodents and the MAK homeostasis in aging humans is still 
unclear. 
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2.4.4 Dendritic cells 
 
The dendritic cell compartment comprises a variety of specialized immune cells 
subsets which were first discovered in 1973 as potent stimulators of naïve T cells 
(Steinman and Cohn, 1973). Dendritic cells are widely distributed in lymphoid and non-
lymphoid organs and characterized by different functions and phenotypes (Carotta et 
al., 2010b). Per definition they functionally belong to the family of antigen-presenting 
cells (APC) and have important effector functions on microbes and pathogens in the 
immune response (Pulendran, 2004). But recent advances in DC classification suggest 
a different definition of DC according to their Flt3+ positive precursor cells. Although 
those DC arise from a different progenitor in the bone marrow, compared to MO and 
MAK, they are still considered to compose a large fraction of the MPS (Jenkins and 
Hume, 2014).  
Dendritic cells are mainly divided into two, specialized subgroups; “classical” (cDC) and 
“plasmatoid” (pDC) DCs. Classical dendritic cells include a variety of non-lymphoid and 
lymphoid tissue DCs which recognize invading pathogens and are specialized for the 
maintenance of self-tolerance (Banchereau and Steinman, 1998; Merad and Manz, 
2009; Steinman et al., 2003). In contrast, pDC are characterized by their ability to 
produce high quantities of type I interferons (IFNs) in response to viral infections 
(Nakano et al., 2001; Siegal et al., 1999). The emerging amount of studies of DC 
subsets revealed further subgroups and overlapping classifications due to their 
functions, phenotypes and locations. Thus a third group of “non-classical” or 
“monocyte-derived DCs” (moDCs) was identified (Mildner et al., 2013; Segura and 
Amigorena, 2013). Those cells are phenotypically similar to cDC but differ in their gene 
expression patterns (Xu et al., 2007). Those studies further identified PU.1 as a key 
driver of DC development. It alters higher-order chromatin structure to regulate the 
expression of Irf8, an important factor for DC development (Schonheit et al., 2013). 
And it controls Flt3 expression in DC precursor cells in mice, to maintain cDC and pDC 
populations (Carotta et al., 2010a).  
Taken together, these studies show that PU.1 is a crucial TF for all members of the 
MPS and questions regarding its regulatory function or mechanistic details can be 
addressed in the in vitro model of this cell system. 
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3 Results 
3.1 The active DNA demethylation mechanism 
in the human mononuclear phagocyte 
system 
 
The main aim of this work was to characterize active demethylation in the mononuclear 
phagocyte system and to identify the factors involved in the process. Furthermore we 
wanted to gain insights into global patterns and its role in regulation of cell fate and 
lineage determination.  
The data presented in the following chapters (3.1.1. and 3.1.2.) have been published in 
Genome Biology (Klug et al., 2013). To present a complete picture of the story, work 
from both co-authors is included in this work. When this is the case, the figures are 
cited and can be found online in (Klug et al., 2013). The figures taken from the 
publication are all slightly adapted in size, format, etc. And at some points additional 
data is shown to give a complete and updated overview of the story. In any case the 
individual co-author’s contribution is clearly stated. 
 
3.1.1 Identification of DMR in the mononuclear 
phagocyte system 
 
The cell system: The human mononuclear phagocyte system 
The mononuclear phagocyte system (MPS) represents a distinct part of the 
hematopoietic cells. Its members are non-granulocytic, myeloid cells derived from 
monocytes, which play a crucial role in the innate and adaptive immune response 
(Hume, 2006; Steinman and Inaba, 1999; van Furth and Cohn, 1968). The phenotypic 
diversity of CD14+ positive blood monocytes contributes to a variety of myeloid cell 
types, like macrophages, dendritic cells and osteoclasts, depending on the surrounding 
environment. This system can be recapitulated in vitro as depicted in Figure 3.1. 
Peripheral blood monocytes (MO), isolated from blood, differentiate into macrophages 
(MAK) in the presence of human serum (Andreesen et al., 1983) and immature 
  Results 
20 
 
dendritic cells (iDC) can be derived by adding IL-4 and granulocyte-macrophage 
colony-stimulating factor (GM-CSF) (Sallusto and Lanzavecchia, 1994) to the culture 
medium.  
 
 
Figure 3.1: Monocyte differentiation in vitro 
Schematic overview of the in vitro monocyte differentiation model. Monocytes don’t proliferate in this setup 
(as demonstrated by the lack of nucleotide incorporation). Therefore DNA demethylation in this system 
requires an active process. 
 
Earlier studies used BrdU and 3H-Thymidine incorporation assays to show that 
monocytes do not proliferate during differentiation. This finding excludes the possibility 
of passive demethylation and confirms that the MPS is a suitable cell system to 
address questions on active DNA demethylation (Klug et al., 2010) (overview in Figure 
3.1). Recently our lab identified a number of differentially methylated regions (DMR) 
(Figure 3.2) in differentiating monocytes using MCIp and microarray techniques (Klug 
et al., 2010). The changes in methylation were highly reproducible and not restricted to 
promoter regions. Further ChIP experiments characterized the surrounding histone 
environment as active. H3K4me3, an active histone mark, was found at demethylated 
TSS and the active enhancer marks H3K4me1 and H3K4me2 were both found at 
promoter-distal sites of demethylation. Taken together, these findings indicated 
recruitment of a demethylation machinery to the DMRs facilitating active DNA 
demethylation and participating in histone-modification processes. In turn these events 
lead to gene activation and transcriptional priming, (Klug et al., 2010) and are the basis 
for the work presented in this thesis (Figure 3.1 and Figure 3.2 are published in (Klug 
et al., 2013)). 
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Figure 3.2: UCSC Genome Browser tracks of DMRs 
Positions of regions (purple) measured by MALDI-TOF analysis of bisulfite converted DNA (MassARRAY, 
shown in Figure 3.3 B) and of primers (red) used for hMeDIP qPCR (see Figure 3.3) are shown relative to 
positions of CpG dinucleotides (green) and neighboring genes (blue). The tracks were generated using the 
UCSC Genome Browser. 
 
3.1.2 Identification of key players in the DNA 
demethylation process 
 
3.1.2.1 Time course of 5mC and 5hmC changes in DC 
 
The conversion of 5mC to 5hmC has recently been proposed to be a possible initiator 
of active DNA demethylation processes. This step is catalyzed by a family of Ten-
Eleven Translocation proteins (TET1-3) (Tahiliani et al., 2009). To test for a possible 
involvement of TET proteins in the demethylation process we followed the methylation 
changes at previously defined sites (Figure 3.2) of active DNA demethylation in time 
courses of differentiating monocytes as displayed in Figure 3.3A. Bisulfite treated DNA 
was measured with the MassARRAY system by using mass spectrometry and six 
exemplary DMRs are shown as heatmaps displaying the differentiation time course of 
every CpG dinucleotide present in the amplicons. As expected all regions show DNA 
demethylation at several CpG residues. In two regions, CCL13 and USP20, 
methylation is removed at early time points whereas DNase1L3 and Stat5 are 
demethylated at later stages of differentiation (“late” DMR). Two control regions are 
included in the figure which show no methylation (MMP7) at all or are constitutively 
methylated (HOXB1) throughout the seven day time course.  
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Figure 3.3: 5mC deposition precedes active DNA demethylation in human monocytes 
(A) MassARRAY analysis of bisulfite-converted DNA at four loci that show active DNA demethylation 
during monocyte to DC differentiation, as well as four two control regions (values are mean of n≥4). Data 
are presented as heatmaps. The methylation content (including both 5mC and 5hmC) is indicated by 
coloring (yellow: no methylation, dark blue: 100% methylation) with each box representing a single CpG 
dinucleotide and each row representing the succession of CpGs measured. Grey boxes indicate CpGs that 
were not detected by MALDI-TOF MS. Red asterisks mark the CpGs that are shown in (B). Methylation 
ratios of single CpG units for individual donors are also available online (Klug et al., 2013). (B) Dynamics 
of DNA methylation (5mC+5hmC) and 5-hydroxymethylation (5hmC) during monocytic differentiation. DNA 
methylation levels of single CpGs as measured by MassARRAY (open squares) are compared with 5hmC 
enrichment (measured by hMeDIP, red squares) at the same loci shown in (A) (n≥4, values are mean + or 
– SD). Exact genomic positions of analyzed CpG residues are given in Table S3, Additional File 3 
(available online, Klug et al., 2013). 
 
In Figure 3.3B we compared the demethylation of single CpG dinucleotides (measured 
by mass spectrometry, indicated by red asterisks in Figure 3.3A) to the appearance of 
5hmc at those regions. 5hmC was detected using 5hmC methyl-DNA immune 
precipitation (hMeDIP) and plotted against methylation levels. The progression of DNA 
demethylation during the differentiation time course coincides with the simultaneous 
appearance of 5hmC which is inversely proportional to methylation levels. In one DMR, 
the CCL13 promoter region, not only 5mC but also 5hmC disappears completely 
towards the end of the time course, indicating completion of the demethylation process. 
DNA demethylation is not restricted to DCs only but can also be observed in MAK as 
displayed at the USP20 region. This finding will be further investigated in later chapters 
(see section 3.2)  
The MassARRAY is a stable and reproducible system to study DNA methylation at 
single CpGs. Unfortunately bisulfite treatment doesn’t differentiate between 5mC and 
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5hmC; both DNA modifications are protected from bisulfite conversion and appear in 
the methylated fraction. To verify the loss of DNA methylation at the example regions 
we measured 5mC using MeDIP and compared it to 5hmC measured with hMeDIP 
(Figure 3.4) using the same samples and amplicons (Figure 3.2). Although the 
methylcytidine antibody displayed a lower affinity compared to the 5hmC antibody 
progressive demethylation was detected at all loci shown except the control regions. 
(The figures (Figure 3.3, Figure 3.4) are available online in (Klug et al., 2013). The 
experiments were performed by M. Klug.) 
 
 
Figure 3.4: Comparison of hMeDIP and MeDIP results 
The same samples were analyzed for 5mC and 5hmC enrichment by MeDIP and hMeDIP, respectively. 
Enrichment is shown relative to the signal observed with the genomic input material. Sensitivities of both 
antibodies were strikingly different with the 5hmC antibody being much more efficient in precipitating DNA. 
Especially at low CpG content regions, signals were difficult to quantify. (n=5, values are means ± SD). 
 
In general antibody based pull-down techniques (like hMeDIP and MeDIP) are likely to 
show bias towards CpG dinucleotide density (Pastor et al., 2011) in the enriched 
regions. Since the methylcytidine antibody did perform with lower affinity at regions 
with low CpG content, a chemical approach was used to independently confirm the 
data. Specific glycosylation of 5hmC followed by glycosyl-sensitive digest with MspI 
and HpaII is shown in Figure 3.5 for five example regions. The results showed similar 
patterns of demethylation and synchronous appearance of 5hmC as observed before. 
The MMP7 region lacks MspI restriction sites and could therefore not be analyzed with 
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this technique. (Figure 3.4 and Figure 3.5 are published in (Klug et al., 2013). 
Experiments have been performed by S. Schmidhofer and M. Klug.). 
 
 
 
Figure 3.5: Alternative 5hmC measurements 
Quantification of 5hmC using glycosyl transfer to 5hmC, followed by glycosylation-sensitive restriction 
(GGSD) with MspI and subsequent amplification of protected regions. DNAs were also digested with 
HpaII, which is sensitive to both 5hmC and 5mC. QPCR results are shown relative to the amplification of a 
CpG-free region. Values represent mean ± SD (n≥3) for control digests (MspI only), digests after glycosyl 
transfer (GT+ MspI) or digests with HpaII (average for DNAs digested before and after glycosyl transfer). 
Exact genomic positions of analyzed CpG residues are given in Table S2, Additional File 2 of (Klug et al., 
2013). The MMP7 region lacks MspI recognition sequences and was not analyzed. 
 
3.1.2.2 Knockdown experiments of possible factors involved in active 
DNA demethylation (Part I) 
 
Taken together the above results strongly indicated the local conversion of 5mC to 
5hmC to be the first step of the demethylation process which suggests a possible 
involvement of TET hydroxylases. Other studies have linked members of the base 
excision repair such as MBD4 and TDG to the active DNA demethylation process. The 
glycosylases are capable of binding and removing deaminated 5mC as well as 5hmC 
or its derivative oxidation products 5caC and 5fC (He et al., 2011; Maiti and Drohat, 
2011; Metivier et al., 2008; Otani et al., 2013). The first part of this chapter focuses on 
the characterization of TET proteins, MBD4 and TDG as prospect candidates 
responsible for the active DNA demethylation mechanism. 
 
To investigate the involvement of each candidate enzyme in the active demethylation 
process, we established a transfection protocol for freshly isolated primary blood 
monocytes. Therefore the cells were transiently transfected with siRNA complementary 
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to candidate mRNAs or a control siRNA and differentiated into dendritic cells under iDC 
culture conditions (for the complete protocol see section 5.2.1.3.3). 
 
3.1.2.2.1 mRNA expression levels of candidate enzymes 
 
Before analyzing a causal link between DNA demethylation and possible candidates 
involved in the process the overall expression of TET proteins as well as DNA 
glycosylases was measured using qRT-PCR. In Figure 3.6 the levels of mRNA in a 
differentiation time course of monocytes to dendritic cells is shown relative to the 
expression of a housekeeping gene (HPRT1). In panel 3A we could observe an 
abundant expression of TET2 as well as TET3, however the latter was expressed at 
much lower levels. Whereas MO and DC mainly express TET2, TET1 was not 
detectable in those cell types, neither on mRNA (Results not shown) nor on protein 
level (see section 3.1.2.2.3). Since TET3 was expressed at low levels and not 
detectable with commercial antibodies in Western blotting (see 3.1.2.2.3) we focused 
on TET2 as a candidate enzyme for further experiments. (Figure 3.6 is modified from 
(Klug et al., 2013). Experiments were performed by S. Schmidhofer and M. Klug.) 
 
 
Figure 3.6: Candidate enzymes are expressed in human monocytes 
The expression profile of TET2 and TET3 (A) or MBD4 and TDG (B) during monocyte differentiation into 
dendritic cells is shown. Quantitative RT-PCR results are shown relative to HPRT1 expression and 
represent mean values ± SD (n=2-6). No mRNA expression was detected for TET1 in monocytes or 
monocyte-derived cells. 
 
MBD4 and TDG expression was measured in time courses of differentiating monocytes 
as well. Both glycosylases were abundantly expressed at every time point of 
differentiation at similar amounts. The results are displayed in Figure 3.6B. These 
  Results 
26 
 
findings confirmed both glycosylases as potential contributors to the active DNA 
demethylation process. Thus both enzymes were included in further experiments. 
(S. Schmidhofer performed the experiments.) 
 
3.1.2.2.2 Cell conditions after siRNA transfection 
 
Monocytes and dendritic cells are members of the immune system and react 
sensitively to foreign nucleic acids and transfection procedures. We therefore choose 
to study early time points to avoid severe transfection-induced effects on survival and 
differentiation. To monitor cell conditions after knockdown the cells were stained and 
analyzed by flow cytometry. As shown in the DAPI staining in Figure 3.7 the large 
majority (>98%) of cultured cells were viable after 42 h of transfection. Two thirds of 
untreated cells displayed induced levels of the surface marker CD1a which is specific 
for dendritic cells, indicating ongoing DC differentiation. In contrast, all transfected cells 
showed reduced numbers of cells bearing CD1a, while most cells presented CD14 (a 
marker for MO) only, representing a delay in differentiation.  
 
 
Figure 3.7: Survival of siRNA transfected monocytes 
Untreated or siRNA-transfected cells after 42h were stained with DAPI (Sigma), anti- CD14-Fitc (My4a, 
Coulter Clone, a marker for monocytes) and anti-CD1a-PE (T6-RD1; Coulter Clone; a marker for iDC) and 
analyzed by flow cytometry using the LSRII from BD (Heidelberg, Germany). The large majority of cells 
(>98%) was viable (as demonstrated by the exclusion of DAPI in most cells, upper panels) and entered the 
DC differentiation pathway (as indicated by the induction of CD1a, lower panels), although numbers of 
differentiating cells were consistently reduced in all transfected samples. 
 
On mRNA level the differentiation marker CD1a as well as the expression of the 
CCL13 region was also reduced in transfected cells compared to untreated cells 
(qPCR levels shown in Figure 3.8). These data showed that survival was largely 
unaffected by transfection, while differentiation was impaired by the procedure. 
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(Figure 3.7 and Figure 3.8 are modified from (Klug et al., 2013). Expression assays 
were performed by S. Schmidhofer and M. Klug. Cells for flow cytometry were 
prepared and stained by S. Schmidhofer. The flow cytometry measurements were 
conducted by Kristina Doser (AG Edinger/Hoffmann).) 
 
 
Figure 3.8: Marker gene expression of siRNA transfected monocytes 
Expression of CD1A and CCL13 marker genes in monocytes either non-transfected (NOT) or transfected 
with TET2-, MBD4-, TDG-siRNA or control siRNA were measured after 27h and 42h of differentiation 
culture. qRT-PCR results were normalized to HPRT1 expression. Values represent mean ± SD (n≥4). 
 
3.1.2.2.3 siRNA knockdown efficiency 
 
Figure 3.9 illustrates knockdown efficiencies on mRNA (normalized to HPRT1 
expression, top panel) and protein level (lower panel).  
The TET2 siRNA (Figure 3.9A) treated cells showed significantly reduced levels of 
TET2 mRNA at 27 h and at 42 h after transfection as well as reduced amounts of 
protein at both time points. While the knockdown of MBD4 (Figure 3.9B) was even 
more distinct after 27 h and 42 h compared to TET2 siRNA, TDG mRNA depletion 
shown in Figure 3.9C was significant after 42 h. On protein level both glycosylases 
displayed decreased levels of protein. 
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Figure 3.9: Knockdown efficiency on mRNA and protein level 
mRNA (upper panels) and protein expression (lower panels) of (A) TET2, (B) MBD4, or (C) TDG in 
monocytes left untreated or transfected with the corresponding TET2-, MBD4-, TDG-, or control siRNA 
after 27 h and 42 h of differentiation culture. qRT-PCR results were normalized to HPRT1 expression (n≥4, 
values are mean ± SD, *P<0.05 Student’s T-test, paired, two-sided). Protein levels of TET2, MBD4, or 
TDG were analyzed using Western blotting (results are representative of n=3 independent experiments). 
 
(Figure 3.9 is published in (Klug et al., 2013); qPCR was performed by S. Schmidhofer 
and M. Klug; Western blotting was done by S. Schmidhofer.) 
 
3.1.2.2.4 Effect of candidate knockdown on methylation kinetics 
 
Since knockdown efficiency of all candidates reached a sufficient level after 27 h and 
42 h of transfection we analyzed the effect of siRNA transfection on the demethylation 
process at both time points. Bisulfite treated DNA isolated from the transfected cells 
was measured by mass spectrometry and is displayed in Figure 3.10A as heatmaps 
showing methylation levels for each CpG in the DMRs. Asterisks indicate selected 
CpGs illustrated as bar charts in Figure 3.10B. 
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Figure 3.10: TET2 is required for active demethylation in human monocytes 
(A) MassARRAY analysis of bisulfite-converted DNA at five loci that show active DNA demethylation 
during monocyte to DC differentiation, as well as for two control regions (values are mean of n≥4). Data 
are presented as heatmaps. The methylation content (including both 5mC and 5hmC) is indicated by 
coloring (yellow: no methylation, dark blue 100% methylation) with each box representing a single CpG 
dinucleotide and each row representing the succession of CpGs measured. Grey boxes indicate CpGs that 
were not detected by MassARRAY. Asterisks mark the CpGs that are shown in (B). Red arrows mark 
TET2-siRNA treated samples that show a specific decrease in demethylation. (DNase1L3 methylation 
didn’t change during the first 42h, but spectra were of low quality and are not shown.). Methylation ratios of 
single CpG units for individual donors are provided in Table S4 in Additional File 4 (available online, Klug 
et al., 2013). (B) Bar charts for MassARRAY results of the indicated CpG residues of actively 
demethylated (CCL13, USP20) or control loci (MMP7, HOXB1). Values are mean ± SD, (n≥4; * P<0.05, *** 
P<0.001 Student’s T-test, paired, two-sided). 
 
Both regions characterized by early loss of methylation (CCL13 and USP20) showed 
significantly higher levels of methylation in TET2 depleted cells after 27 h and/or 42 h 
compared to cells treated with control siRNA. This indicates a delay of demethylation 
after TET2 depletion in both “early” regions. In contrast the “late” regions Stat5 and 
DNase1L3 displayed no loss of methylation at 27 h and 42 h time points (due to low 
spectra quality the results for DNase1L3 are not shown.). These findings are in line 
with results shown above. Those two regions get demethylated at late stages of the 
monocyte to iDC differentiation and thus don’t show changes in methylation at these 
early time points. As expected, in the control regions MMP7 and HOXB1 no changes in 
methylation were observed. 
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Cells with reduced levels of MBD4 and TDG displayed similar levels of methylation 
compared to control siRNA and no significant changes in demethylation rates could be 
detected (Figure 3.10B). In all siRNA transfected cells a slight delay in demethylation 
compared to untreated cells could be observed. This seems to be a method-based 
effect and is in line with the deferred differentiation detected in 3.1.2.2.2. Nonetheless, 
the demethylation process was clearly demonstrated as well as the effects of TET2 
knockdown which still allows addressing questions on the demethylation process using 
this method. 
These experiments show that TET2 is required for the active demethylation process in 
monocyte to DC differentiation, whereas no involvement of MBD4 and TDG in the first 
step of 5mC to 5hmC conversion could be detected with this method. 
(Figure 3.10 is available online in (Klug et al., 2013). MassARRAY experiments for 
TET2 were performed by S. Schmidhofer and M. Klug. MBD4 and TDG were analyzed 
by S. Schmidhofer.) 
 
3.1.2.2.5 5caC or 5fC accumulation at DMRs 
 
Bisulfite treatment of DNA does not only fail to discriminate between 5mC and 5hmC 
but does also not distinguish other 5mC modifications (5fC and 5caC) from unmodified 
cytosines. To detect a possible accumulation of 5fC or 5caC at DMRs in cells 
expressing low levels of MBD4 or TDG this method is not suitable. In a restriction 
digest based approach we used MspI to measure restriction efficiencies after 
knockdown at single restriction sites covering one demethylated CpG dinucleotide 
each. The restriction enzyme is inhibited by the presence of 5fC and 5caC (Ito et al., 
2011) and detection of PCR products after digestion may indicate evidence for 5fC or 
5caC at the DMRs. In Figure 3.11B the cutting efficiency of MspI after depletion of 
MBD4 and TDG as well as TET2 at indicated regions is displayed. All DNAs were 
digested at similar levels at all regions and thus did not show significant differences in 
restriction efficiency of MspI.  
To test if 5fC and 5caC generally appear at DMRs we digested DNAs from dendritic 
cells at day 7, a late time point of the demethylation process. The results are illustrated 
in Figure 3.11A. All regions were cut with similar restriction efficiencies, even at the 
CCL13 locus where 5mC as well as 5hmC are almost completely removed at that time 
point and the demethylation process is likely to have reached completeness. 
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Figure 3.11: MspI restriction efficiency at demethylated CpG residues 
DNA from the indicated untreated (iDC at 7 days of culture, in A) or siRNA transfected cells (27h time 
point, in B) was subjected to MSRE restriction digests as outlined in chapter 5.2.2.7.3.1. qPCR was 
applied to all samples to quantify the amplification of fragments amplicons across single MspI sites. 
Amplification values for the indicated target regions for MspI-digested and control-digested samples were 
normalized against values obtained for a region in the GAPDH locus lacking an MspI restriction site. 
Cutting efficiency is calculated by subtracting the ratio (in percent) of normalized values for MspI-digested 
and control-digested samples from 100%. 
 
Restriction efficiency was similar in all DNAs tested, indicating no accumulation of 5fC 
and 5caC at the CpGs in the restriction sequence. It has to be noted that this method 
only covers one CpG per region and may therefore not represent the modification state 
of all CpGs in the regions. Furthermore restriction efficiencies may also depend on 
methylation of the outer cytosine of the restriction site (5mCCGG). In this case 
restriction efficiency was not inhibited at all, but nevertheless this method may only 
give a first hint. Other methods have to be used to get further insights into modification 
states after knockdown of candidate enzymes. 
(Figure 3.11 is available online (Klug et al., 2013), S. Schmidhofer performed the 
experiments.) 
 
3.1.2.2.6 Effect of candidate knockdown on 5hmC kinetics 
 
Upon TET2 depletion 5mC demethylation rates were clearly delayed. This finding 
indicated an important contribution of TET2 to the demethylation process. To test 
whether TET2 is responsible for the conversion of 5mC to 5hmC we checked if 5hmC 
kinetics were affected as well. Based on pull-down using the hMeDIP method, 5hmC 
levels were measured by qPCR of DNA from transfected cells after 27 h and 42 h. 
Figure 3.12 illustrates 5hmC levels at the indicated demethylated regions. All DMRs 
showed either a tendency or significant reduction of 5hmC in cells with reduced TET2 
expression compared to control siRNA transfected cells. The control regions MMP7 
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and HOXB1 showed minor levels of 5hmC which presumably represents background 
noise since 5mC levels in Figure 3.10 showed no demethylation at the analyzed time 
points. As expected, due to the lack of methylation differences, 5hmC levels of cells 
transfected with either MBD4 or TDG siRNA did not show significant differences in 
comparison with control siRNA treated cells. 
 
 
Figure 3.12: 5hmC levels after siRNA-mediated knockdown of TET2, MBD4 and TDG. 
DNA from the indicated siRNA transfections was subjected to hMeDIP and the enrichment of 
demethylation targets and control regions was measured using qPCR (n=4, values are means ± SD;          
* P<0.05, ** P<0.01 Student’s T-test, paired, two-sided). 
 
To verify the results 5hmC was also quantified with glycosyl transfer followed by 
glycosylation-sensitive restriction (GGSD) with MspI and HpaII. Data is illustrated in 
Figure 3.13 for four DMRs and one control region (MMP7 lacks restriction site.). 
Significant reduction of 5hmC levels in TET2 siRNA treated cells was detected at the 
DNase1L3 and USP20 locus, whereas CCL13 and Stat5 displayed non-significant 
tendencies only. 5hmC levels in MBD4 and TDG siRNA transfected cells were again 
not significantly altered. 
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Figure 3.13: Alternative 5hmC measurements after siRNA-mediated knockdown of TET2, MBD4 and 
TDG 
Quantification of 5hmC using glycosyl transfer to 5hmC followed by glycosylation-sensitive restriction 
(GGSD) with MspI and subsequent amplification of protected regions. DNAs were also digested with 
HpaII, which is sensitive to both 5hmC and 5mC. qPCR results are shown relative to the amplification of a 
CpG-free region. Values represent mean ± SD (n=3) for control digests (MspI only), digests after glycosyl 
transfer (GT+ MspI) or digests with HpaII (average for DNAs digested before and after glycosyl transfer), 
which reflects the presence of both 5mC and 5hmC. Exact genomic positions of analyzed CpG residues 
are given in Table S2, Additional File 2 (available online, Klug et al., 2013). The MMP7 region lacks 
MspI/HpaII recognition sequences and was not analyzed. 
 
These results clearly indicated TET2 to be responsible for the conversion of 5mC to 
5hmC whereas MBD4 and TDG are not important for this conversion step. 
(Figure 3.12 and Figure 3.13 are available online (Klug et al., 2013). hMeDIP 
experiments were performed by S. Schmidhofer and M. Klug. S. Schmidhofer 
conducted GGSD experiments.) 
 
3.1.2.3 Knockdown experiments of possible factors involved in active 
DNA demethylation (Part II) 
 
So far the first step in the active DNA demethylation mechanism in differentiating 
monocytes could be unraveled and TET2 was found to be responsible for the 
conversion of 5mC to 5hmC. Since the succeeding steps of the process still remained 
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unclear we further focused on the characterization of two other possible candidate 
enzymes involved in the demethylation process in the second part of this chapter. 
 
Two recent publications presented a number of DNA readers that are able to recognize 
and physically bind to specific DNA modifications, such as 5mC, 5hmC, 5fC and 5caC 
(Iurlaro et al., 2013; Spruijt et al., 2013). The authors showed that the recognition of the 
5mC oxidation derivatives was target- and cell type-specific. A list of specific readers 
for 5hmC included several DNA glycosylases (Neil1, Neil3) as well as helicases 
(HELLS, Harp, CHD4) and we hypothesized that a direct recognition of 5hmC by 
specific readers may be initiating the final excision steps of demethylation (Klug et al., 
2013). Helicases are involved in DNA repair (Brosh, 2013) and DNA repair was shown 
to play an important role in active DNA demethylation mechanisms (Wu and Zhang, 
2014). Since HELLS was independently identified as a 5hmC reader by both studies, it 
represented a suitable candidate enzyme.  
As was outlined in the introduction, TET proteins are able to regulate transcription 
activity by the recruitment of interacting proteins, like chromatin-modifying enzymes 
(Chen et al., 2013; Deplus et al., 2013; Williams et al., 2011; Yildirim et al., 2011). One 
possible candidate is the OGT enzyme, which has previously been identified to be 
recruited by all three TET proteins (Chen et al., 2013; Deplus et al., 2013; Vella et al., 
2013). It O-GlcNAcylates TET1 post-translational and is a crucial factor for TET1 
protein stability (Shi et al., 2013). In a complex with TET proteins it is involved in 
transcriptional activation (Chen et al., 2013; Deplus et al., 2013).  
 
In order to study a potential role in the active DNA demethylation process, we used a 
siRNA-based approach to deplete OGT and Hells, respectively, in differentiating 
monocytes as described above (3.1.2.2). 
 
3.1.2.3.1 mRNA expression levels of OGT and HELLS in differentiating 
monocytes 
 
To get a first overview of the availability of OGT and HELLS we performed mRNA 
expression analysis in differentiation time courses using qRT-PCR to quantify mRNA 
levels. The results are illustrated relative to the expression of a housekeeping gene 
(HPRT1) in Figure 3.14. Both OGT and HELLS are abundantly expressed at every time 
point to similar amounts, while overall OGT is expressed at a higher level compared to 
HELLS. Although HELLS levels were considerably lower than OGT levels, both 
  Results 
35 
 
enzymes had reasonable potential to be involved in the DNA demethylation process 
and were therefore further investigated. 
 
 
Figure 3.14: OGT and HELLS are expressed in monocytes 
Quantitative expression levels of OGT and HELLS in differentiating monocytes and dendritic cells are 
shown. RT-PCR levels are shown relative to HPRT1 expression. Values are mean ± SD (n=2-4). 
 
3.1.2.3.2 Cell conditions and knockdown efficiency after siRNA transfection 
 
After 42 h transfection, cell condition was surveyed. The cells were stained with DAPI, 
CD1a and CD14 antibodies and analyzed by flow cytometry. The results are shown in 
Figure 3.15 and are similar to those shown earlier in Figure 3.7 and Figure 3.8. The 
cells were mostly viable (>97%) and untreated cells were in advanced stages of DC 
differentiation after 42 h cell culture. All cell populations treated with siRNA, displayed 
comparable numbers of cells in a monocytic state (upper left box in panels) and cells 
entering the DC differentiation pathway (upper right box in panels). Compared to the 
untreated cells (left panels) they showed a delay in differentiation kinetics. 
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Figure 3.15: Survival of siRNA transfected monocytes 
Untreated or siRNA-transfected cells after 42h were stained with DAPI, anti- CD14-Fitc and anti-CD1a-PE 
and analyzed by flow cytometry using the LSRII from BD (Heidelberg, Germany). The large majority of 
cells (>97%) was viable (lower panels) and entered the DC differentiation pathway (upper panels).  
 
On mRNA level the expression of the DC marker CD1A and of a control region CCL13 
was also found to be consistently reduced in transfected versus untreated cells 
(illustrated in Figure 3.16). This is in accordance with the flow cytometry data. 
 
 
 
Figure 3.16: Marker gene expression of siRNA transfected monocytes 
Expression of CD1a and CCL13 marker genes in differentiating monocytes after 42 h post-transfection. 
Cells were either not transfected (NOT) or transfected with OGT-, HELLS-, or control siRNA and qRT-PCR 
results were normalized to HPRT1 expression. Values represent mean ± SD (n=2). 
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The data confirmed that in contrast to untreated cells the transfection has an impact on 
differentiation, but does not alter the overall tendency towards iDC maturation and also 
cell survival was mostly unaffected.  
Figure 3.17 displays mRNA levels of the candidate enzymes after siRNA-mediated 
depletion in monocytes and differentiating cells (either transfected or untreated) relative 
to the expression of a housekeeping gene (HPRT1). OGT siRNA transfection shows 
tendencies of 43% to 65% of knockdown, whereas HELLS levels are significantly 
depleted after siRNA transfection compared to HELLS levels in cells transfected with a 
control siRNA (63% to 71% knockdown). 
 
 
Figure 3.17: Knockdown efficiency on mRNA level 
mRNA expression of candidate genes in monocytes either non-transfected (NOT) or transfected with 
OGT-, HELLS- or control siRNA was measured after 42 h of differentiation culture. qRT-PCR results were 
normalized to HPRT1 expression (n=2, values are mean ± SD, * P<0.05 Student’s T-test, paired, two-
sided). 
 
Taken together all siRNA transfection experiments achieved good knockdown 
efficiencies, while showing only minor effects on the differentiation potential of these 
cells. 
 
3.1.2.3.3 Effect of candidate knockdown on 5mC and 5hmC kinetics 
 
To test if OGT or HELLS are involved in the active demethylation process we analyzed 
the effects of siRNA transfection on methylation levels. Therefore bisulfite converted 
DNA from cells harvested 27 h or 42 h after transfection was measured by MALDI-TOF 
(MassARRAY EpiTYPER system). Methylation levels are shown for selected CpGs as 
bar charts. 
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Figure 3.18: 5mC levels after siRNA-mediated knockdown of OGT and HELLS 
MassARRAY analysis of bisulfite-converted DNA at five loci including two control regions (MMP7, HOXB1) 
is shown. Selected CpGs are presented as bar charts. Values are mean ± SD (n=2). 
 
In both OGT and HELLS-depleted cells the methylation levels are similar compared to 
control siRNA treated cells. All siRNA treated cells show delayed demethylation at the 
indicated time points, which is a result of the transfection protocol, as was observed 
earlier (see chapter 3.1.2.2.4). 
The data presented indicates that decreased levels of neither OGT nor HELLS 
influence the methylation pattern at the analyzed DMRs. As mentioned earlier, the 
MassARRAY method does not distinguish 5mC from 5hmC. To rule out 5mC detection 
problems, we measured 5hmC levels using hMeDIP at 27 h and 42 h time points and 
quantified 5hmC in the DMRs by qPCR. Figure 3.19 summarizes the results. OGT as 
well as HELLS depletion showed no 5hmC changes in any analyzed region compared 
to control siRNA treated cells. This is in line with the results for 5mC levels in those 
regions. The results indicate that neither OGT nor HELLS are involved in the 5mC to 
5hmC conversion step. However, the question if OGT and HELLS play a role in the 
removal of further demethylation intermediates (5fC, 5caC) cannot be addressed with 
this method. The MassARRAY system does not detect those modifications, which 
appear unrecognized in the C fraction. To test the involvement of OGT or HELLS in the 
excision of the modifications, for example a restriction-based efficiency assay with a 
5fC- and 5caC-sensitive enzyme can be performed. 
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Figure 3.19: 5hmC levels after siRNA-mediated knockdown of OGT and HELLS 
DNAs from transfected cells 42 h post transfection were measured with hMeDIP and the enrichment of 
selected regions and control regions was quantified using qPCR (n=2, values are mean ± SD) 
 
With the methods used, we were not able to show an involvement of OGT or HELLS in 
the active DNA demethylation process. Nevertheless other approaches may be better 
suited to identify or rule out a role of those enzymes in this process. 
 
3.1.2.4 Detection of 5fC and 5caC in differentiating monocytes 
 
In the process of active DNA demethylation, TET proteins do not only convert 5mC to 
5hmC, but in addition are also able to further oxidize those modifications to 5fC and 
5caC (He et al., 2011; Ito et al., 2011; Pfaffeneder et al., 2011). Following this, the 
resulting modifications are excised by TDG and finally replaced by cytosine via the 
BER (Cortazar et al., 2011; Cortellino et al., 2011; He et al., 2011; Maiti and Drohat, 
2011; Zhang et al., 2012b).  
The low abundance of 5fC and 5caC (Ito et al., 2011; Pfaffeneder et al., 2011) 
complicates the investigation of those intermediates in the active demethylation 
process. Common detection methods for cytosine modifications like the MassARRAY 
system are based on bisulfite conversion, and are not able to distinguish 5mC from 
5hmC or 5fC and 5caC from C. To overcome those issues, a variety of new methods 
have been published in the last three years (Lu et al., 2013; Raiber et al., 2012; Song 
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et al., 2013). One method, published by Song et al. in 2013, provided a solution for 
both issues at the same time (Song et al., 2013). Utilizing a specific, chemical 
treatment the fCAB-seq method detects 5fC at single-base resolution. In untreated 
cells the 5fC, 5caC and unmodified cytosines are converted by bisulfite treatment and 
appear indistinguishable in the C fraction. In cells treated with the chemical O-
ethylhydroxylamine (EtONH2) 5fC is selectively modified and thus protected from 
bisulfite conversion. In the readout it shifts to the 5mC fraction and can be 
distinguished by comparing untreated to treated cells. To measure 5fC in our cell 
system we adjusted this bisulfite-based method to our MassARRAY EpiTYPER system 
(fCAB-epi, see chapter 5.2.2.7.3.2). To verify the reproducibility of the adjusted method 
we designed control oligos, each containing only two unmodified CpG sites or two 
CpGs carrying specific modifications (5fC, 5caC, 5mC, 5hmC).  
Figure 3.20 shows 5mC levels of oligos untreated or treated with EtONH2 and 
measured by the MassARRAY EpiTYPER system (fCAB-epi). As expected the oligos 
containing 5mC and 5hmC modifications were detected as fully methylated, and the 
CpGs of the unmodified oligo showed no methylation at all. The untreated and 
therefore unprotected 5fC-oligo displayed ~25% of methylation, which indicated 
incomplete bisulfite conversion of the 5fC modification. Although the protocol was 
followed exactly as recommended by the authors (Song et al., 2013) the bisulfite 
conversion did not proceed to completeness. Nevertheless, after treatment with 
EtONH2 the 5fC-oligos were protected from bisulfite conversion and appeared in the 
5mC fraction.  
 
 
Figure 3.20: 5mC levels of modified and unmodified control oligos 
MassARRAY measurement (fCAB-epi) of bisulfite-converted synthetic DNA oligos containing two CpG 
sites with 5fC, 5hmC, 5mC modifications or unmodified cytosines (unmodified oligo). The bar chart 
illustrates averaged DNA methylation (5mC+5hmC) of two CpGs in each oligo with (dark blue bars) or 
without (light blue bars) fCAB treatment. Values are ± SD (n=2). 
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In the experiments presented in Figure 3.21A we measured a region showing early, 
active DNA demethylation in a time course of differentiating monocytes. The DNAs 
were treated with the fCAB method or left untreated before bisulfite conversion and 
MassARRAY analyses. The results show a small increase of the methylation levels in 
the fCAB-treated samples accounting for 5mC, 5hmC and in contrast to the untreated 
samples also 5fC. To check if the finding was reproducible we analyzed DNA of 
differentiating monocytes 42 h after TDG depletion. TDG is responsible for excision of 
5fC at regions harboring this intermediate during demethylation, and a depletion of this 
enzyme results in the accumulation of 5fC (Shen et al., 2013; Song et al., 2013). 
Therefore, it is easier to detect 5fC in samples deprived of this glycosylase. Figure 
3.21B illustrates 5mC and 5hmC levels of two actively demethylated regions measured 
with or without chemical 5fC protection (+/- fCAB treatment). Both regions showed 
inconsistent methylation levels which is probably due to technical variation. The level of 
variation was similar to expected changes resulting from the scarce modification 5fC, 
indicating that the method has to be further adjusted to be able to detect the expected 
low levels of 5fC. First of all, since 5fC is only present at low abundances the bisulfite 
conversion efficiency has to be optimized to be able to detect any changes at a high 
resolution. Furthermore the data presented resulted from pioneering experiments in 
DNA from only one donor. Thus it is necessary to repeat those experiments to confirm 
the results. (Due to exhaustion of TDG-depleted DNA samples we didn’t have enough 
material to repeat the experiments.) 
 
 
Figure 3.21: 5fC detection in differentiating monocytes 
MassARRAY analysis (fCAB-epi) of bisulfite-converted DNA from differentiating monocytes is shown in a 
time course (A) or after 42 TDG siRNA transfection (B). 5mC and 5hmC levels of DNA with (dark blue) or 
without (light blue) fCAB treatment are depicted as bar charts (n=1). 
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3.2 Functional characterization of active DNA 
demethylation at DMRs 
 
Using ChIP-seq data of several hematopoietic cell types our group recently identified 
several promoter-distal DMRs in the myeloid lineage which are associated with cell 
type specific transcription factor binding, e.g. PU.1. Corresponding DNA methylation 
profiles in the DMRs showed a direct correlation between demethylation processes and 
local binding of major hematopoietic transcription factors. Both events co-occurred at 
the same stages of macrophage differentiation (Pham et al., 2013). The synchronous 
appearance of the enhancer mark H3K4me1 at those regions indicated a possible 
enhancer function and led to the hypothesis that methylation levels regulate the usage 
of those elements. In this context the master transcription factor PU.1 seems to be 
necessary for demethylation of those cell type specific elements and thus facilitates the 
accession for further proteins (Pham et al., 2013).  
In order to characterize the DMRs functionally and to test a possible link between 
function, methylation, and cell type specific TFs further experiments were performed 
and are presented in the following chapters. 
 
3.2.1 Reporter Assay reveals enhancer function of 
DMRs 
 
To test the ability of those promoter-distal regions to enhance the activity of a promoter 
we performed luciferase reporter assays. This method is a common tool to study the 
regulatory capacity of DNA elements to activate promoter activity in a heterologous 
context. In brief, the regions of interest are arranged on a plasmid upstream of a basal 
heterologous promoter EF1α and a luciferase gene. This plasmid is transfected into the 
cells of interest and the expression of the luciferase gene is analyzed. Our group 
developed a reporter vector that lacks CpG dinucleotides (Klug and Rehli, 2006), which 
we used to design reporter plasmids containing the DMRs of interest. Since previous 
results hint at a methylation dependent activity we constructed and tested both in vitro 
SssI-methylated and unmethylated reporter plasmids. Two control-constructs, 
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containing the basal EF1α promoter (pCpGL-EF1) or both the EF1α promoter and CMV 
enhancer (pCpGL-cmv) were used as negative and positive control. 
 
3.2.1.1 Reporter plasmid activity in THP-1 and HeLa cells 
 
For the transfection experiments we chose the human myeloid cell line THP-1 to test 
the possible enhancer activity of the DMRs in a heterologous MO and MAK context.  
Since monocytes are fragile and prone to in-vitro stimulation due to their sensitive 
immune cell nature they are difficult to transfect and suffer from severe impairment by 
the transfection. On the other hand the THP-1 cell line does not only share a human, 
myeloid background but is also easy to transfect at sufficient quantities. Furthermore, 
stimulation of THP-1 with PMA (phorbol 12-myristate 13-acetate) drives the cells into a 
monocyte- and macrophage-like phenotype where the cells become adherent and stop 
proliferation (Abrink et al., 1994; Tsuchiya et al., 1982). Thus questions regarding 
enhancer activity in MO and MAK can be addressed in this cell system. 
 
THP-1 cells were transfected and luciferase activities were measured as described 
above. Normalized levels of luciferase measurements from three independent 
experiments are depicted as green bars in Figure 3.22. Of all tested constructs only 
one (ADAP1) showed significantly enhanced activation of the basal promoter 
compared to the promoter alone (significant elevation of luciferase levels compared to 
the basal vector pCpGL-EF1 is not shown in this figure). The lack of significance in 
other constructs may be caused by considerable luciferase level variation between 
experiments. Since the mean over all experiments is used to calculate the statistics, 
visible differences in single experiments are likely to be masked by the deviation. We 
therefore also considered constructs which showed significant enhancer activation 
compared to the basal vector in 2 out of 3 single experiments. In this case two 
additional regions (PIM3, CACNA1C) fulfilled this criterion.  
On average (shown in the left panel) the enhancer activity significantly decreased in 
two regions (ADAP1, PIM3), when plasmids were methylated before transfection. One 
methylated construct (ADAP1) still showed significant luciferase activity compared to 
the basal vector pCpGL-EF1, indicating that methylation influences the activity level of 
the construct but does not suffice to completely abolish reporter activity. The PIM3 
construct lost the ability to enhance the basal EF1α promoter when methylated, 
indicating that its enhancer activity is dependent on the CpG methylation status. 
Methylation of the CACNA1C construct did not alter its potential to enhance the activity 
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of the basal promoter, indicating either a methylation-independent activity or the 
disposal of the mark by enzymes present in the THP1-cells. 
In the right panel the averaged activity of the methylated constructs compared to the 
corresponding, unmethylated constructs is shown. The illustration confirms the results 
shown in the left panel. It displays a significantly reduced enhancer activity for both, 
ADAP1 and PIM3 (but not CACNA1C) in the presence of methylation relative to the 
unmethylated construct. 
 
 
Figure 3.22: Enhancer activity in DMRs 
Eight DMRs were cloned upstream of a basic EF1-promoter into the CpG-free luciferase vector pCpGL. 
The indicated plasmids were in vitro Sssl-methylated (mCpG, light colors) or unmethylated (CpG, dark 
colors) and transiently transfected into THP-1 (green bars, n=3, mean values are ± SD, biological 
replicates) or HeLa cells (purple bars, n=1, mean ± SD of 3 technical replicates). Luciferase activity was 
normalized against the activity of a cotransfected Renilla construct and values ± SD are shown (left panel) 
relative to the unmethylated pCpGL-EF1 construct. Asterisks indicate significant difference between 
methylated and unmethylated plasmids (P < 0.05, paired Student’s t-test). The right panel shows 
averaged, relative activity of methylated compared to the unmethylated constructs (100%) in percent. Only 
plasmids which displayed significant activity compared to the basal vector in at least 2 out of 3 single 
experiments are shown. Values are mean ± SD, (n=3, P<0.05 Student’s paired T-test). Significance 
between constructs and basal vector pCpGL-EF1 is not shown in this figure. 
 
The results above identified three regions with potential enhancer function in reporter 
assays, in the THP-1 cell line. 
Based on first analyses of the DMRs (Pham et al., 2013) our group proposed that 
demethylation at promoter-distal elements as well as enhancer usage may be cell type 
specific. In addition the published results suggested a cell type-specific role of TFs in 
the correct utilization of relevant genomic elements.  
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To check if a transcription factor set resembling a monocyte- and macrophage 
phenotype is able to activate a different set of our constructs we differentiated THP-1 
cells with PMA as described in section (5.2.1.2.1.1) and repeated the reporter assays.  
 
The results are displayed in Figure 3.23 and show by trend elevated basal promoter 
activation, compared to the EF1α promoter alone, for four regions (RSRC1, TSSC1, 
CACNA1C, LINC00111). Except for the positive control vector, none of these 
observations were significant. Due to variable luciferase levels between the 
experiments we calculated the statistics within the single experiments. All four regions 
were able to significantly activate the basal promoter, compared to the promoter alone, 
in every single experiment. One additional region (PIM3), which showed enhancer 
activity in 2 out of 3 experiments, was also included. Methylation of plasmids prior to 
transfection had no significant impact on enhancing properties in the experiment 
average when compared to corresponding unmethylated constructs. Single 
experiments, though, displayed visible reduction of activity in methylated compared to 
unmethylated constructs. This finding is further supported by an illustration of 
methylated construct activities shown relative to the activity of unmethylated regions in 
the right panel of Figure 3.23. All five regions depicted in the chart show significantly 
reduced reporter activity when methylated prior to transfection.  
This way of illustrating the results relative to their reference construct is independent of 
technical variation between the experiments. It confirmed that the averaged values 
calculated for the experiments are actually biased by method deviation. It further 
supported the finding that in both experiments different regions showed their enhancer 
potential depending on the cell context. In the case of CACNA1C the different results in 
regard to the methylation sensitivity of the region hint at a cell type-specific removal of 
the methylation, which is also dependent on cell type-specific conditions.  
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Figure 3.23: Enhancer activity in DMRs in the presence of PMA 
Eight DMRs were cloned upstream of a basic EF1α-promoter into the CpG-free luciferase vector pCpGL. 
The indicated plasmids were in vitro Sssl-methylated (mCpG, light colors) or unmethylated (CpG, dark 
colors) and transiently transfected into THP-1 (green bars, n=3) that were stimulated with PMA 12h after 
transfection or HeLa cells (purple bars, n=1). Luciferase activity was normalized against the activity of a 
cotransfected Renilla construct and mean values ± SD of 3 biological replicates (THP-1) and 3 technical 
replicates (HeLa) are shown relative to the unmethylated pCpGL-EF1 construct. Significance between 
constructs and basal vector pCpGL-EF1 is not shown. 
 
Taken together these results suggest a cell type specific opening and activation of 
regulatory promoter-distal elements. This led to the question if TFs present in the cells 
play a role in activation of those regions. Since most regions featured PU.1 binding 
closely located to the DMRs (Pham et al., 2013) we repeated the experiments in a non-
hematopoietic human cell line (HeLa, derived from cervical cancer cells) expressing no 
endogenous PU.1 (Kwon et al., 2005). 
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The results are presented in Figure 3.22 (and in Figure 3.23) and show no significant 
activation of the basal promoter EF1α by any of the constructs except for the positive 
control pCpGL-cmv. This finding is in line with the hypothesis that only a cell type-
specific repertoire of TF is able to activate distal regulatory elements (Heinz et al., 
2010; Pham et al., 2012) and further discussed in chapter (4.1). 
 
3.2.2 Active demethylation in differentiating MAK 
 
To study a general causal connection between active demethylation and cell type 
specificity in promoter-distal regions we first measured methylation levels of additional 
time points in differentiating monocytes at previously defined sites of DNA 
demethylation. The cells were cultured under appropriate conditions to obtain iDC or 
MAC, respectively. DNAs were bisulfite converted and quantified using the 
MassARRAY system (Sequenom). Results of four representative regions are shown as 
histograms (blue squares) (in Figure 3.24) displaying methylation level time courses of 
one representative CpG each. The figure clearly shows a subsequent loss of DNA 
methylation in all indicated CpG dinucleotides during the differentiation into MAK which 
is in line with previous findings (Pham et al., 2013).  
The demethylation of those regions was not restricted to macrophages but also visible 
in differentiating iDC. Two DMRs, ACP2, and RSRC1, displayed an equal 
demethylation pace whereas three out of six regions showed delayed demethylation 
compared to MAK.  
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Figure 3.24: 5mC deposition precedes active DNA demethylation in differentiating monocytes 
Dynamics of DNA methylation (5mC+5hmC) and 5-hydroxymethylation (5hmC) during monocyte 
differentiation. DNA methylation levels of single CpGs as measured by MassARRAY (blue squares, n≥4) 
are compared with 5hmC enrichment (measured by hMeDIP, red squares, n=2) at four DMRs (values are 
mean + or – SD).  
 
The progressive loss of DNA methylation led to further investigation of the 
demethylation process. In order to verify an active process in those regions we studied 
the appearance of 5hmC at the indicated loci using hMeDIP. Four DMRs were 
quantified using qPCR and compared to methylation levels of single CpG dinucleotides 
measured by mass spectrometry. The results are displayed as red squares in the same 
Figure 3.24. 
In differentiating MAK the experiments clearly show an increase in 5hmC levels in all 
tested regions, which is in line with the corresponding MassARRAY result. Whenever 
5mC levels decrease 5hmC is present at the same locus. The appearance and 
removal of 5hmC was simultaneous to 5mC depletion in all DMRs.  
 
The dendritic cells displayed similar patterns of loss of 5mC and simultaneous gain of 
5-hydroxymethylation in five out of 6 regions. With three of them showing decelerated 
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demethylation kinetics compared to the same loci in macrophages although 5hmC 
levels increased likewise.  
In order to validate the 5hmC detection and to rule out density bias of the antibody-
based method we performed a chemical labeling-based method (GGSD) in one of the 
regions (only one PCR primer pair covered a MspI site necessary for restriction digest, 
region TSSC1). Adequate amounts of 5hmC were detected by qPCR quantification 
(results not shown). This finding reduced the probability of antibody-based bias of the 
method (at least in this region). Furthermore it hinted at a constant rate of 5mC to 
5hmC conversion, with slow excision kinetics at those regions, which can’t be detected 
using the MassARRAY method.  
In one of the tested DMRs we did not detect 5hmC levels relative to the background 
signal despite reduced 5mC levels (data not shown). Further investigation will be 
necessary to determine if high 5hmC turnover or other demethylation mechanisms are 
involved.  
 
3.3 Global 5hmC and PU.1 distribution in 
differentiating monocytes 
 
With the data presented so far we were able to confirm a functional link between cell-
type specific TF binding and local demethylation events. These findings support the 
idea that PU.1 and other TFs are directly involved in the demethylation process (de la 
Rica et al., 2013; Pham et al., 2013; Stadler et al., 2011). PU.1 is a key regulator of the 
hematopoietic compartment and responsible for the development of lymphoid and 
myeloid lineages (Friedman, 2007). In cooperation with other interaction partners and 
TFs it modifies surrounding chromatin structure and regulates transcription activity (for 
a review see Burda et al., 2010; Kihara-Negishi et al., 2001) 
To investigate active demethylation and its association with master TFs on a global 
scale we performed whole genome sequencing of the first intermediate of active 
demethylation, 5hmC, and the master transcription factor PU.1. 
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3.3.1 Comparison of two whole genome 5hmC-
enrichment methods 
 
Global analysis of 5hmC can be performed using a variety of different methods 
available as published methods or as complete kits for purchase. The techniques 
range from pull-down methods, which are antibody- or chemical labeling-based to 
single-base resolution approaches.  
For our purpose we chose to test and compare an antibody-based method hMeDIP 
and the Hydroxymethyl CollectorTM kit, a chemical labeling-based method available 
from ActiveMotif. The protocols were adjusted to the next generation library preparation 
protocol established in our laboratory (5.2.2.7.2.3, 5.2.2.7.2.4). Sequencing was 
performed (as described in 5.2.2.9, 5.2.2.10) on several time points of differentiating 
monocytes and analyzed as described in chapter 5.2.5. 
 
 
3.3.1.1 Validation of two different 5hmC-enrichment methods 
 
To compare pull-down efficiencies of the two methods, two time points of differentiating 
monocytes of one donor were subjected to 5hmC-specific pull-down. The reads 
obtained from the library preparations were individually aligned to the hg19 reference 
genome. For each time point (MO and iDC) peaks were defined and all peaks obtained 
from both methods at one time point were combined. To estimate the pull-down 
efficiency, the individual read (tag) coverage at the defined peaks was estimated and 
compared in the scatterplots depicted in Figure 3.25. The low Pearson correlation 
coefficients (r) of r=-0.26 (MO) and r=-0.07 (iDC) suggest no correlation between the 
5hmC tag count sets enriched by each IP method.  
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Figure 3.25: Global distribution of 5hmC tags by two different IP methods 
Scatterplot representation of 5hmC tag counts from two IP methods, hMeDIP-seq (antibody-based) and 
Hydroxymethyl Collector
TM
-seq (chemical labeling-based).Tag counts of peaks are compared between 
different time points of differentiating monocytes (MO: left panel, iDC: right panel). The colors represent 
the distribution of log2-transformed tag counts of all peaks found at the indicated time points (blue, orange 
and red represent low, medium and high values). The Pearson correlation coefficients (r) are based on 
log2-transformed values. 
 
To validate the diverging 5hmC peak sets enriched by both methods we performed 
5hmC-sensitive restriction digests (GGSD, 5.2.2.7.2.1) as an alternative 5hmC 
detection method.  
We chose several peak regions detected uniquely by each of the methods and 
analyzed 5hmC levels in DNA samples from the same donor and differentiation time 
course used for sequencing. Figure 3.26 shows the result of six representative regions 
measured with the alternative 5hmC detection method. In the left panel unique regions 
enriched by the Hydroxymethyl CollectorTM kit are presented. All four tested regions 
showed rising levels of 5hmC during the time course depicted in two exemplary regions 
in this figure.  
5hmC in hMeDIP-seq specific peak regions (displayed in the center panels) could only 
be reproduced in one out of three tested regions (two of them shown in this figure). The 
two regions on the right hand side represent a positive control region (USP20) and one 
region, which is methylated during DC differentiation and serves as a negative control 
(HOXB1).  
 
  Results 
52 
 
 
Figure 3.26: Validation of 5hmC measurements in differentiating DCs 
Quantification of 5hmC using glycosyl transfer to 5hmC followed by glycosylation-sensitive restriction 
(GGSD) with MspI and subsequent amplification of protected regions in differentiating monocytes. qPCR 
results are shown for control digests (background, green bars) or digests after glycosyl transfer (5hmC, 
blue bars) relative to the amplification of a CpG-free region (n=1).  
 
In summary, only results produced by the chemical labeling-based method were 
reproducible with another method.  
We further analyzed the reproducibility between technical and biological replicates 
obtained with the Hydroxymethyl CollectorTM kit. The comparison of the replicates is 
presented in Figure 3.27. In (A) a technical replicate of the same time point is shown 
and both replicates are compared to biological replicates in (B). The Pearson 
coefficients indicate a good correlation between biological and technical replicates and 
confirm a stable reproducibility of the method. The higher r value (r=0.80) for the 
comparison of donor 1 (technical replicate 2) and donor 2 may be explained by 
technical variation. Samples were produced in one batch, suggesting that replicates of 
this method are more reproducible when generated in the same experiment. It has to 
be noted, that the differences between the two batches may also be resulting from 
protocol alterations. One component (the Biotin Conjugate Solution) was used at 
unknown concentrations in the procedure (in the second batch) and thus the incubation 
time had to be prolonged. Although subsequent qPCR analyses showed equal 
enrichment efficiencies for a control region compared to the first batch, interference 
with the results cannot be ruled out. Further replicates are necessary to clarify the 
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issue. Biological replicates are compared in (Figure 3.27C) and corresponding Pearson 
coefficients (DC18h, r=0.73 and DC 168h, r=0.77) confirm good correlation between 
the samples and stable reproducibility of the method. 
 
 
Figure 3.27: Global distribution of 5hmC tags in replicates 
Scatterplot comparison of 5hmC tag counts covered by Hydroxymethyl Collector
TM
-seq (chemical labeling-
based method) of two independent experiments (donor1, 2).Tag counts of peaks are compared between 
technical replicates (A), biological and technical replicates (B) and biological replicates (C) of several time 
points of differentiating monocytes. The colors represent the distribution of log2-transformed tag counts of 
all peaks in the indicated time points (blue, orange and red represent low, medium and high values). The 
Pearson correlation coefficients (r) are based on log2-transformed values. 
 
In summary the glycosyl-sensitive restriction digest experiments validated the 
Hydroxymethyl CollectorTM method, which is characterized by high levels of 
reproducibility. Thus the Hydroxymethyl CollectorTM method was used for the 
subsequent whole genome 5hmC analyses.  
 
3.3.2 Global genome analysis of 5hmC 
3.3.2.1 Genome-wide 5hmC dynamics in DC differentiation 
 
To get a global picture of 5hmC dynamics, a complete peak file of time point-specific 
5hmC peaks from two biological replicates (donor 1 and 2) was generated (5.2.5.2). 
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The significantly enriched differential peaks (11909 peaks) were clustered using the k-
means method and grouped into four subsets. All peaks were evenly distributed among 
the clusters with around 2200-3300 peaks in each subset.  
For each time point the averaged tag coverage was either visualized as heatmaps of 
genomic distance distributions (sorted by decreasing tag counts) or as histograms for 
the separate clusters and is shown in Figure 3.28. In addition to 5hmC peaks, 
corresponding PU.1 ChIP-seq tag coverage is presented in the same figures. 
Figure 3.28A displays heatmaps of both 5hmC and PU.1 for three time points of DC 
differentiation separated into the four clusters estimated by k-means clustering. In the 
left part of the figure two cluster sets (#2=2597 peaks and #4=2231 peaks) show a high 
5hmC enrichment in monocytes which decreases during DC differentiation (in cluster 
#4 to a higher degree than cluster #2). Corresponding PU.1 levels (right part of figure) 
display scattered patterns of binding in the surrounding 1 kb area which become more 
distinct upon transition to DC concentrating at the 5hmC peak center. Irregular 
distributions of 5hmC peaks complicate the mapping of PU.1 in their vicinity, which 
may in part explain the finding. Later analyses of 5hmC in the surrounding of well-
defined PU.1 peaks are much more informative (see chapter 3.3.3.1). At least in cluster 
#4, PU.1 is present in the areas of 5hmC enrichment, indicating a connection between 
the two features. In contrast to clusters #2 and #4, cluster #1 (3692 peaks) and #3 
(3389 peaks) both gain 5hmC upon differentiation into dendritic cells. PU.1 tag counts 
are almost absent in monocytes and gain only low amounts with no distinct distribution 
pattern over time. The same data is visualized for each cluster as histograms in Figure 
3.28B showing tag coverage of 5hmC and of PU.1 ChIP-seq. In concordance with the 
results from Figure 3.28A the progressive depletion of 5hmC upon transition into DCs, 
in cluster #2 and #4, is also visible in the corresponding histograms. In cluster #4, PU.1 
tags seem to accumulate in the 5hmC peak center region at the 18h time point (DC 
18h) and decrease with further differentiation. The overall PU.1 levels in cluster #2 are 
also elevated at DC18h but show no peak in the center regions. In contrast, monocytes 
leave a small dip in the center region with low levels of PU.1 at the shores of 5hmC 
peaks. For cluster #1 and #3, 5hmC dynamics are also visible in the left panels of the 
histograms but again no distinct PU.1 binding patterns could be observed.  
These results revealed different 5hmC dynamics in pairs of two clusters (#2/ #4 and 
#1/ #3) and represent events of active demethylation in cluster #2/#4, at least. In order 
to confirm if 5hmC levels are associated with demethylation events in the peak cluster 
sets, 5hmC peaks of each cluster were annotated with CpG methylation data, obtained 
from bisulfite-sequencing of MO and DC at day 7 (see chapter 5.2.5.9.2 for details). 
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Since bisulfite treatment does not distinguish between 5mC and 5hmC, the indicated 
methylation levels account for a combination of 5mC and 5hmC levels.  
The four methylation histograms presented in Figure 3.28C show similar 5mC patterns 
in cluster set #2/ #4 and #1/ #3. Cluster #2 and #4 both display a major reduction of 
5mC upon DC differentiation most prominent at the center of 5hmC peaks. In 
combination with the observed local loss of 5hmC (Figure 3.28A) the decrease in 5mC 
levels most likely represents DNA demethylation events at 5hmC peaks in those 
clusters. In contrast, cluster #1 and #3 only depict a moderate overall reduction of 
methylation during monocyte differentiation without local demethylation in the peak 
center. 
 
 
Figure 3.28: 5hmC peak dynamics and corresponding PU.1 and 5mC levels 
5hmC peaks were clustered according to their Hydroxymethyl Collector
TM
-seq profiles. Tag counts of two 
biological replicates were combined and annotated to associated 5hmC peaks. The genomic distance 
distribution of corresponding 5hmC tag counts of two biological replicates (combined, left panel) or PU.1 
ChIP-seq tags (right panel) of several time points of differentiating monocytes are shown in heatmaps (A) 
or histograms (B) (regions 1 kb) relative to the peak center. (C) Histograms of methylation levels as 
assessed by bisulfite sequencing of differentiating monocytes (MO n=4, DC n=6). 5mC and 5hmC levels of 
all valid CpGs in 1kb regions of the indicated cluster sets in are shown in % of methylation relative to 
5hmC peak centers. 
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Since bisulfite data, presented in Figure 3.28C, were generated in different 
laboratories, the observed methylation changes may be resulting from technical 
variation. To check if the demethylation events were specific for the 5hmC peak set we 
compared it to 5mC distribution in a set of 7899 random peaks (for details see chapter 
5.2.5.3) illustrated in Figure 3.29. In A and B the genomic distance distribution of 5hmC 
and PU.1, respectively, is shown as heatmaps or histograms. As expected neither 
5hmC nor PU.1 were enriched on a global level in differentiating monocytes. This 
finding supports the previous findings of 5hmC specific PU.1 accumulation in the 5hmC 
peak set. In Figure 3.29C methylation levels of MO and DC (at day 7) in the proximity 
of random peaks are shown in a histogram. The methylation dynamics in this figure are 
similar to the changes observed in the 5hmC specific peak set. This finding indicates 
that the overall loss of methylation during monocyte differentiation observed in the four 
5hmC peak subsets is not a specific feature of 5hmC peaks but a global phenomenon 
based on methodical diversity. Nevertheless, the prominent loss of 5mC in the center 
of 5hmC peaks, observed in cluster #2/#4, can only be in part explained by a global 
loss of 5mC altogether and does account for demethylation events present at the 
peaks in those subsets. 
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Figure 3.29: Global 5hmC, PU.1 and 5mC distributions 
A set of random peaks was annotated with corresponding PU.1 ChIP-seq (A) or 5hmC tag counts 
(Hydroxymethyl Collector
TM
-seq) (B) and is shown as heatmaps of genomic distance distributions or 
histograms in a 1 kb genomic region relative to the peak centers. (C) Histogram of methylation levels 
obtained by bisulfite sequencing at random peaks in differentiating monocytes (MO n=4, DC n=6). 5mC 
and 5hmC levels of all valid CpGs across a 1 kb genomic interval of the indicated random peak set (A, B) 
are shown in % of methylation relative to peak centers. 
 
Taken together the results show different 5hmC- as well as corresponding PU.1- and 
5mC dynamics in the four clusters. In the next chapter the functions of the cluster sets 
were analyzed and compared.  
 
3.3.2.2 Gene ontology analysis of 5hmC peak cluster sets 
 
To further characterize the biological functions of regions present in the different 5hmC 
clusters (Figure 3.28), the peak sets were subjected to gene ontology analyses using 
the Homer GO analysis tool (described in chapter 5.2.5.4).  
Figure 3.30 lists significantly enriched gene ontology (GO) terms related to biological 
processes. The top 38 terms enriched in at least one of the four cluster sets (Figure 
3.30A) are shown as heatmaps of log2 transformed GO term fold enrichment (GFE) 
with the corresponding generic terms and GO accession numbers.  
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The major fraction of enriched GO terms is related to immunological processes, which 
is in line with known roles of monocytes and dendritic cells. As members of the immune 
system they are enriched for GO terms corresponding to immune response and 
inflammation. DCs are involved in T cell activation, whereas endocytosis and wound 
healing are important functions of monocytes (Martin, 1997). A minor fraction of 
enriched GO terms is involved in cell signaling and hemostasis. Most terms listed in (A) 
were enriched in Cluster #2 and #4 only. Since the top GO terms did not contain any 
terms uniquely enriched in set #1/#3, only a selection of uniquely enriched terms in 
cluster #2/#4 is presented in Figure 3.30B. Unique terms of set #2/#4 are exclusively 
enriched for terms related to immune response and for one term involved in 
hemostasis. The observed local demethylation in the sets indicates selective opening 
and activation of important, cell type-relevant genes via active demethylation. 
 
 
Figure 3.30: 5hmC peak cluster-based GO and pathway analyses 
Heatmaps (log2 scale) of fold enrichment values for GO terms related to biological processes. Fold 
enrichment for GO terms was calculated for cluster-specific gene sets using the Homer tool. And log2 
transformed values for each term were analyzed using the hypergeometric test and corrected for multiple 
hypothesis testing using the Benjamini-Hochberg method. Term enrichment values are indicated by color 
code intensity (blue=depletion, red=enrichment). Generic terms and GO accession number are given for 
the top 38 enriched terms of all cluster-specific sets (A) and a selection of GO terms enriched uniquely in 
cluster set #2 and #4 is shown in (B). 
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3.3.2.3 mRNA expression profiles in 5hmC peak cluster sets 
 
Several groups have shown a direct link between active DNA demethylation and gene 
expression levels in several cell types (Mellen et al., 2012; Szulwach et al., 2011; Wu 
et al., 2011a). In differentiating monocytes the loss of DNA methylation at DMRs 
coincides with activated chromatin and leads to gene activation in approximately 50% 
of the cases, including the CCL13 promoter region (Klug et al., 2010). The remaining 
50% of the tested regions did not show altered mRNA expression, thus no global 
correlation between demethylation and transcription levels could be detected. 
To test whether the observed individual 5hmC cluster demethylation dynamics are 
linked to expression levels, the peak sets (cluster #1-#4) were annotated (see section 
5.2.5.5) with mRNA expression data obtained by whole genome microarray analyses of 
monocyte differentiation time courses (Klug et al., 2010). For each time point-specific 
5hmC peak, expression levels of the closest gene were annotated. The results are 
displayed as boxplots in Figure 3.31. In line with previous observations similar patterns 
were observed for cluster #1 and #3 as well as for #2 and #4. Cluster #1 and #3 
showed a significant increase of gene expression at cluster-specific peaks upon 
differentiation of MO into DC. Cluster #2 and #4 display a significant reduction in 
transcription levels upon differentiation initiation. In summary the observed cluster-
specific expression patterns indicate an expression-dependent clustering. 
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Figure 3.31: Gene expression level dynamics during monocyte to dendritic cell differentiation 
Box plots showing the distribution of median-normalized mRNA expression levels for genes closest to 
differentiation time point-specific 5hmC peak regions. Box frames display the interquartile ranges (25%-
75%) with an intersection representing the median; whiskers extend to the data extremes; outliers are not 
shown. The base line is plotted in red. Asterisks indicate significant difference of mRNA expression levels 
for MO compared to DC time points (**P < 0.01 and ***P < 0.001, Mann-Whitney-U test). Only significant 
differences upon transition of MO to DC and compared to differentiated iDC are shown. 
 
3.3.3 Global analysis of PU.1 distribution 
 
3.3.3.1 Genome-wide PU.1 distribution analyses of differentiating 
monocytes 
 
To get further insights into global PU.1 binding dynamics a set of all differential, time 
point-specific PU.1 ChIP-seq peaks (16208 peaks) was further analyzed (5.2.5.6). 
Performing k-means clustering on the PU.1 peak set resulted in 6 clusters of different 
sizes. Illustrated as heatmaps of genomic distance distributions in Figure 3.32A two 
clusters, #4 and #6 (#4=3227 peaks, #6=3237 peaks), show a steady loss of PU.1 
peaks in the progress of differentiation. In contrast, a constant gain of PU.1 binding 
during monocyte differentiation is visible in peaks of the remaining clusters. Regions at 
the MO time point in cluster #5 (1773 peaks) almost completely lack PU.1 binding at 
these sites but display a similar amount of PU.1 enrichment on day 7 of the time 
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course. The differences in pace and quantity of PU.1 binding dynamics is even more 
obvious in histograms of the same data (Figure 3.32B, left panels). Regions in cluster 
#3 and #2 (#3=3124 peaks, #2=2534 peaks) accumulate PU.1 binding much faster 
than regions in cluster #1 (2313 peaks). Whereas cluster #3 and #1 enrich more PU.1 
until DC day 7, PU.1 binding at regions in cluster #2 decreases from after 18h of 
differentiation. These findings indicate different PU.1 binding dynamics at regions of 
the different cluster sets. 
Among others, our group observed PU.1 binding events at differentiation time point-
specific DMRs and suggested that local binding of sequence specific TFs is involved in 
active DNA demethylation processes in differentiating macrophages (Pham et al., 
2013). To check if PU.1 involvement was associated with active DNA demethylation 
events in differentiating DC, we compared the localization of 5hmC around PU.1 
binding sites. Therefore we annotated the individual PU.1 cluster sets with 5hmC tag 
counts obtained from whole genome sequencing (see chapter 5.2.5.6). The results are 
illustrated in Figure 3.32A (heatmaps) and Figure 3.32B (histograms). Clusters 
characterized by progressive loss of PU.1 binding (#4, #6) showed a constant 
depletion of 5hmC at the center of PU.1 binding sites. In contrast, in clusters with 
increasing PU.1 binding during monocyte differentiation, 5hmC accumulates in the 
direct proximity of PU.1 binding sites and shifts from the center to the shores of PU.1 
binding in DCs at day 7 of differentiation. In cluster #5, 5hmC accumulation precedes 
the appearance of PU.1 at the regions in this set. This finding hints at a distinct 
chronology of PU.1 and 5hmC accumulation in, at least, one subset of the peaks.  
PU.1 binding events, in all clusters of PU.1 accumulation during the time course, seem 
to be correlated to 5hmC appearance supporting the theory of a connection between 
PU.1 binding and active DNA demethylation events. Based on this assumption, cluster 
#4 and #6 may represent regions at later stages of the demethylation process, where 
PU.1 is not needed anymore and removed. To test this hypothesis CpG methylation in 
the area surrounding PU.1 binding sites was analyzed. Again, individual PU.1 binding 
clusters were annotated with 5mC tag counts obtained from whole genome bisulfite 
sequencing (data processing described in 5.2.5.9.2) and plotted in Figure 3.32C. In all 
clusters an overall reduction of CpG methylation was observed. This is in line with 
earlier findings of a global reduced level of methylation levels due to method 
discrepancies. However, the depletion of 5mC in the direct vicinity of the PU.1 peak 
center of differentiating monocytes cannot be entirely explained by technical 
differences. In cluster #4 and #6, 5mC levels in the peak center were already depleted 
in monocytes and the levels did not change during differentiation. This finding indicates 
that the demethylation process in the PU.1 peak centers is completed. The remaining 
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clusters show a 5mC reduction in the proximity of PU.1 binding in monocytes. 5mC 
further decreases in the center regions with progression of demethylation. In regions of 
cluster #5, which are devoid of PU.1 in monocytes, 5mC levels are reduced but to a 
lesser extent than in clusters marked by PU.1 binding in monocytes. Taken together 
PU.1 dynamics seem to be linked to 5hmC in differentiating monocytes. 
 
 
Figure 3.32: PU.1 binding dynamics and corresponding 5hmC and 5mC levels 
PU.1 peaks were clustered according to their dynamic binding profile in differentiating monocytes. 
Genomic tag count distance distribution of PU.1 ChIP-seq (left panel) and Hydroxymethyl Collector
TM
-seq 
tags (right panel) of several differentiation time points are shown in heatmaps (A) or histograms (B) across 
a 1 kb genomic interval relative to the transcription factor peak center. (C) Histograms of methylation levels 
assessed by bisulfite sequencing at PU.1 binding sites of differentiating monocytes (MO n=4, DC n=6). 
5mC and 5hmC levels of all valid CpGs in 1kb regions of the indicated PU.1 cluster sets in (A) is shown in 
% of methylation relative to peak centers. 
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3.3.3.2 PU.1 binding dynamics at promoter elements 
 
So far PU.1 binding has been investigated in several human and murine tissues 
(Ghisletti et al., 2010; Heinz et al., 2010; Pham et al., 2012; Ridinger-Saison et al., 
2012; Wilson et al., 2010; Wontakal et al., 2011; Zhang et al., 2012a) and was found to 
be associated with promoters and enhancers where it is regulating gene expression 
(Kihara-Negishi et al., 2001). To assess a possible link of PU.1 binding and 
transcription levels in our cell system we sorted an existing set or promoter regions 
produced by the FANTOM consortium (Consortium et al., 2014) for actively transcribed 
promoters and compared it to local PU.1 ChIP-seq and Hydroxymethyl CollectorTM-seq 
tag counts from our own analyses (details in chapter 5.2.5.7 and 5.2.5.9.3). 
 
3.3.3.2.1 PU.1 binding dynamics in the context of gene transcription 
 
The genomic PU.1 tag distance distribution for two sets of actively transcribed 
promoters (MO- and DC-specific) is shown as heatmaps in Figure 3.33A (left panels) 
and as histograms in Figure 3.33B (left panels). In monocytes, the number of promoter 
regions (5882) is more than twice as high as the number of DC promoter regions 
(2666). The majority of these promoters are associated with PU.1 accumulation. This 
finding confirms a link between PU.1 binding and active promoter usage. However a 
small set of MO-specific (and also DC-specific) promoters lack PU.1. CpG density 
coverage (illustrated in the right panel of Figure 3.33A) indicates that those peaks 
mainly represent CpG-rich promoter regions or CpG islands (CGI), which are generally 
devoid of this TF. In both promoter sets, PU.1 enrichment is slightly shifted to the left of 
the center, indicating preferential binding upstream of the TSS. At monocyte-specific 
promoters, PU.1 occupancy is progressively receding during differentiation. In contrast, 
DC-specific promoters display a rapid increase of PU.1 binding upon MO to DC 
transition. These findings indicate specific binding dynamics of PU.1 at cell type-
specific promoters.  
In the MO-specific promoter set, 5hmC occurrence is rare (Figure 3.33A and B, right 
panel), and completely absent at preferential binding sites of PU.1. In contrast, 5hmC 
appearance is not directly related to PU.1 binding in the DC-specific promoter set. At 
the beginning of the time course, the modification is randomly distributed in the 
analyzed region surrounding the TSS but seems to clear the center region of PU.1 
binding and shift to the shores until day 7 of differentiation. This may be due to the fact 
that the core PU.1 consensus motif lacks CpG dinucleotides and therefore 5hmC 
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(Pham et al., 2013). Promoters devoid of PU.1 binding support this idea, since they 
lack any regions of complete 5hmC depletion in both promoter sets.  
In Figure 3.33C both sets of cell-specifically transcribed promoters were annotated with 
CpG methylation data, obtained from bisulfite sequencing of MO and DC at day 7 (see 
chapter 5.2.5.9.3 for details). In line with the 5hmC distribution, 5mC levels in both sets 
are overall depleted in the TSS region during differentiation. This observation confirms 
that while proximal promoter regions may acquire 5mC and 5hmC, the centers at the 
TSS are generally devoid of those marks (Szulwach et al., 2011; Weber et al., 2007; 
Wu and Zhang, 2011). Taken together these results show distinct PU.1 dynamics at 
cell type-specific promoters, which are not correlated with demethylation events. 
 
 
Figure 3.33: Correlation of PU.1 accumulation with promoter expression levels 
A CAGE-based promoter set was divided into time point-specific expression sets (MO, iDC, n=3) and 
annotated with associated tag counts of PU.1 ChIP-seq, Hydroxymethyl Collector
TM
-seq and global CpG-
coverage. (A) CpG density and coverage in 1 kb regions around PU.1 peak centers is illustrated as 
heatmaps in the right panel and the genomic distance distribution (PU.1, 5hmC) of three time points of 
differentiating monocytes (1-kb regions centered on the TSS) are shown in the left panels (A) or 
histograms (B). (C) Methylation levels obtained by bisulfite sequencing of differentiating monocytes (MO 
n=4, DC n=6) are shown as histograms. 5mC and 5hmC levels of all valid CpGs in 1kb regions of the time 
point-specific sets is shown in % of methylation in relative distance to the TSS.  
 
3.3.3.3 PU.1 binding dynamics at promoter-distal transcribed elements 
 
Enhancers are promoter-distal regulatory elements that drive cell type specific gene 
expression. They are associated to a variety of cell type-specific TFs which aid in the 
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regulation of transcription (Heintzman et al., 2009; Ong and Corces, 2011). Pioneering 
TF like PU.1 are initiating the access to and open new enhancer elements (Heinz et al., 
2010; Serandour et al., 2011). In fact, cell type-specific PU.1 binding sites are much 
more abundant at promoter-distal sites than at promoters (Pham et al., 2013). 
To assess the PU.1 binding dynamics at enhancers in monocyte differentiation, a set of 
bidirectionally transcribed enhancers (Andersson et al., 2014) was sorted for cell type-
specific enhancer elements in MO and DC and compared to PU.1 tag counts (details in 
chapter 5.2.5.8 and 5.2.5.9.3). Heatmaps (Figure 3.34A) and histograms (Figure 
3.34B) illustrate genomic PU.1 tag density distribution in the two sets of MO (3018 
enhancer regions) and DC (278 enhancer regions) specific enhancers. MO-specific 
enhancers show decreasing PU.1 binding intensity during the differentiation time 
course. In contrast, active DC enhancers enrich PU.1 during monocyte differentiation. 
This observation is similar to promoter PU.1 dynamics.  
In summary, PU.1 targeting is mainly found at promoter and promoter-distal regions 
that are activated in a cell type-specific manner. Accordingly, upon transition into a new 
cell type PU.1 is removed from cell type-specific regulatory elements of the former cell 
type. These findings support the notion of general acquisition of the key regulators, like 
PU.1 to cell type-specific sites (Heintzman et al., 2009; Ong and Corces, 2011; Pham 
et al., 2012). Compared to promoters, the fraction of enhancer regions bound by PU.1 
is elevated in the MO-specific set. This is in line with other data sets that show cell 
type-specific PU.1 binding mainly at promoter-distal regulatory sites (Pham et al., 
2013). PU.1 binding is mainly located in the center of the enhancer transcription start 
sites (eTSS). This finding reflects the nature of the enhancer set, which was centered 
between the two transcription start sites of the bidirectional eRNA transcripts. 
The small numbers of DC-specific enhancers (10-fold lower compared to number of 
MO enhancers), may be explained by methodical problems in enhancer detection 
using CAGE; overall low tag counts in the DC samples impede proper detection of 
those elements.  
Compared to promoters, 5hmC levels in the vicinity of actively transcribed enhancers 
(shown in Figure 3.34A and B, right panels) are increased and display a similar, but 
more distinct pattern. At PU.1-acquiring DC-specific enhancers, 5hmC is randomly 
distributed in monocytes and moves to the shores of PU.1 binding sites until day 7 of 
differentiation. However, in the MO-specific enhancer set 5hmC is absent from PU.1 
peak sites at all time points and its levels decrease until day 7 of monocyte 
differentiation.  
Analysis of 5mC (Figure 3.34B) in general, confirms the distribution of 5hmC. 5mC is 
also constantly absent at the core PU.1 binding sites in the MO- and DC-specific 
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enhancer set, and shows a slight reduction at the shores during differentiation. This is 
in line with earlier findings and may be explained by technical variation (3.3.2.1). 
 
 
Figure 3.34: PU.1 dynamics at MO and DC specific enhancer regions 
A CAGE-based enhancer set was divided into time point-specific expression sets (MO, iDC, n≥2) and 
annotated with associated tag counts of PU.1 ChIP-seq (left panel), Hydroxymethyl Collector
TM
-seq 
(middle panel) and genomic CpG coverage (right panel). Genomic 5hmC and PU.1 tag distribution at three 
time points of differentiating monocytes as well as CpG density is shown in heatmaps across a 1 kb 
genomic interval relative to the eTSS or the center of the enhancer. (C) Histograms of methylation levels 
as assessed by bisulfite sequencing of differentiating monocytes (MO n=4, DC n=6). 5mC and 5hmC 
levels of all valid CpGs in 1 kb regions of the time point-specific sets is shown in % of methylation in 
relative distance to the eTSS. 
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4 Discussion 
4.1 The active DNA demethylation mechanism 
and its functional relevance 
 
At beginning of this thesis the oxidative enzymatic modification of 5mC had just been 
discovered as a part of active demethylation processes in mammals. Until now, the 
active DNA demethylation process has been the topic of ongoing research. In the 
previous years, numerous publications emerged and contributed to the understanding 
of the process (He et al., 2011; Ito et al., 2011; Iyer et al., 2009; Kriaucionis and Heintz, 
2009; Tahiliani et al., 2009). To date the relative importance of the various pathways is 
still under debate and it is not clear which components are associated with the 
demethylation machinery or how these mechanisms contribute to gene regulation in 
different cell types (Kohli and Zhang, 2013; Wu and Zhang, 2014). In this work we 
further characterized the active DNA demethylation processes in the hematopoietic 
compartment and gained insights into the functional relevance and spatio-temporal 
patterns of the demethylation events. At the beginning, most studies regarding DNA 
demethylation focused on proliferating or pharmaceutically arrested cells 
(Kangaspeska et al., 2008; Metivier et al., 2008). Both approaches are not ideal suited 
for the investigation of this process. First, drugs are globally interfering with the cells 
and may influence the molecular processes. Second, demethylation processes 
observed in proliferating cell systems do not exclude a possible contribution of passive 
demethylation events and are therefore not suited to study active demethylation. The 
data presented in this work are obtained from a non-proliferating in vitro cell system. 
This in vitro setting provides many advantages compared to other model systems. It 
utilizes primary monocytes directly obtained from human blood donors and thus 
simulates the original in vivo setting of monocytes. The cells are easily isolated from 
whole blood, providing abundant studying material from the organism of interest. Most 
important, the cells differentiate in the absence of DNA replication (Klug et al., 2010), 
thereby excluding passive demethylation processes to interfere with the experiments. 
Taken together, this model system is ideally suited to address questions regarding 
active DNA demethylation processes. Using this system we were able to gain further 
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insights into the active demethylation mechanism in differentiating monocytes and to 
identify TET2 as a key player in this process. 
Our group had previously detected active demethylation at several DMRs in 
differentiating monocytes. DMRs were identified as differentially methylated regions in 
monocyte-derived DC compared to MAK and characterized by loss of methylation 
during differentiation (Klug et al., 2010). These demethylation events occurred 
preferentially but not exclusively at promoter-distal regions and featured the 
synchronous appearance of activating histone marks. The findings indicated the 
recruitment of an active DNA demethylation machinery to the DMRs in the context of 
histone-modifying processes (Klug et al., 2010). The main aim of this thesis was to 
further characterize this active DNA demethylation process and to identify the enzymes 
involved. Although many demethylation pathways had been described to that date, the 
active demethylation pathway, initiated by the oxidation of 5mC by the TET proteins, 
was predominantly observed in mammalian cell systems (Bruniquel and Schwartz, 
2003; Ma et al., 2009; Mayer et al., 2000; Morgan et al., 2005; Oswald et al., 2000). It 
was further noted that the oxidation of 5mC is more likely to occur than direct removal 
of 5mC, since the oxidation of 5mC has much lower energy costs (Kohli and Zhang, 
2013). To test if the loss of 5mC observed at DMRs in our cell system was associated 
with the conversion into 5hmC we followed (in chapter 3.1.2.1) 5mC and 5hmC levels 
and observed a loss of 5mC accompanied by a synchronous appearance of 5hmC with 
different kinetics at those loci. Using alternative methods to clearly distinguish both 
marks, and to exclude bias towards CpG-density or off-target effects due to unspecific 
cross-reaction of the AB (Matarese et al., 2011; Pastor et al., 2011), we could confirm 
the results. As outlined in the introduction, the conversion to 5hmC is a major step in 
the demethylation mechanism in many other human cell types (reviewed in Wu and 
Zhang, 2014). This modification as well as further oxidation steps of 5hmC into 5fC or 
5caC are catalyzed by TET proteins (He et al., 2011; Ito et al., 2011; Tahiliani et al., 
2009), indicating an involvement of these enzymes in the process. A restriction-based 
approach (3.1.2.2.5) confirmed the complete removal of possible further oxidation 
products like 5fC or 5caC at the demethylated regions. Since this method only covered 
one CpG it is possible that this result does not reflect the modification state of all CpGs 
in this region. Thus, other methods to detect 5fC and 5caC, like the adapted version of 
fCAB-seq, will be useful to clarify this issue in the future. In summary, these findings 
confirmed that the conversion of 5mC to 5hmC is the first step in the demethylation 
process in the utilized cell system and indicated a possible involvement of TET 
hydroxylases. 
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After the discovery of their potential to initiate active demethylation processes, TET 
proteins have been the focus of many studies. They were identified as key players in 
developmental as well as cell type-specific processes and their expression in different 
tissues leads to overlapping and distinct functions at different stages of development 
(reviewed in Branco et al., 2012; Pastor et al., 2013). As a major regulator of 
differentiation, TET2 is ubiquitously expressed in the hematopoietic lineage (Ko et al., 
2011; Li et al., 2011; Moran-Crusio et al., 2011; Quivoron et al., 2011). This finding is in 
line with the expression data obtained in our setting. In chapter 3.1.2.2.1 and 3.1.2.2.3 
we could show that of all TET proteins only TET2 was abundantly expressed and 
showed stable protein levels at all time points of the differentiation time course. Thus 
TET2 represented a potential candidate enzyme for the demethylation events observed 
in differentiating monocytes. The depletion of TET2 (3.1.2.2.4 and 3.1.2.2.6) confirmed 
a lagged loss of 5mC as well as reduced 5hmC levels indicating a delay in the active 
demethylation process. Since TET2 is the major TET protein expressed in the 
hematopoietic lineage, it was not surprising to identify an involvement in the 
demethylation process. As illustrated in the introduction, TET2 has been linked to the 
demethylation process in other cell types before and the loss of this protein resulted in 
malignant transformation of the hematopoietic compartment, indicating important 
functions as a tumor repressor (Huang and Rao, 2014; Pastor et al., 2013; Wu and 
Zhang, 2014). Indeed loss of 5hmC and aberrant 5mC patterns are hallmarks of 
malignant hematopoietic cells (Ko et al., 2010; Konstandin et al., 2011). Taken together 
we identified TET2 as the initiator of the active DNA demethylation process in 
differentiating monocytes and as being responsible for the conversion of 5mC to 5hmC. 
In the next steps, we investigated an involvement of further factors in the active DNA 
demethylation mechanism, in particular in the remaining steps following the conversion 
of 5mC to 5hmC.  
Members of the BER have gained a lot of attention in the last years as important 
players in the last steps of active DNA demethylation processes (Kohli and Zhang, 
2013). The glycosylase TDG for example was shown to be involved in the active DNA 
demethylation process and responsible for the excision of 5mC oxidation derivatives 
5fC and 5caC (He et al., 2011; Zhang et al., 2012b). Other studies linked TDG to 
embryonic development (Cortazar et al., 2011; Cortellino et al., 2011), where TDG is 
crucial for the assembly and function of activating histone complexes, thus regulating 
the expression of developmental genes (Cortazar et al., 2011). Combining the ability to 
contribute to the demethylation pathway and its potential to recruit chromatin modifying 
complexes, TDG presented a possible candidate for the demethylation mechanism in 
our cell system. In mammals, the glycosylase MBD4 was so far known to be involved 
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in a demethylation mechanism initiated by the deamination of 5mC (Bhutani et al., 
2010; Popp et al., 2010; Rai et al., 2010) and a possible role in other active processes 
was hypothesized (Chen and Riggs, 2011). Although both glycosylases were 
ubiquitously expressed in differentiating monocytes (3.1.2.2.1), siRNA experiments 
(3.1.2.2.4 and 3.1.2.2.6) indicated that neither TDG nor MBD4 are responsible for the 
conversion of 5mC into 5hmC, which is in line with previous studies (Zhang et al., 
2012b). It is still unclear, if these enzymes are involved in the later steps of the DNA 
demethylation pathway. We tested if 5hmC was converted to 5fC or 5caC, further 
downstream oxidation products of 5mC. This process is catalyzed by TET proteins (He 
et al., 2011; Ito et al., 2011) and in cells where TDG is involved in the demethylation 
mechanism, TDG depletion was shown to result in accumulation of those modifications 
(He et al., 2011; Shen et al., 2013; Song et al., 2013). The generally impeded base and 
DNA double-strand break repair in blood monocytes (Bauer et al., 2011) may have 
been responsible for a delayed conversion to 5fC and 5caC and thus for a delay in the 
demethylation process, as was observed. But we could not observe any impairment in 
restriction efficiency (3.1.2.2.5) and thus no enrichment of 5fC or 5caC after TDG or 
MBD4 depletion at the DMRs, which suggested the complete removal of 5fC and 5caC 
at least at one CpG. A different approach using the fCAB method (3.1.2.4) resulted in 
inconclusive results, due to technical variation. Further adjustments of the method or 
more sensitive detection methods for 5fC and 5caC, will be necessary to gain further 
insights into these processes. Although a direct involvement in the demethylation 
process, via the excision of 5fC and 5caC, was so far only shown for TDG (He et al., 
2011; Maiti and Drohat, 2011; Zhang et al., 2012b), a possible role for MBD4 cannot be 
ruled out at this stage. A recent study detected the interaction of TDG as well as MBD4 
with all three TET proteins, further supporting a possible involvement of both MBD4 
and TDG in the demethylation process (Muller et al., 2014). However, the authors 
show that TDG, but not MBD4, is able to activate oxidation-dependent reporter gene 
expression and suggest different regulatory roles for both enzymes. In support of this 
theory both glycosylases were shown to play a role in different mechanisms of 
transcriptional regulation. TDG regulates the maintenance of active and bivalent 
chromatin via the recruitment of histone modifying complexes (Cortazar et al., 2011) 
and MBD4 is involved in transcriptional repression in cooperation with Sin3A and 
HDAC1 (Kondo et al., 2005). Since we were previously able to link demethylation 
processes in our cell system to the simultaneous appearance of active histone 
modifications (Klug et al., 2010), it will be important to investigate histone modifications 
surrounding the DMRs in cells, depleted of TDG or MBD4. This may give further 
insights into the recruitment of the demethylation machinery, its association with 
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histone-modifying processes and a possible function for TDG and MBD4 in this 
process.  
The 5mC mark is a known epigenetic regulator and recruits 5mC binding proteins to 
DNA (Hendrich and Bird, 1998; Meehan et al., 1989). Given the vast abundance of 
5mC oxidation derivatives in the genome it has been hypothesized that those may as 
well act as epigenetic regulators (Delatte et al., 2014). Two recent publications have 
supported that theory (Iurlaro et al., 2013; Spruijt et al., 2013) by presenting a number 
of DNA readers capable of targeted recognition and physical binding to specific DNA 
modifications, such as 5mC, 5hmC, 5fC and/or 5caC. These results suggested 
potential candidates involved in the active demethylation process, such as the helicase 
HELLS, which was shown to bind directly to 5hmC in both studies (Iurlaro et al., 2013; 
Spruijt et al., 2013). Furthermore helicases are involved in DNA repair (Brosh, 2013), 
which plays an important role in the active DNA demethylation mechanism in several 
cell types (for a review see Wu and Zhang, 2014). Another candidate enzyme, O-linked 
β-D-N-acetylglucosamine transferase (OGT), was recently identified as an interaction 
partner of TET proteins (Chen et al., 2013; Deplus et al., 2013; Vella et al., 2013). It 
could be shown, that these proteins are both forming a complex, which is involved in 
transcriptional activation (Chen et al., 2013; Deplus et al., 2013). Using a siRNA-based 
method we could show that neither of the candidate enzymes is involved in the 
conversion of 5mC to 5hmC (3.1.2.3.3). Nevertheless, a possible involvement of OGT 
or HELLS in the demethylation process cannot be ruled out altogether. Helicases play 
a role in DNA repair (Brosh, 2013) and HELLS may be involved in the excision of 
further 5mC derivatives. To test this possibility a modification-sensitive restriction-
digest (MSRE, as described in chapter 5.2.2.7.3.1) or the fCAB method (Song et al., 
2013) could be performed in cells depleted of HELLS or OGT. OGT is an important 
factor of TET1 protein-stabilization and OGT-inhibition was shown to result in a 70% 
depletion of TET1 (Shi et al., 2013). Since we did not see any effect of OGT-depletion 
on the 5mC to 5hmC conversion rate, the protein-stabilizing effect may be limited to 
TET1 and not be important for TET2. This is in line with previously published data 
(Chen et al., 2013). The authors reported that OGT does neither affect the TET2-
mediated 5hmC synthesis nor convert TET2-derived 5hmC into other derivatives in 
vitro. Of note, Shi et al. reported that the stabilization of TET1 was due to the O-
GlcNAcylation of TET1 by OGT (Shi et al., 2013). O-GlcNAcylation of TET2 and TET3 
has been controversially discussed. While several groups detected an O-GlcNAcylation 
of TET2 or TET3 by OGT (Ito et al., 2014; Vella et al., 2013; Zhang et al., 2014), 
Deplus et al. reported the contrary (Deplus et al., 2013). It is thus still unclear if the O-
GlcNAcylation of TET2 and TET3 occurs in general and if it is a prerequisite for the 
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stability of all TET proteins. Alternatively, TET2 levels may also be sustained by other 
unknown factors. In addition to the catalytic activity of TET2 in the active demethylation 
process, the recruitment of chromatin modifiers, such as OGT may present a possible 
link between active DNA demethylation and the simultaneous accumulation of 
activating histone marks, like H3K4 methylation, we observed earlier (Klug et al., 
2010). This hypothesis is supported by several studies reporting that OGT controls the 
activity of interacting histone methyltransferases, like CARM1 (co-activator associated 
arginine methyltransferase) or MLL5 (mixed lineage leukemia 5) (Cheung et al., 2008; 
Deplus et al., 2013; Fujiki et al., 2009; Sakabe and Hart, 2010). One of these studies 
detected a recruitment of OGT by TET2 and TET3. OGT promoted the stabilization of 
an associated Set1/COMPASS complex and targeted the SETD1A methyltransferase 
within the complex to chromatin. The depletion of TET or OGT resulted in a loss of 
H3K4me3 (Deplus et al., 2013). Taken together, OGT may be involved in later steps of 
the active demethylation process in our cell system and/or it may be responsible for the 
maintenance of the surrounding chromatin in a “hydroxymethylation independent” 
model of gene regulation (Delatte et al., 2014). It will be interesting to investigate 
histone mark profiles at the DMRs after depletion of OGT and TET2 to address this 
question.  
In summary, we were able to characterize the active DNA demethylation mechanism in 
differentiating monocytes in the first part of the thesis. We discovered that the targeted, 
locus-specific active DNA demethylation process is initiated by the conversion of 5mC 
to 5hmC and identified TET2 is required for this step. We further presented first 
insights into a possible involvement of TDG, MBD4, HELLS and OGT in the 
demethylation pathway. Further investigation of this issue will be important to define 
their importance for the active demethylation process. For the results of MBD4, TDG, 
OGT, and HELLS it might be possible, that minor effects on the demethylation process 
were obscured due to the heterogeneous nature of the transfected samples. As 
previously discussed, the transfection procedure affected the differentiation progress 
and the majority of cells did not yet enter the differentiation pathway at the early time 
points measured. To overcome this problem, a cell sort using flow cytometry may 
enrich for cells entering the differentiation pathway and thus provide bias-free results in 
subsequent experiments.  
 
In monocyte-derived macrophages, derived from the same in vitro model of the MPS, 
our group has also detected DMRs (Pham et al., 2013). Since the differentiation of MO 
into MAK takes place in the absence of cell proliferation we hypothesized that those 
are active demethylation events (Pham et al., 2013). In chapter 3.2.2 we could confirm 
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this notion. The loss of 5mC was correlated with the synchronous appearance of 
5hmC. These results were in line with earlier findings in DMRs in monocyte-derived 
dendritic cells (see chapter 3.1.2.1), but the functional relevance of the demethylation 
events was still unclear. Active DNA demethylation is, in cooperation with other 
processes, involved in the transcriptional regulation of adjacent genes and makes the 
DNA accessible for methylation-sensitive transcriptional regulators (Pastor et al., 2013; 
Wu and Zhang, 2014). These changes in methylation are not always immediately 
associated with gene activation (Klug et al., 2010). DNA demethylation has previously 
been linked to promoter-distal enhancer regions, where it contributes to the 
establishment of enhancers which are either active or pre-marked for later activation 
(Buecker and Wysocka, 2012; Pham et al., 2012; Schmidl et al., 2009). Since the loss 
of methylation in the macrophage DMRs was paralleled by an enrichment of H3K4me1, 
which marks enhancer regions (Heintzman et al., 2007), this led to the assumption that 
those regions may be activated for enhancer functions. The question was addressed 
functionally in reporter gene assays. For human dendritic cells there is no suitable cell 
line available to be subjected to reporter gene assays. So we chose a human cell line 
that can be transformed into a related, macrophage-like cell type (Abrink et al., 1994; 
Tsuchiya et al., 1982). Enhancer reporter assays testing DMRs upstream of a 
heterologous promoter in THP-1 cells (section 3.2.1) revealed enhancer activity for 
several regions, identifying those demethylated sites as potential enhancers. Strikingly, 
the enhancing properties were dependent on the methylation level of those regions. In 
almost all regions SssI-mediated methylation of the plasmid DNA impaired or 
completely abolished the enhancing potential, supporting the hypothesis that 
demethylation is necessary for the activation of distal-regulatory enhancer regions. 
This hypothesis is consistent with the previously reported link between demethylation 
events and enhancer activity, both in a related and un-related cell type (Klug et al., 
2010; Schmidl et al., 2009). Klug et al. showed enhancer activity for several DC-
specific, demethylated regions, which was lost after in vitro SssI-methylation of the 
plasmid DNAs (Klug et al., 2010). The demethylation events at the DMRs in MAK were 
correlated with the local binding of key TF, like PU.1, C/EBPβ and EGR2, co-occurring 
at the same stages of MAK differentiation that displayed demethylation (Pham et al., 
2013). It was therefore likely that the local binding of cell type-specific TF initiates the 
demethylation process (Pham et al., 2013). In support of this theory, most of the 
regions displayed enhancer potential, but their activation depended on the cell context. 
THP-1 cells developed into a monocyte-macrophage like cell type in the presence of 
PMA and enabled (compared to THP-1 cells cultured without PMA) a different set of 
regions to enhance a basal promoter, indicating cell type-specific enhancer usage 
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(chapter 3.2.1). In line with these findings, one region showed methylation-sensitivity in 
one cell context but not in another, indicating a cell type-specific removal of the 5mC 
mark. This is consistent with reporter gene assays in regulatory T cells (Treg). Treg-
specific enhancer elements were activated in a related cell type, suggesting the 
presence of required activating factors in both cell types. The authors further 
suggested an important role of DNA methylation in the restriction of lineage-specific 
promoter-distal regulatory elements in other cell types than Tregs (Schmidl et al., 
2009). Our results in a non-myeloid cell system lacking the key TF PU.1 (Kwon et al., 
2005) (3.2.1) confirmed this theory. The activation of cell type-specific enhancer 
elements requires a corresponding set of TF to open the regions, and may include the 
removal of 5mC in this process. In support or this finding it has been shown, that 
C/EBPβ and EGR2 are upregulated during MO to MAK differentiation and that the 
binding of each of those TFs is associated with MAK-specific gene regulation (Pham et 
al., 2012; Pham et al., 2007). The demethylation events in the DMRs were not 
restricted to MAK, but were also seen in differentiating dendritic cells, albeit with 
different demethylation kinetics (3.2.2). It seems likely that related cell types are able to 
activate a common set of regulatory elements (Schmidl et al., 2009), but with different 
kinetics, depending on the present set of transcriptional activators.  
Taken together we were able to confirm active DNA demethylation in monocyte-
derived macrophages and link these events to enhancer function. We demonstrated 
that the enhancer regions were methylation-sensitive and that demethylation led to 
enhancer activation in a cell type-specific manner. It has to be noted that those findings 
were obtained in an artificial cell system only resembling the actual TF content of MAK 
and lacking the surrounding chromatin structure. Nevertheless, the experiments gave 
first hints at cell type-specificity and enhancer usage and supported the results of other 
colleagues (Pham et al., 2013).  
 
4.2 Global dynamics of active demethylation 
and the master transcription factor PU.1 
 
The first part of this work further characterized the demethylation mechanism in 
differentiating monocytes and identified TET2 as a key player in this process. 
Functional analysis of selected DMRs, associated with key TF, linked the local binding 
of these factors and the simultaneous demethylation events to functional purposes. 
These findings support the theory suggested by us (Pham et al., 2013) and others 
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(reviewed in Ong and Corces, 2011) that master TFs like PU.1 are directly involved in 
the demethylation process. Since active demethylation events occur on a global level 
and are not restricted to enhancer elements (Klug et al., 2010), we further investigated 
the previous results on a global scale. The following chapters give a genome-wide 
overview on the dynamics of 5mC oxidation and the association with the key TF PU.1 
in differentiating monocytes.  
In the last years a variety of methods have been developed to map 5hmC distribution 
across the genome. They can be divided into pull-down methods including antibody-or 
chemical labeling-based methods and single-base resolution approaches, such as 
bisulfite-sequencing. The single-base resolution strategies are able to cover scattered 
CpGs that may escape the detection of affinity-based methods. Base-resolution 
methods measure the average modification of each single cytosine and are dependent 
of the sequencing depth and coverage of 5hmC. Improved protocols like the oxBS-seq 
and TAB-seq method (Booth et al., 2012; Yu et al., 2012) overcome the former 
problem of discrimination between 5mC and 5hmC. The main disadvantage of base-
resolution methods is the sequencing costs which increase with the sequencing depth 
necessary to detect rare cytosine modifications. Affinity-based approaches on the other 
hand are cost-effective and cover the majority of cytosines which are mostly clustered 
in the genome (Yu et al., 2012). Those methods are limited by their resolution, which is 
dependent on the DNA fragment size (reviewed in Wu and Zhang, 2014). To measure 
5hmC levels genome-wide, we tested and validated two affinity-based methods. First, 
the hMeDIP based on a 5hmC antibody and second, the Hydroxymethyl CollectorTM kit, 
which includes selective, chemical labeling of 5hmC. The comparison of sequencing 
read counts from both methods, presented in chapter 3.3.1.1 revealed highly diverging 
results. Although they did not show any correlation, we were able to detect the DC-
derived example DMRs in both sets. The methods did however show different spatial 
accuracies, which may be due to the low resolution of the method (data not shown). 
Another criterion we took into account was that antibody-based methods, compared to 
chemical labeling, may be prone to non-specific enrichment of simple repeats 
(Matarese et al., 2011). However, both sets derived from our methods equally enriched 
for simple repeats, and LINE1 repeats (data not shown). Since those features were 
inconclusive, we validated a number of regions that were uniquely detected by each 
method with an alternative 5hmC detection method (3.3.1.1). In conclusion only the 
results from the Hydroxymethyl CollectorTM kit were reproducible with the other method. 
It has to be noted that the alternative method is also based on glycosylation of 5hmC 
and may therefore not present an entirely independent approach. Nevertheless, also 
within biological and technical replicates the kit showed good correlations and high 
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reproducibility, even after slight alterations to the protocol. Interestingly other groups 
compared the same methods (with a slightly altered hMeDIP protocol, as well as a 
different polyclonal AB from the same company) in murine neuronal progenitor cells, 
mature neurons, brain and liver cells and obtained similar enrichment between the two 
methods (Hahn et al., 2013; Thomson et al., 2013). In contrast to our approach both 
studies used the same polyclonal antibody from Active Motif, indicating a consensus of 
the data obtained using this antibody with results from the Hydroxymethyl CollectorTM 
kit. In order to validate selected regions enriched by both tested methods Thomson et 
al. used glycosyl transfer to 5hmC followed by glycosylation-sensitive restriction digest. 
This approach is similar to the validation protocol we used (see chapter 5.2.2.7.2.1). 
They were able to reproduce the results from both methods (hMeDIP, Hydroxymethyl 
CollectorTM), supporting the earlier notion. The authors further detected significant bias 
of the hMeDIP method towards simple repeats as well as LINE1 elements (Thomson et 
al., 2013), whereas Hahn et al. did not detect any bias regarding CA-repeats (Hahn et 
al., 2013). Our results obtained with the AB-based method were consistent with the 
results of the second group (Hahn et al., 2013). The discrepancies may be explained 
by the different antibodies used in the studies and variations in the protocol. In any 
case, the results for the Hydroxymethyl CollectorTM kit were concordant and supported 
our data. Taken together, the Hydroxymethyl CollectorTM kit presented itself as an 
accurate and stable method and was therefore chosen for further 5hmC analyses. 
 
Genome-wide mapping of 5hmC has previously been performed in a number of cell 
types to gain insights into the functional relevance of demethylation processes. In 
combination with global maps of other 5mC oxidation derivatives and distribution 
profiles of TET proteins those studies contributed to a better understanding of the 
purposes of active DNA demethylation events in various tissues and developmental 
stages (Pastor et al., 2013; Wu and Zhang, 2014). This work presents a genome-wide 
profile of 5hmC dynamics and its association with the key TF for hematopoiesis, PU.1, 
in a hematopoietic cell context. In chapter 3.3.2.1 we focused on the question, if active 
demethylation events in monocyte to DC differentiation can be clustered into functional 
entities and if there is a connection between 5mC oxidation and PU.1 binding. The k-
means clustering indeed classified the 5hmC peak set into four sub-clusters with 
different 5hmC dynamics during the differentiation time course. The subsets exhibited 
similar dynamics in pairs of two clusters, either gaining or loosing 5hmC over time. The 
loss of 5hmC was accompanied by a simultaneous loss of 5mC, indicating ongoing 
active DNA demethylation at those regions. The quality-control of 5mC data presented 
in the same chapter identified the global reduction of 5mC to be introduced by 
  Discussion 
77 
 
biological or technical variation due to the different methods and donors used for whole 
genome 5mC analysis (see chapter 3.3.2.1). Nevertheless the distinct local loss of 
5mC and 5hmC at 5hmC peak centers, respectively, was still clearly detected and not 
explicable by method or donor variation. On the basis of this control data analysis we 
considered the dynamics extending the global variations as specific demethylation 
events. Further investigation of methylation levels in selected regions by the 
MassARRAY system may be used to validate the active demethylation events in those 
regions and thus to confirm the assumption. The recruitment of PU.1 to sites of 5hmC 
enrichment and 5mC loss supports the idea of a correlation between demethylation 
and PU.1, which has been hypothesized in previous chapters and is supported by 
several publications. Pham and colleagues also detected loss of methylation at sites of 
PU.1 accumulation in macrophages, a related cell type. DNA methylation and PU.1 
binding were found to be mutually exclusive and even the majority of non-bound PU.1 
motifs did not correlate with 5mC (Pham et al., 2013). Similar observations were made 
for another transcription factor, CTCF, in methylome studies of murine neuronal and 
ESC. The binding of this TF resulted in local loss of methylation at the binding site and 
indicated an involvement of CTCF in the initiation of demethylation (Stadler et al., 
2011). For the regulation of demethylation via transcription factors two opposing modes 
of action are discussed at the moment. First, TF like PU.1 may induce local 
demethylation processes to open the DNA for other 5mC-sensitive TF as was 
previously shown by Stadler et al. (Stadler et al., 2011). Or second, the demethylation 
process removes 5mC to provide access for PU.1 and other factors (Pham et al., 2013; 
Stadler et al., 2011). The results presented in chapter 3.3.2.1 speak in favor of the 
latter theory. One subset of PU.1 target regions recruit PU.1 to sites with abundant 
5hmC accumulation, indicating the involvement of other factors in the initiation of the 
demethylation process, at least for regions in this cluster. This is further supported by 
observations in chapter 3.3.3.1 and will be discussed later. Regions gaining 5hmC 
during monocyte differentiation did not show any loss of 5mC, which may indicate that 
the active demethylation proceeds at a slower pace, similar to the observations at 
single DMRs with “slow” kinetics (see chapter 3.1.2.1). It is also possible that the 
demethylation process pauses at the 5hmC step. Previous studies suggested this 
possibility for the male and to a lesser extent for the maternal pronucleus of 
preimplantation embryos. In the early zygote 5hmC is in general not further oxidized 
and may serve as a stable epigenetic mark before it is passively diluted in a replication-
dependent manner (Inoue and Zhang, 2011; Iqbal et al., 2011; Shen et al., 2014; Wang 
et al., 2014). Similar results have been observed in several tumor tissues, like brain, 
lung, breast, uterus and pancreatic tissue (Jin et al., 2011). In murine neurogenesis 
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5hmC levels increase during differentiation, and consistent with our results are 
associated with stable 5mC levels (Hahn et al., 2013). In our cell system the 5hmC 
mark may therefore not only serve as an intermediate of the demethylation process. Its 
presence at many sites that are not subjected to demethylation suggests additional 
functions, e.g. as an epigenetic mark with regulatory potential, which has been 
discussed previously (Calo and Wysocka, 2013; Szulwach and Jin, 2014). Those 
studies suggest that 5hmC may recruit specific “readers” to the DNA, which recognize 
5hmC and may contribute to transcription regulation. In support of this theory two 
recent studies identified several specific binding proteins for 5hmC, including 
glycosylases and DNA repair proteins (Iurlaro et al., 2013; Spruijt et al., 2013). Spruijt 
et al. detected different sets of 5hmC binders in mESC, neural progenitor cells or adult 
mouse brain tissue, suggesting different functions of 5hmC depending on the cell 
context (Spruijt et al., 2013). The second study confirmed many 5hmC readers in an 
independent approach using mESC extracts and detected sequence-specific binding 
preference of several reader proteins. These findings added an additional 
characteristic to the distinct recognition of 5hmC, further supporting its functional 
diversity (Iurlaro et al., 2013). 5hmC may also represent a negative signal, blocking 
5mC-specific readers. Most 5mC-binding proteins do not recognize 5hmC and may 
therefore be removed from the DNA when 5mC is converted into 5hmC (Jin et al., 
2010; Valinluck et al., 2004). UHRF1 is involved in methylation-maintenance in 
cooperation with DNMT1 and is known to bind both 5hmC and 5mC albeit with much 
lower affinity to 5hmC (Hashimoto et al., 2012; Valinluck et al., 2004). The 
accumulation of 5hmC may therefore lead to impaired methylation maintenance during 
replication, as several other studies have shown (Shearstone et al., 2011; Valinluck 
and Sowers, 2007). Shearstone et al. reported a replication-dependent loss of 5hmC in 
erythropoiesis, in the presence of functional DNMT1 and UHRF1 (Shearstone et al., 
2011). In addition Valinluck et al. observed the prohibition of DNMT1-mediated 
methylation in the presence of 5hmC, pointing at a role of this mark in the maintenance 
of an unmethylated state (Valinluck and Sowers, 2007). There are several other DNA 
binding proteins targeting both 5hmC and 5mC in vitro, like MeCP2, MBD1, MBD2, and 
MBD4 (Hashimoto et al., 2014; Jin et al., 2010; Mellen et al., 2012; Otani et al., 2013). 
In vivo experiments confirmed 5mC but not 5hmC as a target modification for those 
readers, so far (Baubec et al., 2013). Further studies will be necessary to investigate 
the functional relevance of 5hmC readers and to what extent they contribute to 5hmC-
specific transcriptional regulation. It will be interesting to test a possible role for 5hmC 
as a stable mark in differentiating monocytes and to identify possible 5hmC readers in 
the corresponding 5hmC-accumulating regions.  
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Gene ontology analyses of the four 5hmC subsets confirmed the immunological 
background of monocytes and dendritic cells, displaying mainly GO terms related to 
immunological processes (3.3.2.2). Along with common functions of MO and DC as 
positive regulators of the immune system (Abbas et al., 2007), GO terms related to 
distinct functions of either MO or DC were also enriched. The majority of GO terms 
covered genes involved in immune response and inflammation, which are common 
characteristics of monocytes (Ginhoux and Jung, 2014). Those terms were mainly 
enriched in clusters correlated with active demethylation and PU.1 recruitment. 
Interestingly, previous studies reported an important role of PU.1 in the regulation of 
genes involved in inflammation (Rehli, 2000; Smith et al., 1998) and PU.1 binding sites 
are enriched in regulatory regions of inflammatory pathways in MAK (Ghisletti et al., 
2010; Heinz et al., 2010; Turkistany and DeKoter, 2011). Therefore these sets may 
represent PU.1 target genes that regulate MO function. Lymphocyte activation, a 
common feature of DCs, was predominantly enriched in one of the two clusters. Given 
the important function of PU.1 as a key driver of DC development (reviewed in Carotta 
et al., 2010b), this cluster may further comprise a set of PU.1 target genes that are 
activated upon differentiation into DC. In both sets, active demethylation correlated with 
an overall repression of gene expression (chapter 3.3.2.3) in the corresponding 
regions. This finding is interesting, since active demethylation is mostly but not 
exclusively associated with transcriptional activation (Wu and Zhang, 2014). However, 
our observation is supported by earlier analyses of the same expression data set, 
which associated active demethylation with gene activation as well as with gene 
repression (Klug et al., 2010). The accumulation of PU.1 at these sites may indicate an 
involvement in the down-regulation of those genes. In support of that theory, studies in 
other myeloid cells show, that PU.1 is not only involved in the regulation of gene 
expression (Carotta et al., 2010b; Ghisletti et al., 2010), but is further able to recruit 
activating as well as repressing interaction partners (Bai et al., 2005; Imoto et al., 2010; 
Suzuki et al., 2006). In addition, recent observations in monocyte-derived osteoclasts 
linked PU.1 to repressive as well as actively transcribed regions. However PU.1 
binding was associated with hypermethylation in the context of transcriptional 
repression (de la Rica et al., 2013). This feature differs from the observations in MO 
differentiating into DC, presented in this work, as well as from studies in monocyte-
derived MAK (Pham et al., 2013), where PU.1 binding is predominantly associated with 
hypomethylation. This discrepancy may indicate different regulatory roles of PU.1 in 
related, yet different cell types. It will be interesting to assess the surrounding 
chromatin structure, identify further TF bound at the sites of demethylation and 
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possible binding partners of PU.1 in the different cell types in the future. This may 
provide further insight into the regulatory functions of PU.1 and its association and 
cooperation with cell type-specific factors in different cell types. In macrophages this 
has previously been done and revealed distinct TF motif signatures corresponding to 
differentiation-associated epigenetic changes (Pham et al., 2012; Pham et al., 2013). 
Nevertheless, our data indicate that PU.1 may be involved in the regulation of 
transcriptional changes during differentiation of MO into DC. However, it has to be 
noted that the expression analyses using Homer, associate 5hmC enrichment with 
expression changes of the nearest gene. The next gene can be located at a certain 
distance from the demethylated CpGs, which may introduce a bias for false positive 
genes flanking large intergenic regions (Lowe et al., 2007; Taher and Ovcharenko, 
2009). Additionally we can only assume that local demethylation affects the closest 
gene. TF binding for example usually spans from proximal to several kb distal binding 
events and consideration of the proximal peaks, only, may neglect effects of distal 
binding events (McLean et al., 2010). If the nearest gene is affected by the 
demethylation it is possible that it is not or not yet associated with transcriptional 
changes. These regions may be pre-marked for later activation or exhibit other 
regulatory functions (Buecker and Wysocka, 2012). The other two sets of regions were 
mostly depleted of the major GO terms and did not enrich any of the terms uniquely 
(3.3.2.2). This finding may result from the nearest gene approach used by Homer gene 
ontology analyses as was discussed above and thus represent only a fraction of the 
affected genes. Additionally, for the analysis mainly major GO terms were considered. 
Since PU.1 did also not accumulate to those regions it is tempting to speculate that 
those sites are a heterogeneous set of regions maintaining important, but less 
prominent genes, which did not appear in the top GO terms, and are regulated 
independent of PU.1. When taking the gene expression analyses (3.3.2.3) into 
account, these sets were associated with an overall increase in gene expression. As 
was discussed in detail earlier in this chapter, the demethylation process in both sets 
presumably paused at the 5hmC mark. In combination with the transcriptional 
activation these results support the idea that 5hmC attracts specific readers, which are 
able to regulate transcription (Delatte et al., 2014; Iurlaro et al., 2013; Spruijt et al., 
2013; Yildirim et al., 2011). In support of this finding Yildirim et al. identified MBD3 as a 
potential reader of 5hmC in vitro and observed a repressive gene regulatory function in 
association with the MBD3/NuRD complex (Yildirim et al., 2011). This notion could not 
be reproduced by other groups, who did not find evidence for 5hmC binding in vitro 
(Hashimoto et al., 2012; Spruijt et al., 2013). Further investigation of 5hmC function in 
differentiating monocytes will clarify, if there is one (or more) possible reader of 5hmC 
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directly recruited to activate the expression at those loci, or if an accumulation of 5hmC 
simply repels 5mC-binding proteins in order to maintain an unmethylated, de-repressed 
state (Shearstone et al., 2011; Valinluck et al., 2004). In this case other methylation-
sensitive DNA binding proteins may benefit from a conversion of 5mC to 5hmC and be 
recruited to the unmethylated regions to activate transcription. 
Taken together, the global screen of 5hmC revealed functionally distinct clusters of 
regions, which are partly associated with the key transcription factor PU.1 and 
differential gene expression profiles. We were able to further characterize the 
previously detected bimodal regulation of gene expression (Klug et al., 2010) and 
correlate it to distinct 5hmC dynamics, TF binding, as well as biological functions.  
 
To deepen the understanding of PU.1 recruitment to its target genes and the 
association with active demethylation events, we analyzed PU.1 binding patterns on a 
genome-wide level. The results revealed different binding dynamics of PU.1 at several 
sets of regions during monocyte differentiation and led to the assumption that each 
cluster of regions represents different target sites with varying functions of PU.1. On 
the basis of PU.1 dynamics the six clusters could be divided into two groups (3.3.3.1). 
One group of PU.1 target sites showed increased PU.1 binding during the 
differentiation time course and simultaneously gained 5hmC at PU.1 sites. With rising 
PU.1 levels the 5hmC pattern became more distinct and localized next to the PU.1 
binding site, which is in line with observations from other TFs (Lister et al., 2013; Yu et 
al., 2012). The accumulation of both marks was accompanied by the distinct loss of 
5mC (and 5hmC) confirming the direct correlation between PU.1 and demethylation 
events as was observed in previous chapters. This is in line with earlier findings in 
MAK where our group detected only small overlap between PU.1 and 5mC and 
assumed a possible recruitment of the demethylation machinery by PU.1, leading to 
local demethylation (Pham et al., 2013). In support of this notion de la Rica et al. 
recently reported a direct interaction between PU.1 and TET2 at demethylated genes 
resulting in gene expression changes (de la Rica et al., 2013). Interestingly 
observations in one cluster of PU.1 target regions argued against this theory, and 
confirmed earlier observations in a subset of 5hmC-enriched regions (see section 
3.3.2.1). Regions in this PU.1 cluster clearly showed demethylation events at the 
monocyte stage, but recruited PU.1 primarily upon the transition into dendritic cells. 
This finding indicated, that at those regions other factors than PU.1 are responsible for 
the initiation of the demethylation process and that PU.1 was possibly either recruited 
by those factors or benefited from the opening of those regions. Targeted depletion of 
PU.1 or TET2 at selected loci will be helpful to validate this finding. A recent study from 
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our group showed that most potential binding sites of PU.1 in hematopoietic cells are 
not occupied, which is in part due to their location in inaccessible heterochromatin 
(Pham et al., 2013). Further generation of global chromatin maps in combination with 
motif analyses may help to understand, if those sites are located in heterochromatic 
regions and therefore not accessible for PU.1. TET2 binding to DNA was shown to be 
dependent on PU.1 levels in differentiating osteoclasts (de la Rica et al., 2013), 
indicating that PU.1 is prerequisite for TET2 recruitment to demethylated regions in this 
cell type. The aforementioned distinct chronology of PU.1 and 5hmC in a subset of 
PU.1 target region in dendritic cells may not necessarily display a discrepancy but 
rather one possible function of PU.1. It may still be possible that PU.1 and 5hmC 
exhibit different spatio-temporal patterns in different cell types or even at different 
target regions of the same cell type, depending on the cooperation of local factors. 
Cooperation was shown for PU.1 binding patterns in other cell types and may 
determine PU.1 function at bound loci (Heinz et al., 2010; Pham et al., 2012; Pham et 
al., 2013). In the remaining subsets of this group it is still not clear, which mark 
precedes which and PU.1 may initiate the demethylation process in association with 
TET2 recruitment at those sites. Characterization of selected regions in the sub-
clusters may give further insight into the chromatin context and the involvement of 
other factors. Further analyses of PU.1 and 5hmC dynamics in monocyte progenitor 
cells will help to solve the question of the “chicken and the egg” at regions in these 
clusters. These experiments may help to confirm a dual role for PU.1 depending on the 
set of target sites or a general recruitment of PU.1 to demethylated sites in 
differentiating monocytes. 
The other group of regions lost PU.1 peaks present in monocytes during the 
differentiation into DC. The rare 5hmC abundance as well as the absence of 5mC (and 
5hmC) in the vicinity of PU.1 binding sites supported the idea that those regions 
represent later stages of the demethylation process where the demethylation is 
completed and PU.1 is dispensable and removed from those sites. This theory implies 
a functional role of PU.1 in the demethylation process as was hypothesized by Pham 
and colleagues who suggested an involvement of sequence-specifically recruited TFs 
like PU.1 in the initiation of this process (Pham et al., 2013). In differentiating 
monocytes there is so far no evidence for this theory, but it cannot be excluded either. 
The close association to demethylation events observed in differentiating monocytes 
and the data from other studies support an involvement of PU.1 in the demethylation 
process at least in subsets of PU.1 target genes. To date it is still not clear if PU.1 is 
capable of the initiation of the demethylation process by the recruitment of the 
demethylation machinery, or if it is required for the stabilization of other factors and 
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complexes in this cell system. Since cooperation of TFs is an important feature for 
binding site selection (Pham et al., 2013; Tallack et al., 2010) it may also be possible 
that PU.1 binding recruits other relevant TFs or selectively blocks their binding to the 
site of demethylation. In support of this theory several studies reported a dynamic 
change of TF composition at cell type specific elements during development (Lin et al., 
2010; Pham et al., 2012; Pilon et al., 2011). The loss of PU.1 at this group of regions 
may thus indicate the establishment of a different TF signature at the demethylated 
sites upon transition into a new cell type, which does not include PU.1. Further 
analyses of motif occurrence and occupancy by other TF may resolve these questions. 
 
During monocyte differentiation we observed distinct PU.1 patterns upon the transition 
into a new cell type. The gain or loss of PU.1 was associated with distinct 5hmC 
dynamics resulting in or maintaining a demethylated state at the PU.1 target regions.  
In general, key regulators are recruited to cell type-specific sites, such as enhancers 
where they regulate cell type-specific gene expression (Heintzman et al., 2009; Ong 
and Corces, 2011; Pham et al., 2012). In differentiating monocytes we observed similar 
binding patterns for the TF PU.1 at regulatory elements. We divided two sets of actively 
transcribed promoters and enhancers into groups of MO- or DC-specific elements and 
assayed surrounding PU.1 and 5hmC distribution. The results showed that whereas 
DC-specific promoter regions acquired PU.1, MO-specific promoters exhibited receding 
levels of PU.1 binding during monocyte differentiation (3.3.3.2.1). This has previously 
been observed in macrophages, too, where PU.1 was lost at promoter regions during 
MO to MAK differentiation and PU.1 displayed distinct cell type-specific binding 
patterns in both cell types (Pham et al., 2012). Consistent with the PU.1 patterns at 
promoters, cell type-specific, active enhancer regions acquired PU.1 at DC-specific 
sites and lost the TF at MO-specific regions upon transition into a new cell type. Taken 
together, PU.1 is mainly targeted to promoter and promoter-distal regulatory regions 
that are activated in a cell type-specific manner. The active nature of the regions in 
both enhancer and promoter sets may indicate a functional relevance of the 
corresponding PU.1 dynamics. Sérandour and colleagues reported dynamic 5hmC 
patterns at cell type-specific enhancer regions in mice, which is associated with active 
histone marks, chromatin opening and an intermediate CpG density (Serandour et al., 
2012). The authors suggested an important role of demethylation in the regulation of 
enhancer elements. Consistent with this report, cell type-specifically activated 
enhancer regions in differentiating monocytes were associated with low to intermediate 
CpG-content and distinct 5hmC patterns (3.3.3.3). In contrast the 5hmC distribution 
was less dynamic than observed at other PU.1 target regions and indicated that PU.1 
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recruitment to cell type-specific enhancer or promoter elements did not significantly 
alter the demethylated state of those regions. Yet it may be involved in the 
maintenance of an active transcriptional state. In support of this finding the loss of PU.1 
binding at macrophage-specific enhancer regions was associated with reduction of the 
active enhancer histone signature at those loci in earlier studies of macrophages. This 
finding indicated that PU.1 may be responsible for the maintenance of active enhancer 
histone marks (Heinz et al., 2010; Pham et al., 2012) and supported the hypothesis of 
PU.1 participating in the transcriptional regulation of the transition into a new cell type 
as was discussed earlier in this chapter. During monocyte differentiation PU.1 is 
removed from regions that characterize the former cell type. The loss of PU.1 may 
indicate the decommissioning of the regions which was shown to proceed with the loss 
of activating histone marks at enhancer region in differentiating mESC (Whyte et al., 
2012). This is consistent with the theory that PU.1 may be involved in transcriptional 
regulation via histone marks, but further investigation will be necessary to validate this 
hypothesis. Mapping of histone marks in the vicinity of the cell type-specific enhancer 
and promoter regions may help to get insights into the processes at regulatory regions. 
Given the vast abundance of PU.1 in myeloid cells like MO and MAK (Carotta et al., 
2010b; Pham et al., 2012) its specific binding to target sites may be dependent on the 
cooperative binding of other TF (Pham et al., 2013). It is still not clear if PU.1 actively 
interferes in transcriptional regulation of the regulatory target genes. To address the 
question a conditional knockout may be helpful to assess the gene expression levels in 
the absence (or presence) of PU.1 at example regions. It has to be noted that the 
depletion of a key hematopoietic TF in hematopoietic cells is difficult to interpret. 
Secondary effects on cell homeostasis and development may interfere with global 
mechanisms, but a careful interpretation of the approach may still help to resolve this 
question. 
In summary the global distribution of PU.1 showed distinct binding profiles at different 
PU.1 target regions. These dynamics were again directly correlated with demethylation 
events and represented target gene specific PU.1 patterns accompanying the transition 
into a new cell type. Our results present evidence for a distinct chronological 
succession of TF binding and demethylation events at a subset of effector regions. 
Dynamic PU.1 binding was further linked to the active usage of functionally relevant 
elements, which supported an involvement of PU.1 in hematopoietic cell differentiation.  
 
The data presented in this work contributed to the understanding of the active DNA 
demethylation mechanism and revealed distinct patterns of transcription regulation 
upon cell fate decisions in hematopoietic cells. We could show first evidence of PU.1 
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as a beneficiary of demethylation events at certain subsets of PU.1 target regions and 
further confirmed a direct correlation between this master transcription factor and 
active DNA demethylation. 
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5 Material and Methods 
5.1 Material & Equipment 
5.1.1 Technical devices 
 
8-Channel PipettorImpact2 Equalizer 384 Thermo Fisher Scientific, Hudson, USA 
Autoclave  Technomara, Fernwald, Germany 
Bioanalyzer 2100 Agilent Technologies, Böblingen, Germany 
Biofuge fresco Heraeus, Osterode, Germany 
Caliper LapChip XT Perkin Elmer, Waltham, USA 
Casy Cell Counter Innovatis/Roche, Basel, Schweiz 
Centrifuges  Heraeus, Hanau; Eppendorf, Hamburg, Germany 
Chemi Doc XRS+ System Bio-Rad, Hercules, USA 
Covaris S2 Covaris, Woburn, USA 
Electrophoresis equipment  Biometra, Göttingen, Germany 
Electrophoresis equipment  Bio-Rad, Hercules, USA 
Fast-Blot machine  Agfa, Köln 
Heat sealer Eppendorf, Hamburg, Germany 
Heatblock  Stuart Scientific, Staffordshire, UK 
Hemocytometer Marienfeld, Lauda-Königshofen, Germany 
Illumina HiSeq1000 Illumina, San Diego, USA 
Incubators  Heraeus, Hanau, Germany 
Intelli-Mixer RM-2L Elmi-Tech, Riga, Latvia 
J6M-E centrifuge  Beckmann, Munich, Germany 
Laminar air flow cabinet  Heraeus, Hanau, Germany 
LSRII BD, Heidelberg, Germany 
Luminometer (Sirius)  Berthold Detect. Systems, Pforzheim, Germany 
Magnetic Particle Concentrator  Life Technologies, Carlsbad, USA 
MassARRAY Compact System Sequenom, San Diego, USA 
MassARRAY MATRIX Liquid Handler Sequenom, San Diego, USA 
MassARRAY Phusio chip module Sequenom, San Diego, USA 
Megafuge 3,0 R Heraeus, Osterode, Germany 
Microscopes Zeiss, Jena, Germany 
Microwave Privileg 8020 Privileg 
Minigel gelelectrophoresis equipment  Biometra, Göttingen 
Multifuge 3S-R Heraeus, Osterode, Germany 
Multipipettor Multipette plus Eppendorf, Hamburg, Germany 
NanoDrop 1000 PeqLab, Erlangen, Germany 
PCR Thermocycler PTC-200 MJ-Research/Biometra, Oldendorf, Germany 
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pH-Meter  Knick, Berlin, Germany 
Picofuge Heraeus, Osterode, Germany 
Pipetboy Integra Biosciences, Fernwald, Germany 
Pipettes Gilson, Milddleton, USA 
Pipettes Eppendorf, Hamburg, Germany 
Power supplies  Biometra, Göttingen, Germany 
Qubit  2.0 Flourometer Life Technologies, Carlsbad, USA 
Realplex Mastercycler epGradient S Eppendorf, Hamburg, Germany 
Rocking plattform HS250 IKA Labortechnik, Staufen, Germany 
Rotilabo®-mini-centrifuge Carl Roth, Karlsruhe, Germany 
Sigma 2 – Sartorius Sartorius, Göttingen, Germany 
Sonifier 250  Branson, Danbury, USA 
Sonorex Ultrasonic Bath Bandelin, Berlin, Germany 
Sorvall RC 6 plus Thermo Fisher Scientific, Hudson, USA 
Thermomixer  Eppendorf, Hamburg, Germany 
Thermomixer compact Eppendorf, Hamburg, Germany 
Typhoon 9200 Molecular Dynamics, Krefeld, Germany 
Typhoon™  Amersham Biosciences, Germany 
Ultracentrifuge Optima L-70  Beckman, Munich, Germany 
UVT-20 M Transilluminator Herolab, Wiesloch, Germany 
Veriti 384 well Thermal Cycler Life Technologies, Carlsbad, USA 
Vortexer Scientific Industries Ink., Bohemia,  USA 
Water purification system  Millipore, Eschborn, Germany 
Waterbath Julabo, Seelstadt, Germany 
 
5.1.2 Consumables 
 
384-well PCR plate Thermo Fisher Scientific, Hudson, USA 
8-channel pipettor tips Impact 384 Thermo Fisher Scientific, Hudson, USA 
Adhesive PCR sealing film Thermo Fisher Scientific, Hudson, USA 
Amersham Hyperfilm™ ECL GE Healthcare, Chalfont St Giles, UK 
AMPure XP Magnetic Beads Beckman Coulter Genomics, Krefeld, Germany 
Cell culture dishes Nunc/Thermo Fisher Scientific, Hudson, USA 
Cell culture dishes Greiner Bio-one, Frickenhausen, Germany 
Cell culture flasks and pipettes  Costar, Cambridge, USA 
CLEAN resin Sequenom, San Diego, USA 
Cryo tubes  Corning, Corning,  USA 
Disposable scalpel  Feather, Osaka, Japan 
DNA LoBind Tubes Eppendorf, Hamburg, Germany 
Einweg-Pasteurpipette Carl Roth, Karlsruhe, Germany 
ep Dualfilter T.I.P.S.
®
 Eppendorf, Hamburg, Germany 
GenePulser Electroporation Cuvette (1mm) Bio-Rad, Hercules, USA 
Heat sealing film  Eppendorf, Hamburg, Germany 
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LabChip XT DNA 300 assay kit PerkinElmer, Waltham, USA 
MATRIX Liquid Handler D.A.R.Ts tips Thermo Fisher Scientific, Hudson, USA 
Micro test tubes (0.5 ml, 1.5 ml, 2 ml)  Eppendorf, Hamburg, Germany 
Micro test tubes DNALoBind (0.5, 1.5, 2 ml)  Eppendorf, Hamburg, Germany 
Multiwell cell culture plates and tubes  Falcon, Heidelberg, Germany 
Nitrocellulose Membrane (0.45 µm) Life Technologies, Carlsbad, USA 
Non-Adhesive sealing film (LightCycler) Roche, Basel, Switzerland 
nProteinA Sepharose 4 FastFlow  GE Healthcare, Munich, Germany 
Nylon Transfer membrane  MSI, Westboro, USA 
PCR plate Twin.tec 96 well Eppendorf, Hamburg, Germany 
Pipettes  Costar, Cambridge, USA 
Plug molds Bio-Rad, Hercules, USA 
ProteinA Dynabeads  Life Technologies, Carlsbad, USA 
rProteinA Sepharose 4 FastFlow GE Healthcare, Munich, Germany 
Sepharose CL-4 Beads Sigma-Aldrich, St. Louis, USA 
SpectroCHIP bead array Sequenom, San Diego, USA 
Sterile combitips for Eppendorf multipette Eppendorf, Hamburg, Germany 
Sterile micropore filters  Millipore, Darmstadt, Germany 
Sterile plastic pipettes Costar, Cambridge, USA 
Syringes and needles Becton Dickinson, Heidelberg, Germany 
Teflon foils Heraeus, Hanau, Germany 
Tubes (5ml, 15 ml, 50 ml, 220 ml)  Falcon, Heidelberg, Germany 
Whatman® Chromatography Paper Sigma-Aldrich, St. Louis, USA 
 
5.1.3 Chemicals 
 
All chemicals were purchased from Sigma-Aldrich (St. Louis, USA) or Merk (Darmstadt, 
Germany) if not otherwise stated. 
 
5.1.4 Molecular tools  
5.1.4.1 Enzymes and reagents 
 
Agarase NEB, Frankfurt, Germany 
Amersham™ ECL™ Prime Western Blotting 
Detection Reagent 
GE Healthcare, Chalfont St Giles, UK 
Ammoniumperoxidisulfat Merck, Darmstadt, Germany 
Beetle-Juice KIT PJK, Kleinblittersdorf, Germany 
Bio-Safe™ Coomassie Bio-Rad, Hercules, USA 
Biozym Plaque GP Agarose Biozym, Oldendorf, Germany 
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BSA Sigma-Aldrich, St. Louis, USA 
Cell Culture Medium Supplement Life Technologies, Carlsbad, USA 
dATP Solution NEB, Frankfurt, Germany 
Deoxynucleotide (dNTP) Solution Set NEB, Frankfurt, Germany 
DNA Ladder 1 kb plus Life Technologies, Carlsbad, USA 
DNA ladder 50 bp NEB, Frankfurt, Germany 
DNA ladder Generuler 50 bp Thermo Fisher Scientific, Waltham, USA 
DNA light loading dye (6x)  NEB, Frankfurt, Germany 
Dual-Luciferase® Reporter Assay System Promega, Madison, USA 
Enzymatics enzymes (Library prep) NEB, Frankfurt, Germany 
Ethidium bromide Sigma-Aldrich, St. Louis, USA 
Fermentas DNA loading dye (6x) Thermo Fisher Scientific, Waltham, USA 
Fetal Bovine Serum Gibco/Life Technologies, Carlsbad, USA 
GE Healthcare, Chalfont St Giles, UK 
Glycogen Ambion/Life Technologies, Carlsbad, USA 
Lipofectamin 2000 Invitrogen/Life Technologies, Carlsbad, 
USA 
M-MLV Reverse Transcriptase kit  Promega, Madison, USA 
N,N,N',N'-Tetramethylethylenediamine Sigma-Aldrich, St. Louis, USA 
NEXTflex™ DNA Barcodes HiSS Diagnostics, Freiburg, Germany 
Nuclease-free water Gibco/Life Technologies, Carlsbad, USA 
Oligo Only Kit Illumina, San Diego, USA 
peqGOLD Protein-Marker VII Peqlab, Erlangen, Germany 
Phusion Hot Start High-Fidelity DNA 
Polymerase  
NEB, Frankfurt, Germany 
Phusion Taq Polymerase Thermo Fisher Scientific, Waltham, USA 
Phorbol 12-myristate 13-acetate Sigma-Aldrich, St. Louis, USA 
Ponceau S-Solution AppliChem, Darmstadt, Germany 
Precision Plus Protein™ Kaleidoscope™  Bio-Rad, Hercules, USA 
Proteinase K  Roche, Basel, Switzerland 
QuantiFast SYBR green  Qiagen, Hilden, Germany 
Random Decamers Life Technologies, Carlsbad, USA 
Restriction endonucleases NEB, Frankfurt, Germany 
Roche, Basel, Switzerland 
RNase  Roche, Basel, Switzerland 
RNase A Sequenom, San Diego, USA 
Rotiphorese® Gel 30 (37.5:1) Carl Roth, Karlsruhe, Germany 
SAM (S-adenosyl-methionine) NEB, Frankfurt, Germany 
Shrimp Alkaline Phosphatase (SAP) Sequenom, San Diego, USA 
SssI CpG methyltransferase  NEB, Frankfurt, Germany 
Taq DNA Polymerase Roche, Basel, Switzerland 
T-Cleavage MassCleave Reagent kit Sequenom, San Diego, USA 
Transcriptor High fidelity cDNA Synthesis kit  Roche, Basel, Switzerland 
Trypan blue solution Merck, Darmstadt, Germany 
Tween® 20 Sigma-Aldrich, St. Louis, USA 
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5.1.4.2 Antibiotics 
 
Antibiotic Stock concentration Dilution Final concentration Company 
Ampicillin 100 mg/ml 1:1000 100 µg/ml Ratiopharm, Ulm, Germany 
Zeocin 100 mg/ml 1:4000 25 µg/ml Invitrogen, Karlsruhe, Germany 
 
5.1.4.3 Antibodies 
 
Antibody for FACS Product Company 
CD14-Fitc My4a Coulter Clone, Brea, USA 
CD1a-PE T6-RD1 Coulter Clone, Brea, USA 
DAPI 4′,6-Diamidino-2-phenylindole dihydrochloride Sigma, St. Louis, USA 
 
Antibody for ChIP Company 
hmC ActiveMotif, Carlsbad, USA 
PU.1 SantaCruz, Dallas, USA 
H3K4me1 Abcam, Cambridge, UK 
IgG Merck, Darmstadt, Germany 
 
Antibody for 
Western blotting 
Source/Company 
TET2 Dr. Olivier Bernard, Institut Gustave Roussy, Villejuif, France  
b-Actin Sigma-Aldrich, St. Louis, USA 
TDG Prof. Dr. Primo Schär, University of Basel, Switzerland 
MBD4 Diagenode, Seraing, Belgium 
anti-rabbit IgG-HRP Dako, Glostrup, Denmark 
 
5.1.4.4 Molecular biology kits 
 
Agilent DNA 1000  Agilent, St. Clara, USA 
Agilent High Sensitivity DNA kit Agilent, St. Clara, USA 
Agilent RNA 6000 Nano kit Agilent, St. Clara, USA 
Amaxa® Human Monocyte Nucleofector® Kit Lonza, Basel, Switzerland 
Blood & Cell Culture DNA Kit Qiagen, Hilden, Germany 
Clean and concentrator(TM) kit Zymo Research, Irvine,  USA 
DNeasy Blood & Tissue Kit Qiagen, Hilden, Germany 
EndoFree Plasmid Midi Kit Qiagen, Hilden, Germany 
EpiTect Bisulfite Kit Qiagen, Hilden, Germany 
EZ DNA methylation kit Zymo Research, Irvine,  USA 
Genomic DNA Clean & Concentrator Zymo Research, Irvine,  USA 
Hydroxymethyl Collector™ ActiveMotif, Carlsbad, USA 
MinElute Gel Extraction Kit Qiagen, Hilden, Germany 
MinElute PCR Purification Kit Qiagen, Hilden, Germany 
MycoAlert™ Mycoplasma Detection Kit Lonza, Basel, Switzerland 
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NucleoSpin® Plasmid Macherey-Nagel, Düren, Germany 
QIAamp DNA Micro/Mini Kit  Qiagen, Hilden, Germany 
QIAGEN Plasmid Plus Kit  Qiagen, Hilden, Germany 
QIAquick Nucleotide Removal Kit Qiagen, Hilden, Germany 
QIAquick PCR Purification Kit Qiagen, Hilden, Germany 
QuantiFast SYBR® Green PCR Kit Qiagen, Hilden, Germany 
Qubit® dsDNA HS Assay Kit Life technologies, Carlsbad, USA 
Qubit® ssDNA Assay Kit Life technologies, Carlsbad, USA 
Quest 5-hmC Detection Kit™ Zymo Research, Irvine,  USA 
REPLI-g Mini/Midi Kit Qiagen, Hilden, Germany 
Rneasy Mini Kit Qiagen, Hilden, Germany 
 
 
5.1.5 Oligonucleotides 
 
Oligonucleotides for qRT-PCR and qPCR were synthesized by Eurofins MWG 
(Ebersberg, Germany). Oligonucleotides for the MassARRAY system were purchased 
from Sigma-Aldrich (St. Louis, USA). 
 
 
5.1.5.1 Oligonucleotide primers 
5.1.5.1.1 qPCR primers 
 
Gene   Primer sequence (F, forward; R, reverse) Assay 
ACP2 F 5' CAGTAGAGAAGCAGAGGCGTCAG 3'  a 
  R 5' AATTGGCTCGTTCTCCCACC 3'   
C9ORF78/USP20 F 5' AGTACGCGTGTTTGGATTTGGG 3’ a,b,c 
  R 5' TGCTCTGAACACTCAGCTCCAC 3’   
CACNA1B F 5' AAGTGATGAGAAATACCAGTGCGG 3' b 
  R 5' CAAGCCACAATGAGCCCTTCC 3'   
CCL13 F 5' CTAGAAAAGTCTTTGGTGCCCAG 3' a,e,g 
  R 5' CTTGGAACTCTCAGAGGACCTTG 3'   
CCL13  F 5' CAAGTGAGATTTAAGAGGAGGGAGGG 3'  d 
  R 5' AGTGTCTGGTACATATTCGGTGCT 3'   
CCL13  F 5' ACTTGGTCAACGCCCTGCT 3'  b,c 
  R 5' TCTGCTCCTCTGGCTGTTCC 3'   
DNase1L3 F 5' GGGCTCACCTTCACAATGACATCC 3'  a,g 
  R 5' TCTGCTCCTTCAACGTCAGGTC 3'   
DNase1L3 F 5' CGCCATCCTCCACAAAGTCAC 3'  b 
  R 5' GACCACTTCCGAGTTCATCCAC 3'   
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Empty F 5´ GAAACCCTCACCCAGGAGATACAC 3´ b,g 
  R 5´ TGCAGTGGGACTTTATTCCATAGAAGAG 3´   
FBX041 F 5' TTCCAAATGAAAGTTGGCAGGAC 3' b 
  R 5' CAAAGGATCAGGTCTCAGAACCA 3'   
GAPDH F 5´ AGGCTGGATGGAATGAAAGGCAC 3´ c 
  R 5´ CTCCCACAAAGGCACTCCTG 3´   
HCGP39 F 5' GATCTGATCTGCAGCCCACC 3' d 
  R 5' TGCACCATCAGAACCAGAACC 3'   
HCGP39 F 5' CTTGTCGGATTGTAGGTCATAAG 3' d 
  R 5' GACAAGAAGGGTGTGGTCTAATA 3'   
HOXB1 F 5' CCTCGGAGAGGAGATCAGCA 3'  a,b 
  R 5' CCATATCCTCCGCAGCATCC 3'   
KCNE2 F 5' CATTCAGAAGGTCACAGAGGGCA 3'  a 
  R 5' CCACAAACTCACTCTCAGGCGA 3'   
LRGUK F 5' TGACTTGGTGCAGAAACTTGCT 3' b 
  R 5 'TGGTATCTGTTGCTAAGTCTTGGG 3'   
MMP7 F 5' GCTGTGACATACCTGAGCCTG 3'  a 
  R 5' CTATGCGACTCACCGTGCTG 3'   
RSRC1 F 5' CTGCCATGTGAGAAAGACCTG 3'  a 
  R 5' CAGAAGGAGGTGGAATGAGGA 3'   
Spi1 F 5´ CCAGTCACCACAGGAAGCATG 3´  d 
  R 5´ CGTTTCTCTGGGCCGCTGTG 3´   
STAT5 F 5' GCACAGACTCTGCATCCTCTTCTC 3' a,b,c,g 
  R 5' AGTCCTGCTTCCTCTGCCCA 3'   
TSSC1 F 5' TCCCACGGAGTTGACTGATCCA 3'  a 
  R 5' GTGCCGGTGGTGATCAATGTG 3'   
TSSC1 F 5' GACTTCCCTGGTCCTTTCCC 3' b 
  R 5' CCATGAGTGGGAGGTGTGAG 3'   
UNQ6496 F 5' AAACAGAGGCAGCTGACTCTCAGG 3' b 
  R 5' TGCGCCCTTCACAGATGGAG 3'   
VRK2 F 5' TTTCCGTTCCTCTGTGTTTATGCT 3'  a 
  R 5' ACCTCTTCTGACACCCATCCTC 3'   
        
    
a
 hMeDIP-qPCR   
    
b
 GGSD    
    
c
 MSRE   
    
d
 ChIP-qPCR   
    
e
 hmC-enrichment qPCR   
    
f
 Mass spectrometry analysis of bisulfite-converted DNA   
    
g
 Amplicons described in Ref. (Klug et al., 2010)   
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5.1.5.1.2 Sequencing primers 
 
Name Primer sequence 
pCpG-LUC_Seq_AS 5' CACAGACATCTCAAAGTATTCAGC 3' 
pCGS 5' TAAATCTCTTTGTTCAGCTCTCTG 3' 
 
5.1.5.1.3 Primer for molecular cloning 
 
Name/Gene   Primer sequence (F, forward; R, reverse) 
CACNA1C_PstI F tgtatctgcagGAAGCTGAGAACTGAATCAATGAATGCC 
CACNA1C_SpeI R tgataactagtATTACACAGACAAATTCCACTTGGTCCC 
RSRC1_NsiI F tgtatatgcatGGAGATTTCCCGTCTGTGCCTG 
RSRC1_XbaI R tgatatctagaGGAAGCTCAGCATTAAGAAGCAAGGG 
TSSC1_PstI F tgtatctgcagATAAATGTCAAGGCAAAGAGGGAAAGGG 
TSSC1_XbaI R tgatatctagaTGAGTGGGAGGTGTGAGCTCGT 
ADAP1_NsiI F tgtatatgcatAGCATCTCCCTAGTCCAGAGCC 
ADAP1_XbaI R tgatatctagaCTGAGCCTGGATGTTGAAGACCC 
SMAD7_NsiI F tgtatatgcatCTAACACCCAGCTCACCCAGGA 
SMAD7_XbaI R tgatatctagaCTAGAAGATGAGGCAGGAGGCAGAG 
LINC00111_NsiI F tgtatatgcatGACTTGAAGCCGGGACACTTAAGGA 
LINC00111_XbaI R tgatatctagaGCCCTGCGGATTTCAGAGAAGAC 
PIM3_PstI F tgtatctgcagCCAGACTGAGTCCTTCTCAGCTCC 
PIM3_XbaI R tgatatctagaAGGCCCTTCCTGCTTGACCA 
VRK2_PstI F tgtatctgcagAATTGCCATTCTCTGGGAACTATGAGTG  
VRK2_XbaI R tgatatctagaGCAGCAATGTGAAGGAGAAACTTTGAG 
 
5.1.5.1.4 qRT-PCR primers 
 
Gene   Primer sequence (F, forward; R, reverse) Assay 
CCL13 F 5' GAAGATCTCCTTGCAGAGGCT 3'  qRT-PCR 
g
  
  R 5' GGGTCAGCACAGATCTCCTTG 3'   
CD1a F 5' TATTCCGTATACGCACCATTCGGTC 3' qRT-PCR  
  R 5' CAGCCTCCTGTCACCTGTATCTC 3'   
HELLS F 5' TTCAGCAGGCTTGATGGGTC 3' qRT-PCR 
  R 5' AGATTAATGCCCAGGCCACCA 3'   
HPRT F 5' AAGTTTGTTGTAGGATATGCCC 3' qRT-PCR 
g
  
  R 5' GAACATTGATAATTTTACTGGCG 3'   
MBD4 F 5' TGGCTCTGAAATGGACAACAACTG 3'  qRT-PCR 
  R 5' TTCTATCTGTGTTCGTGGGATGGT 3'   
OGT F 5' TCCGAGTGAAGGTGATGGCAG 3' qRT-PCR 
  R 5' TTCGAGCGCCCTTAGTATAGCC 3'   
TDG F 5' AAATCCATGCAGCAGTGAACCT 3'  qRT-PCR 
  R 5' CACTGCCCATTAGGAATGCCA 3'   
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TET1 F 5' GCTCTCATGGGTGTCCAATTGCT 3' qRT-PCR 
  R 5' ATGAGCACCACCATCACAGCAG 3'   
TET2 F 5' AAGGCTGAGGGACGAGAACGA 3'  qRT-PCR 
  R 5' TGAGCCCATCTCCTGCTTCCA 3'   
TET3 F 5' CCTGCCGATGACAAGCTGGA 3'  qRT-PCR 
  R 5' GAGTTCCCGGATAGAGGCGA 3'   
 
 
5.1.5.1.5 MassARRAY primers 
 
Amplicon   Primer sequence 
Epi00103_STAT5A.1 10F aggaagagagAGTTGTTTGGTTTTGTGTGTTTTTT 
  T7R cagtaatacgactcactatagggagaaggctAAAAAAATCCTACTTCCTCTACCCA 
Epi00104_STAT5A.2 10F aggaagagagAAAGTGATTTTTTTGAAGAGTGGTG 
  T7R cagtaatacgactcactatagggagaaggctTCCAAAAAAACAAATCAAAACCTAA 
Epi00108_STAT5A.1 10F aggaagagagTTTATAGGGAGGTATTAGGGTTTGG 
  T7R cagtaatacgactcactatagggagaaggctTCCCTTCTTCAAAAAAAATTCCTAT 
Epi00109_CCL13.1 10F aggaagagagTTTGTGGTTTGAATAGTTAGAAGGA 
  T7R cagtaatacgactcactatagggagaaggctCAACAAACACAAAAACACTACAAAAA 
Epi00110_CCL13.2 10F aggaagagagTTTATGGTTTTTTATGGTGAATGGT 
  T7R cagtaatacgactcactatagggagaaggctAAAATAACTTACCTAACTAAACAAATCCC 
Epi00111_P2RY6.1 10F aggaagagagTTTGGTTATGTTTGGAGTTTGTAGA 
  T7R cagtaatacgactcactatagggagaaggctAAAAAAATACCCTTACCAACCATTT 
Epi00112_P2RY6.2 10F aggaagagagGAGTGTAAATGGTTGGTAAGGGTAT 
  T7R cagtaatacgactcactatagggagaaggctAAATCCCAAATATCTTCAAAAAACC 
Epi00123_DNASE1L3.1 10F aggaagagagTTTTTTAGGAAAGGGGTTTATTTTT 
  T7R cagtaatacgactcactatagggagaaggctAAAATCCAACACTCCAAACACTACT 
Epi00124_DNASE1L3.2 10F aggaagagagGGAGGAGAAGTAGTAGTGGGGTTAG 
  T7R cagtaatacgactcactatagggagaaggctCACCCCAAATACCCTCTAAAATAAA 
Epi00125_DNASE1L3.3 10F aggaagagagTGGTTTATTTTAGAGGGTATTTGGG 
  T7R cagtaatacgactcactatagggagaaggctTCTCTAACAACACACTCCTAATATTTATAC 
Epi00147_C9ORF78.2 10F aggaagagagAGAGGTTTTTGTGAGGAAGTTTTTT 
  T7R cagtaatacgactcactatagggagaaggctACTACCCACACACTTCTATATCTCCTC 
Epi00148_C9ORF78.3 10F aggaagagagGGAATTTTGTTATTTTTTAGGGTGG 
  T7R cagtaatacgactcactatagggagaaggctAAAACCACCATCCTCTAACTCTC 
Epi00162_MMP7.1 10F aggaagagagGGAATTTTAAGTAAGTGGGTTGTGA 
  T7R cagtaatacgactcactatagggagaaggctACAATCACTAACAAAAAACACCAAA 
Epi00184_CLEC10A.1 10F aggaagagagGAAGATAAGGTTGGAAATGGGTTAT 
  T7R cagtaatacgactcactatagggagaaggctACCTCTAATCCTTACAACACAACCA 
Epi00185_CLEC10A.2 10F aggaagagagTATTATTATTTGTGGGAGGTTTGGA 
  T7R cagtaatacgactcactatagggagaaggctAACAAAACTAACCTCAAACCCAACT 
Epi00193_HOXB1_01 10F aggaagagagTTTGAGTTTTATTTGTTTTGGGTGG 
  T7R cagtaatacgactcactatagggagaaggctCCTAAAAATACCCTTCCCCAACTC 
Epi00194_HOXB1_02 10F aggaagagagTTATTTTTTGGGTTAATTAGAAGGAGA 
  T7R cagtaatacgactcactatagggagaaggctAAATTTCTCTTAACCTTCATCCAATC 
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Epi00195_HOXB1_03 10F aggaagagagTATTTTTTGGGTTAATTAGAAGGAGA 
  T7R cagtaatacgactcactatagggagaaggctAAATTTCTCTTAACCTTCATCCAATC 
SQ00011_fCAB-epi_ctrl 10F aggaagagagGGGAGGGTTTATTATTTGGTTTTAG 
  T7R cagtaatacgactcactatagggagaaggctCACCAATCACAAAAAAACATCTTAC 
 
5.1.5.2 Plasmids 
 
Internal number Gene/Plasmid Name Backbone 
437 Renilla luciferase phRL-TK Vector pRL (Promega) 
865 pCpGL-cmv pCpG-CMV pCpG-mcs (Invivogen) 
995 pCpGL-EF1 pCpGL-EF1 pCpG-mcs (Invivogen) 
1146 CACNA1C pCpG-CACNA1C-RA pCpG-mcs (Invivogen) 
1147 LINC00111 pCpG-NCRNA00111-RA pCpG-mcs (Invivogen) 
1148 PIM3 pCpG-PIM3-RA pCpG-mcs (Invivogen) 
1149 RSRC1 pCpG-RSRC1-RA pCpG-mcs (Invivogen) 
1150 SMAD7 pCpG-SMAD7-RA pCpG-mcs (Invivogen) 
1151 VRK2 pCpG-VRK2-RA pCpG-mcs (Invivogen) 
1152 TSSC1 pCpG-TSSC1-RA pCpG-mcs (Invivogen) 
1153 ADAP1 pCpG-ADAP1-RA pCpG-mcs (Invivogen) 
 
5.1.5.3 siRNAs 
 
All siRNAs (siGENOMEsiRNA SMARTpool) were purchased from Thermo Scientific 
Dharmacon (Lafayette, USA).  
 
5.1.6 Cell lines and E. coli strains 
 
Name Origin Source/Company 
THP-1  human DSMZ (ACC 16) 
Daudi human DSMZ (ACC 78) 
HeLa human DSMZ (ACC 57) 
PIR1 (F- Δlac169 rpoS(Am) robA1 creC510 E.coli strain Invitrogen, Karlsruhe, Germany 
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5.2 Methods 
5.2.1 Cell culture 
5.2.1.1 General cell culture conditions 
 
In general all cells were cultivated according to “Current protocols in molecular biology” 
(Ausubel, 1987) if not otherwise stated. The cells were handled in a sterile lamina flow 
hood with sterile consumables only.  
Cells lines were cultivated in the indicated medium (see Table 5.1) and primary cells 
were cultivated in RPMI (Gibco). All media were supplemented with 10% FCS, L-
glutamine (2mM), sodium pyruvate (1mM), antibiotics (50 U/ml penicillin, 50 µg/ml 
streptomycin), 2 ml vitamins, non-essential amino acids and 50 µM ß-mercaptoethanol, 
if not otherwise stated. All supplements were purchased from Gibco and Biochrome, 
respectively. FCS (fetal calve serum) was heat inactivated before use for 30 min at 
56°C and each new batch of FCS or medium was tested before use. All cells were 
cultured at general cell culture conditions in a standard incubator (37°C, 5% of CO2, 95 
% of relative humidity). All suspension cells were harvested by gentle rocking of the 
flask, transferring the suspension into a falcon tube and removal of the supernatant 
after centrifugation at 300xg for 8 min at 4°C. In all washing steps the cells were 
resuspended in PBS and centrifuged again. 
 
5.2.1.1.1 Cell number and viability 
 
To asses cell number and viability cell solutions were stained with Trypan blue solution 
and counted in a Neubauer hemocytometer according to the manufacturer’s 
recommendation. Since cell membranes of living cells are still intact Trypan blue is only 
absorbed in dead cells, which turn blue and can be easily detected. 
 
5.2.1.1.2 Mycoplasma assay 
 
All cells primary or cell lines were routinely checked for mycoplasma contamination 
with the MycoAlertTM Mycoplasma Detection kit (Lonza). 
Cell culture supernatants were measured according to manufacturer’s 
recommendations. 
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5.2.1.2 Cell lines 
 
All cell lines were obtained from DSMZ (Deutsche Sammlung von Mikroorganismen 
und Zellkulturen) and cultivated according to Table 5.1. 
 
Table 5.1: Culture conditions 
Name Culture medium Adherence DSMZ accession number 
THP-1  RPMI 1640 no ACC 16 
Daudi RPMI 1640 no ACC 78 
HeLa DMEM yes ACC 57 
 
Suspension cell lines were split 1:3 to 1:6 into fresh medium every 2-3 days. Adherent 
cells were washed with PBS and detached from the surface using 0.05% trypsin/0.2% 
EDTA/PBS (3 ml per 75 cm2 per culture vessel area) incubated 5-10 min at 37°C with 
slight rocking of the plate. The reaction was stopped using 5-15 ml of medium including 
10% FCS. After one washing step the cells were seeded in the appropriate medium 
with all supplements and FCS. 
 
5.2.1.2.1 Design, assembly, and transfection of reporter constructs 
 
To verify regulatory functions of the DMRs reporter constructs were designed for 
luciferase assays.  
The predicted enhancer sequences were extracted from the UCSC Genome Browser 
and PCR primers covering the enhancer and control regions were designed. The 
primers included distinct PstI, NsiI, SpeI or XbaI restriction sites (listed in 5.1.5.1) which 
were introduced into the sequence during PCR. Enhancer fragments ranged from 291 
to 586 bp covering the site of transcription factor binding as well as the CpGs showing 
methylation dynamics.  
The design of the pCpGL-cmv vector used in this study is described elsewhere (Klug, 
2010, urn:nbn:de:bvb:355-epub-134293). The CpG-free vector contains a basal EF1α 
promoter and a CMV enhancer which was removed using PstI and SpeI and replaced 
with the DMRs.  
Enhancer and control regions were amplified from genomic DNA, ligated into the vector 
and cloned into the E. coli strain PIR 1 matching the plasmids origin of replication. The 
amplified Plasmids were isolated from the host cells, purified and controlled with 
restriction digest followed by agarose gel electrophoresis. Glycerol stocks were made 
from positive clones with verified sequences only. 
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Human cell lines (THP-1, HeLa) were co-transfected with either in vitro SssI-
methylated or unmethylated reporter plasmids including an internal Renilla control 
plasmid (Rehli, 2000). DEAE dextran or Lipofectamine® reagent were used according 
to manufacturer’s recommendations (see following chapters). The cells were cultivated 
for 48 h with or without 10-8 of PMA 12h after transfection until harvesting at 48h post 
transfection. Individual activity of firefly and Renilla luciferase was measured in 
duplicates and triplicates in three independent experiments and firefly luciferase was 
normalized to Renilla luciferase activity. A control construct containing the basal EF1α 
promoter only was included in the transfections to further correct enhancer activity for 
basal luciferase activity originating from the promoter element. Vice versa the original 
pCpGL-cmv vector containing both EF1α promoter and CMV enhancer was used as a 
positive control. 
 
5.2.1.2.1.1 Transfection with DEAE dextran 
 
This method was used to transfect THP-1 cells with reporter plasmid constructs. In 
principle dextran (polycation) forms complexes with the DNA (anionic charge) which 
are then transported into the cells via endocytosis.  
THP-1 cells can be differentiated into a mature monocyte- and macrophage-like 
phenotype by adding phorbol myristate acetate. Upon stimulation the cells become 
adherent and stop proliferation (Abrink et al., 1994; Tsuchiya et al., 1982). Luciferase 
activity was measured using the Dual-Luciferase Reporter Assay System (Promega) or 
the Beetle-Juice KIT (PJK) according to manufacturer’s recommendations. 
 
Throughout the first part of the protocol the cells were handled at sterile conditions. 
One day before transfection confluent cells were split and diluted to a concentration of 
5 x 105 cells/ml. After incubation for 24 h cells were pooled, divided into 6 ml samples 
(3 x 106 cells), washed with 6 ml of STBS buffer and centrifuged 12 min at 1200 rpm 
(14 ml round bottom tubes, polypropylene). Meanwhile the Renilla control plasmid was 
diluted in STBS buffer (20 ng/70 µl), divided into 70 µl samples and mixed with 200 ng 
of plasmid DNA (either methylated or non-methylated). DEAE stock solution was 
prepared dissolving DEAE dextran in STBS buffer to a final concentration of 800 µg/ml. 
Cell pellets were now transfected with a fresh mix of 70 µl DEAE stock solution and 70 
µl of plasmid-STBS-mix and vortexed. After 20 min of incubation at 37°C the 
transfection was terminated adding 10 ml of STBS buffer and centrifuged 12 min at 
  Material and Methods 
99 
 
1200 rpm. The pellets were resuspended in 6 ml of RPMI (10% FCS), transferred to a 
cell culture dish (Ø 60mm) and incubated 48 h at 37°C.  
If necessary, 24 h after incubation the cells were supplemented with a final 
concentration of 10-8 µg/µl PMA and incubated for another 24 h.  
 
48 h after transfection without PMA the cells were harvested using a Pasteur’s pipet 
into 14 ml round bottom tubes (poly-styrene). Remaining liquid in the dishes was 
recovered by rinsing the dishes with 5 ml of PBS and added to the cell suspension. 
After centrifugation (1200 rpm, 10 min, 4°C) the wash step was repeated with another 
5 ml of PBS, the supernatant was discarded and cells were resuspended in 1 ml of 
PBS. The suspension was then transferred to a smaller tube (1.5 ml, Eppendorf), 
centrifuged (1200 rpm, 10 min, 4°C) and mixed thoroughly with 300 µl of 1 x Passive 
lysis buffer.  
If PMA was added to the cells, the harvesting process was slightly different. The 
adherent cells were washed with 5 ml PBS, the supernatant was discarded and the 
cells were detached from the surface by adding 300 µl of 1 x Passive lysis buffer and 
slight scraping with a cell scraper. The solution was recovered and centrifuged. 
After precipitation (13000 rpm, 1 min) of remaining debris, luciferase and firefly activity 
of the cell lysates were measured on a luminometer, respectively. 
 
Required buffers and solutions: 
STBS Buffer (10x) 25 ml (25 mM) Tris (1 M), pH 7.4 
  8 g (137 mM) NaCl 
  6.372 g (5 mM) KCl 
  0.160 g (0.6 mM) Na2HPO4/7H2O 
  0.102 g (0.7 mM) CaCl2 
  Add ddH2O to 1 l, autoclave. 
        
DEAE Dextran 10 mg/ml STBS   
 
5.2.1.2.1.2 Transfection with Lipofectamine® Reagent 
 
Lipofectamine® Reagent (Invitrogen) is a lipid transfection reagent which contains 
polycationic and neutral lipids in a 3:1 ratio. In principle it forms complexes with the 
negatively charged DNA which are incorporated into the cells via endocytosis. This 
method was used to transfect the HeLa cell line for luciferase reporter assays. The 
Lipofectamine® 2000 assay was performed according to manufacturer’s instructions. 
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Since the reagent is sensitive to antibiotics, cells were transfected in Opti-MEM® I 
medium (Gibco) lacking antibiotics. 
One day before transfection HeLa cells were seeded at 0.4 x 106 cells in 2 ml of DMEM 
(including 10% FCS, PAA) per well into 6-well cell culture plates. 
Shortly before transfection the cells were washed two times with 2 ml of PBS while 
100 µl Opti-MEM® were mixed with 20 ng and 1 µg plasmid DNA per reaction in 14 µl 
round bottom tubes (poly-styrene, Falcon). A mixture of 100 µl Opti-MEM® and 7 µl of 
Lipofectamine® reagent was added to the DNA solution, mixed and incubated 30 min 
at room temperature. While 800 µl of Opti-MEM® were added to the reagent-mix, the 
last PBS wash buffer was removed from the cell pellets. The cells were now 
resuspended and incubated with the transfection mixture at 37°C for 5 h. The reaction 
was stopped with 1 ml of DMEM (incl. 10% FCS) and further incubated 43 h. 24 h after 
transfection the medium was changed and fresh 2 ml of DMEM were added per well. 
 
48 h after transfection the cells were harvested. First the medium was removed and the 
cells were washed with 4 ml of PBS. After discarding of the wash buffer, the cells were 
scraped from the surface (with a cell scraper) and at the same time lysed with 300 µl of 
1 x Passive lysis buffer. The solution was transferred to a 1.5 µl tube, centrifuged at 
13000 x rpm for 1 min before measuring transgene expression. Luciferase and firefly 
activity of the cell lysates were measured on a luminometer using the Beetle-Juice KIT 
(PJK) according to manufacturer’s instructions. 
 
5.2.1.3 Primary cells 
5.2.1.3.1 Isolation of PB-MNCs 
 
The collection of blood cells was performed in compliance with the Helsinki Declaration 
and all donors signed an informed consent. 
Peripheral blood mononuclear cells (PB-MNC) were isolated from healthy donors by 
leukapheresis and separated by density gradient centrifugation over Ficoll/Hypaque 
(Johnson et al., 1977). Monocytes were isolated from the MNC fraction using counter 
current centrifugal elutriation as described in Sanderson et al. (Sanderson et al., 1977). 
Usually monocyte yields ranged between 10-20% of total MNCs depending on donor 
variation. 
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5.2.1.3.2 Monocyte cell culture 
 
Blood monocytes isolated from healthy donor blood were cultivated at 1 x 106/m in 
RPMI supplemented as described in 5.2.1.1. The cells were further stimulated adding 
20 U/ml recombinant human IL-4 (Promokine, Heidelberg, Germany) and 280 U/ml 
GM-CSF (Berlex, Seattle, USA) in order to differentiate the cells into immature 
dendritic cells (iDC) and with 2% human AB serum to obtain macrophages. The cells 
were cultured for 7 days at according conditions and harvested after 6 h, 18 h, 27 h, 
42 h, 66 h and after 7 days of stimulation or immediately after elutriation. At 66 h after 
stimulation the cells were supplemented with fresh differentiation promoting factors. 
Macrophages were cultivated in Teflon foil and harvested by gentle rocking of the bag 
after cooling it down to 4°C (described in Andreesen et al., 1983). 
 
5.2.1.3.3 Small interfering RNA (siRNA) transfection 
 
Principle 
Depletion of the protein of interest can be facilitated using a variety of different 
methods. RNA interference is a very effective yet easy way to degrade mRNAs before 
their translation. Small interfering RNAs (siRNAs) are a pool of small single stranded 
RNAs targeting different epitopes on the target mRNA. Once injected into the cell, they 
form stable double stranded RNA molecules with the target mRNAs and thus block 
further processing of the mRNAs.  
 
In order to transmit siRNA in to primary cells the Amaxa device and the Human 
Monocyte Nucleofector® Kit (Lonza) were used according to manufacturer’s protocol 
with modifications.  
 
Protocol 
Freshly isolated blood monocytes were washed once and pelleted at 6 x 106 cells per 
transfection. After removing the supernatant completely 600 nM of siRNA (Thermo 
Scientific Dharmacon, Lafayette, USA) were added to the cells, resuspended carefully 
in 100 µl of Human Monocyte Nucleofector® solution (82 µl of Nucleofector® solution, 
18 µl supplement) and transferred to a cuvette. The cuvette was immediately placed 
into the Nucleofector® device. After transfection using the Y-01 program the cells were 
resuspended in 500 µl pre-warmed RPMI medium (supplemented with 10% FCS, 
antibiotic-free). The suspension was further transferred into a cell flask containing more 
medium (10% FCS, 20 U/ml IL-4, 280 U/ml GM-CSF). The cells were cultured at a 
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density of 1 x106 cells/ml for 27 h or 42 h. RPMI medium without antibiotics was used 
in the whole procedure to avoid increased cell death. The cells were harvested as 
described in 5.2.1.1 and subjected to DNA, RNA and protein isolation as well as flow 
cytometry measurements. 
 
5.2.1.4 E. coli culture and methods 
5.2.1.4.1 Culture 
 
Glycerol stocks of the E. coli strain PIR1 (F- Δlac169 rpoS(Am) robA1 creC510 
(Invitrogen, Karlsruhe, Germany) were streaked on a LB agar-plate and grown 
overnight at 37°C to obtain isolated colonies. Single colonies were picked and one 
colony per 30 ml of LB medium containing the appropriate antibiotics was cultured in a 
shaking device (200 rpm) over night at 37°C.  
 
Antibiotic Stock concentration Dilution Final concentration Company 
Ampicillin 100 mg/ml 1:1000 100 µg/ml Ratiopharm, Ulm, Germany 
Zeocin 100 mg/ml 1:4000 25 µg/ml Invitrogen, Karlsruhe, Germany 
 
Required medium: 
LB medium 10 g BactoTrypton (Difco) 
  5 g BactoYeastExtract (Difco) 
  10 g NaCl 
  Add ddH2O to 1 l, autoclave and adjust pH to 7.5 
 
5.2.1.4.2 Freezing 
 
In order to preserve cells, glycerol stocks were prepared. The cells were cultivated to 
confluency and 500 µl glycerol (80% in LB medium) were added to 500 µl of cell 
suspension. The vials were mixed thoroughly and stored at -80°C. 
 
5.2.1.5 Molecular cloning 
5.2.1.5.1 Construction of reporter plasmids 
 
Insert sequences for cloning were generated from genomic DNA using PCR and 
precipitated according to chapter 5.2.1.5.2. The used primers introduced two matching 
restriction sites (PstI or NsiI and SpeI or XbaI) in order to generate sticky ends after 
restriction digest (see section 5.2.2.4). The first two and the last two restriction 
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enzymes produced identical overhangs non-complementary to the other, which 
prevented self-ligation of the digested vector. 
The CpG-free vector pCpGL-cmv was isolated from cryo cultures and digested 
overnight using PstI and SpeI restriction enzymes to cut out the CMV enhancer and to 
match the inserts’ sticky ends. After size validation of inserts and vector on an agarose 
gel, both were purified from the gel (see chapter 5.2.2.3) and mixed in a ligation 
reaction with a 3:1 molar excess of insert compared to vector. Each insert was ligated 
into the vector over night at 16°C as well as one vector control without insert DNA (see 
section 5.2.1.5.4.). As described in chapter 5.2.1.5.5, 5 µl of the ligation mix were 
transformed into competent E. coli PIR1 cells (50 µl, Invitrogen). To validate accurate 
insertion, selected clones were picked, cultured and plasmids were isolated according 
to section 5.2.1.4.1 and 5.2.1.5.6. After control digest on an agarose gel the constructs 
were sequenced to check sequence integrity (Geneart, Regensburg, Germany) and 
preserved for long term storage (see chapter 5.2.1.4.2). 
 
5.2.1.5.2 Polyethylene glycol (PEG) precipitation 
 
PCR products for cloning were cleaned and precipitated with polyethylene glycol. DNA 
and PEG were mixed at equal amounts and incubated for 15 min at room temperature. 
After centrifugation for 15 min at 15000 rpm (RT) the supernatant was carefully 
discarded and 100 µl ethanol added without disturbing the pellet. Another 
centrifugation step followed (15 min, 15000 rpm, RT). The pellet was left to dry at RT 
for 5 min and dissolved in 20-25 µl H2O. 
 
Required solution: 
PEG-mix 26.2 g (26.2%) PEG 8000 
  20 ml (0.67 M) NaOAc (3M), pH 5.2 
  660 µl (0.67 mM) MgCl2 (1M) 
  Add ddH2O to 100 ml   
 
5.2.1.5.3 Dephosphorylation of DNA 
 
To prevent self-ligation of the vector after digestion the plasmids were treated with 1 U 
alkaline phosphatase (calf intestine, Roche) per 1 pmol of vector for 1 h at 37°C. The 
enzyme excises phosphate groups and thus allows vector ligation with the phosphate 
containing insert only. 
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5.2.1.5.4 Ligation of vector and insert 
 
After preparation of corresponding sticky ends on insert sequences and vector the two 
DNA fragments were ligated. Therefore a mixture of 1 U of T4 DNA ligase (NEB, 
Frankfurt, Germany) in a final concentration of 1 x T4 DNA ligase reaction buffer and in 
a final volume of 10-20 µl, including insert and vector DNA, was prepared. The insert 
DNA was added in a 3:1 molar excess to 100-200 ng of plasmid DNA and the mixture 
was incubated over night at 16°C. To monitor insert ligation compared to vector self-
ligation a vector control containing plasmid DNA only was included in the procedure. 
 
5.2.1.5.5 Transformation of competent bacteria 
 
To amplify plasmid constructs chemically competent E.coli PIR1 cells were 
transformed according to the following protocol. 
50 µl of competent bacteria were thawed on ice and carefully mixed with 5 µl of ligated 
vector or vector control and incubated 30 min on ice. The cells were heat-shocked for 
30 seconds at 42°C in a water bath and immediately stored on ice for 2-5 min. To 
select transformed cells only, the cells were incubated for 90 min at 37°C (shaking) in 
250 µl SOC medium and plated on an LB agar-plate supplemented with the antibiotic 
zeocin. Only plasmid-containing clones acquired the resistance and were able to grow. 
Colonies were grown over night at 37°C and DNA was isolated (see chapter 5.2.1.5.6) 
and stored at - 20°C until further usage. 
 
Required medium: 
SOC medium 20 g (2%) BactoTrypton (Difco) 
  5 g (0.5%) BactoYeastExtract (Difco) 
  0.6 g (10 mM) NaCl 
  0.2 g (3 mM) KCl 
  Add ddH2O to 1l, autoclave and add: 
  10 ml (10 mM) MgCl2 (1 M, sterile) 
  10 ml (10 mM) MgSO4 (1 M, sterile) 
  10 ml (20 mM) Glucose (2 M, sterile) 
 
5.2.1.5.6 Isolation of Plasmids 
 
Plasmid isolation from 2 ml liquid bacterial culture was performed using the 
NucleoSpin® Plasmid Quick Pure kit from Macherey & Nagel. To isolate larger 
amounts of plasmid DNA for cloning or transfection experiments, 30 ml of cultured 
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bacteria were purified using the EndoFree Plasmid Midi kit and Plasmid Plus kit 
(Qiagen). 
 
5.2.2 Working with DNA 
 
All standard molecular procedures were performed according to “Current protocols in 
molecular biology” (Ausubel, 1987) if not otherwise stated. The same applies for all 
purchased kits which have been used according to the manufacturer’s manual. 
 
5.2.2.1 Isolation of genomic DNA 
 
Cultured cells were trypsinated if necessary and/or washed twice. After removal of the 
supernatant the pellets were stored at -20°C or subjected to DNA isolation using either 
the Qiagen Blood and Tissue kit or the Qiagen Blood and Cell culture kit. 
 
5.2.2.2 DNA quantity and quality 
5.2.2.2.1 Agarose gel electrophoresis 
 
To routinely check the quality of purified genomic DNA agarose gel electrophoresis 
was the method of choice. Electrophoresis separates nucleic acids in porous agarose 
gels according to their size and shape. 
Depending on the size of the DNA 1% to 2% of agarose dissolved in 1 x TAE was 
melted in a microwave and mixed with 2,5 µl ethidium bromide (10 mg/ml) /50 ml gel 
after cooling down to ~50°C. The gel was poured into the gel chamber to polymerize. 
Meanwhile the DNA samples were mixed 4:1 with DNA loading dye (1:5). The solid gel 
was covered with 1 x TAE running buffer, loaded with the DNA samples and run for 
30 min to 1.5 h at 80 to 120 V. 
 
Required buffers: 
TAE (50x) 252.3 g (2 M) Tris/HCL, pH 7.8 
  20.5 g (250 mM) NaOAc/HOAc, pH 7.8 
  18.5 g (50 mM) EDTA 
  Add ddH2O to 1l   
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DNA loading dye (5x) 500 µl (50 mM) Tris/HCL, pH 7.8 
  500 µl (1%) SDS (20%) 
  1 ml (50 mM) EDTA (0.5 M), pH 8.0 
  4 ml (40%) Glycerol 
  10 mg (1%) Bromphenol blue 
  Add ddH2O to 10 ml   
 
5.2.2.2.2 NanoDrop spectrophotometer 
 
DNA concentrations were measured using the NanoDrop spectrophotometer device 
according to the manufacturer’s instructions. 
 
5.2.2.2.3 Qubit® 
 
The Qubit® system was used to detect very low DNA concentrations with the Qubit® 
dsDNA HS Assay Kit or single stranded DNA using the Qubit® ssDNA Assay kit.  
Samples were prepared and measured according to the manufacturer’s manual. 
 
5.2.2.2.4 2100 Bioanalyzer 
 
For fragmented DNA the 2100 Bioanalyzer (Agilent Technologies) was an alternative 
method to check quality, quantity and fragment length at the same time. DNA samples 
were prepared and measured with the Agilent DNA 1000 or Agilent High Sensitivity 
DNA kit. The device was also used to detect RNA quality and quantity using the Agilent 
RNA 6000 Nano kit. 
 
5.2.2.3 Purifying DNA with Gel extraction 
 
To obtain homogenous, size-selected PCR fragments and plasmid DNA the whole 
sample was separated on an agarose gel. The band of interest was excised from the 
gel with a scalpel and DNA was purified and recovered with the QIAquick Gel 
Extraction kit (Qiagen) according to the manufacturer’s instructions.  
 
5.2.2.4 Enzymatic restriction digest 
 
To check or prepare DNA in several methods enzymatic restriction digests were 
performed. All enzymes were purchased from New England Biolabs or Roche. If not 
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otherwise stated the enzyme was mixed in excess (see table Table 5.2) in a final 
concentration of 1 x corresponding buffer containing BSA, if required, and DNA. The 
solution volume was adjusted to the volume of enzyme in a 9:1 ratio and incubated at 
37°C for 1-2 hours or overnight. 
 
Table 5.2: Parameters for enzymatic restriction digest of DNA 
Method Amount DNA Amount enzyme Volume Incubation time 
Inserts for cloning 1-2.5 µg 15 U each 35-45 µl 1 h 
Vector for cloning 10 µg 20 U each 40 µl O/N 
Check ligation 8 µl 10 U each 20 µl 1 h 20 min 
GGSD 400-500 ng 30 U/60 U 50 µl O/N 
hMeDIP after TF 4 µg 30 U 100 µl O/N 
MSRE 100 ng 20 U each 12 µl O/N 
 
5.2.2.5 Polymerase Chain Reaction (PCR) 
 
The polymerase chain reaction (PCR) is a simple method to perform in vitro synthesis 
and amplification of DNA. In brief 100 ng DNA was amplified using the Phusion Hot 
Start High-Fidelity DNA Polymerase (Thermo Fisher Scientific, Waltham, USA) and the 
appropriate primers in the following mix. The annealing time was adjusted to the lowest 
primer TM (annealing temperature = TM,lowest+3°C).  
 
   10 µl 5 x Phusion HD Buffer 
   1 µl dNTPs (10 mM) 
   1 µl Primer S (10 pmol/µl) 
   1 µl Primer AS (10 pmol/µl) 
   0.5 µl Phusion Hot Start Taq Polymerase (2 U/µl) 
   X µl Template DNA 
    Add to 50 µl with nuclease-free H2O 
 
Table 5.3: Reaction parameter for general PCR 
PCR step Cycling parameter 
Initial melting 98°C, 30 s 
35 cycles 
Melting 98°C, 10 s 
Annealing 69°C, 20 s 
Extension 72°C, 20 s 
Final extension 72°C, 7 min 
Cooling 12°C, forever 
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5.2.2.6 In-vitro methylation and removal of methylation 
 
DNA was in-vitro methylated using 4 U SssI CpG methyltransferase (NEB) per 1 µg 
DNA supplemented with 320 µM of S-adenosyl methionine (SAM). The reaction was 
incubated 5 h at 37°C, replenished with enzyme and SAM after 2 hours and terminated 
by heating it to 65°C for 10 min. To clean-up the DNA the QIAamp DNA Kit (Qiagen) 
was used according to the manual. 
 
In order to erase all methyl marks present on genomic DNA, whole genome 
amplification was performed using the Repli-g Mini or Midi (Qiagen). 
 
To obtain DNA with a distinct level of methylation; for example 50%, both 100% and 
0% methylated DNAs were mixed in a ratio of 1:1. This DNA was used as control DNA 
for methylation analysis on the MassARRAY system. 
 
5.2.2.7 Detection of DNA modifications  
5.2.2.7.1 Detection of 5-methylcytosine (5mC) 
5.2.2.7.1.1 Quantitative DNA methylation analysis using the MassARRAY system 
 
The MassARRAY system is a bisulfite-based method to detect and quantify DNA 
methylation levels at single-base resolution. Most methods to measure DNA 
methylation require an amplification step to ensure sufficient resolution. Since the 
methyl mark is lost within two PCR steps, the methylation patterns have to be 
transferred into gene code information. This is accomplished by sodium bisulfite 
treatment. This chemically deaminates all regular cytosines and converts them into 
uracil but it doesn’t affect methylated cytosines which stay unchanged. This treatment 
results in methylation dependent sequence variation from C to T in the PCR products. 
The change in the underlying sequence leads to a G/A variation on the reverse strand 
and a mass difference of 16 Da per CpG-residue in the cleavage products which can 
be detected by the MassARRAY system (MALDI-TOF mass spectrometry). A complete 
overview of the method can be found in Ehrich et al., 2005 or in the EpiTYPER User 
Guide (Ehrich et al., 2005, www.sequenom.com). 
 
Protocol 
The experiments were performed according to the EpiTYPER application guide and 
protocols (Sequenom). DNA bisulfite treatment was carried out using either the EZ 
  Material and Methods 
109 
 
DNA methylation kit (Zymo) or the EpiTect Plus kit (Qiagen). Cycling times were 
adjusted to following conditions if not otherwise stated:  
 
1) 95°C for 30 min 
2) 50°C for 15 min 
3) Go back to step 1, 19 times 
4) 4°C for ever 
 
PCR, SAP treatment, in vitro transcription, RNA cleavage and MALDI-TOF mass 
spectrometry was done as recommended by Sequenom. The EpiDesigner tool 
(Sequenom, Hamburg, Germany) was used to design PCR primers including a T7 
polymerase promoter tag added to the 5’ end of the reverse primer and a 10-mer 
overhang added to the forward primer to balance melting temperature differences. 
Raw data was processed using the EpiTYPER software (v1.2, Sequenom). 
 
5.2.2.7.2 Detection of hydroxymethylcytosine (5hmC) 
5.2.2.7.2.1 Glycosylation and glycosyl-sensitive digest of DNA (GGSD) 
 
This method was adapted from the Quest 5-hmC Detection Kit™ (Zymo). The kit 
permits sequence specific detection of 5hmC using a 5hmC glycosyltransferase 
enzyme which specifically tags and therefore protects residual hydroxymethylcytosine 
by glycosylation. In a subsequent digestion step glycosylated 5hmCs are protected 
from a glycosyl-sensitive restriction enzyme (MspI), whereas all other non-protected 
cytosines are cleaved. We optionally utilized a second enzyme (HpaII), which is 
sensitive to 5mC, 5hmC, and glycosyl-5hmC to obtain absolute levels of 5mC and 
5hmC. The locus specific cleavage or protection of DNA can be quantified by qPCR. 
 
Protocol 
Instructions of the manufacturer’s manual were followed with slight alterations. 400-500 
ng gDNA was glycosylated for 3 h at 37°C in the following reaction setup: 
 
  400-500 ng DNA 
  5 µl 10 x Glycosyltransferase Reaction Buffer 
  5 µl 10 x Uridine Diphosphoglucose (UDPG, 1 mM) 
  2 µl Glycosyltransferase (2 U/µl) 
 Fill up with ddH2O to a final volume of 50 µl 
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In the next step the DNA was purified using the Zymo Clean and ConcentratorTM-5 kit 
and eluted in 22 µl EB (70°C) after incubation of the elution buffer on the membrane of 
the column for 2 min. The DNA was now digested with 30 U of MspI or 30 u HpaII 
(NEB) overnight at 37°C in the corresponding buffer. After incubation another clean up 
step followed as described above with an elution volume of 20 µl and was eluted from 
the column twice. The samples were now randomly measured in the NanoDrop device 
and diluted in elution buffer to a final concentration of ~1-2 ng/µl. In the following qPCR 
step the digestion and protection of the DNA was measured, respectively. 
 
5.2.2.7.2.2 MeDIP and hMeDIP (Hydroxy-/methylated DNA Immunoprecipitation) 
 
The MeDIP (hMeDIP) method is an antibody based immunoprecipitation to enrich for 
(hydroxyl-) methylated DNA fragments. It was originally adapted from a protocol of 
Mohn et al. (Mohn et al., 2009) which was designed to pull-down methylated DNA. The 
enriched DNA fragments can be further quantified using qPCR. 
 
In principle 4 µg of gDNA was digested with MseI in a final volume of 100 µl for 1,5 h at 
37°C, then purified using the Qiaquick PCR Purification kit (Qiagen) and eluted twice in 
50 µl pre-heated (55°C) EB after incubation for two minutes.  
In the next step 1-2 µg DNA was diluted in 300 µl TE buffer (pH 8,0) and denatured for 
10 min at 95°C followed by immediate cooling on ice for another 10 min. 10% of input 
DNA was set aside at 4°C. 30 µl of 10 x IP buffer were now added to the denatured 
DNA together with 1-2 µg of 5-methylcytidine or 5-hydroxy-methylcytidine antibody 
(Diagenode and ActiveMotif, respectively) and incubated 2. In the meantime 30 µl 
ProteinA Dynabeads (Invitrogen) per sample were washed with 800 µl of 0,1% 
BSA/PBS for 5 min at room temperature to block unspecific binding of the antibody. 
The beads were separated from the wash buffer on a magnetic rack, the supernatant 
was discarded and the wash step was repeated once. The blocked beads were 
resuspended in 30 µl of 1 x IP buffer, added to the antibody-DNA mixture and 
incubated 2 h at 4°C with overhead shaking.  
After 2 to maximum 3 h of rotation the beads were separated on a magnetic rack, the 
supernatant was discarded and the beads were washed three times with 700 µl 1 x IP-
buffer in a shaking Thermomixer (800 rpm, Eppendorf) for 10 min at RT. After 
discarding the supernatant the beads were resuspended in 250 µl Proteinase K 
digestion buffer, which was also added to the input sample, together with 3.5 µl of 
Proteinase K (20 mg/ml, Roche) and incubated 3 h at 50°C in a shaking Thermomixer 
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(Eppendorf). After incubation the supernatant was separated from the beads on a 
magnetic rack and transferred to a new Eppendorf tube.  
Finally the enriched DNA and input were purified using the Qiaquick PCR Purification 
Kit (Qiagen), eluted twice in 30 µl EB (55°C, 2 min incubation) and further quantified 
with qPCR.  
 
Required buffers and solutions: 
 
Na-Phosphate buffer (1 M), pH 7.0  39 ml 2 M NaH2PO4 (276 g/L) 
       61 ml 2 M Na2HPO4  (284 g/L) 
       Add ddH2O to 100 ml 
 
IP buffer (10x)     100 mM Na-Phosphate buffer, pH 7.0 
       1.4 M NaCl 
       0.5% Triton X-100 
 
TE buffer (1x)     10 mM Tris-HCl pH 8.0 
       1 mM EDTA pH 8.0 
 
IP buffer (1x)     1 volume 10×IP buffer 
       9 volumes TE buffer 
 
BSA/PBS solution    9 ml PBS 
       1 ml BSA (10 mg/ml)  
 
Proteinase K digestion buffer   50 mM Tris/HCl, pH 8.0 
       10 mM EDTA 
       0.5% SDS 
 
5.2.2.7.2.3 hMeDIP-seq 
 
In order to measure 5hmC levels genome-wide it was part of this thesis to adapt the 
hMeDIP protocol for hMeDIP-sequencing (hMeDIP-seq). The protocol was altered with 
slight modifications and performed as already described in chapter 5.2.2.7.2.2.  
First, the DNA was sonicated using the Covaris device instead of digestion to obtain a 
homologous fragmentation range of approximately 200 bp. Therefore gDNA was 
diluted in TE buffer and fragmented according to the amount using the following 
settings.  
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Covaris settings 4-12 µg DNA 2-3 µg DNA 
Duty cycle 10% 10% 
Intensity 5 5 
Cycles per burst 200 200 
Duration 180 s 120 s 
Water level 12 12 
Tube DNA micro DNA micro 
Volume 130 µl 50 µl 
 
Fragment length was confirmed on an agarose gel and 2 µg of sonicated DNA further 
subjected to immunoprecipitation. The purification step was also modified to improve 
DNA yield. The DNA was incubated in binding buffer for 15 min. After centrifugation the 
flowthrough was loaded on the column again and centrifuged one more time. The wash 
buffer was incubated for 2 min on the column and centrifuged one minute from every 
side. Residual wash buffer was aspirated from the inner ring and the membrane was 
dried one minute at RT. Then 37 µl of pre-heated (55°C) EB were pipetted on the 
center of the membrane, incubated for 2 min and eluted twice from the column. Of the 
remaining 33 µl of eluate 3 µl were quantified using qPCR to check enrichment 
performance and 30 µl were further processed. 
During the procedure the DNA was denaturated by heat resulting in single stranded 
DNA fragments. Before subjecting the DNA to library preparation, the second strand 
had to be generated in order to perform effective adapter ligation further downstream of 
the procedure. This was done using the NEBNext® Second Strand Synthesis Module 
following the manufacturer’s instructions with slight alterations. Random primer were 
taken from the Retroscript® kit (50 µM, Life Technologies) and 450 ng added to the 
following mixture in a final volume of 80 µl. 
 
  Mastermix: 
   30 µl 5hmC-enriched DNA 
   2.9 µl Random Decamers (50 µM, Ambion) 
   8 µl 10 x Second Strand Synthesis Reaction Buffer 
   4 µl Second Strand Synthesis Enzyme Mix 
   35.1 µl H2O (nuclease-free) 
 
The solution was mixed thoroughly and incubated 2.5 h at 16°C in a thermal cycler. 
After incubation the DNA was purified as described above and eluted in 44 µl of EB 
which accounts for 4 µl loss of DNA and the remaining 40 µl were further processed 
using the library preparation protocol described in chapter 5.2.2.9. 
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5.2.2.7.2.4 Hydroxymethyl CollectorTM-seq 
 
This method was used to measure 5-hydroxymethylcytosine on a genome-wide level 
and is based on the Hydroxymethyl CollectorTM kit (ActiveMotif). The kit chemically 
modifies 5hmC residues and thus enriches for hydroxymethylated DNA fragments. 
Hydroxymethylated cytosines are specifically glycosylated and further tagged with 
biotin at the glycosyl group. Streptavidin-conjugated magnetic beads are used to pull-
down captured DNA which can be further quantified by qPCR. Samples enriched for 
5hmC are then subjected to library preparation as described in section 5.2.2.9 and 
sequenced according to chapter 5.2.2.10. 
 
Protocol 
First the DNAs were sonicated to an approx. fragment length of 200 bp using the 
Covaris S2 with the following settings: 
 
Covaris settings  
Duty cycle 10% 
Intensity 5 
Cycles per burst 200 
Duration 180 s 
Water level 12 
Tube DNA micro 
DNA 12 µg 
Volume 130 µl 
 
After checking fragment size on an agarose gel (2%) and quantity using the NanoDrop, 
2 µg DNA of each source were further processed using the Hydroxymethyl CollectorTM 
kit. 5hmC enrichment was performed according to manufacturer’s manual (version B2) 
including the negative control but with slight alterations to the protocol. The biotin 
solution was incubated for 1 h or 1.5 h. To improve the yield elution buffer was heated 
to 50°C and incubated 2 min on the column before the elution centrifugation. End-to-
end rotation was done on an Intelli-Mixer (program F5). In the last step DNA was 
eluted in 45 µl elution buffer, quantified by qPCR and subjected to library preparation. 
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5.2.2.7.3 Detection of formylcytosine (5fC), carboxylcytosine (5caC) 
5.2.2.7.3.1 DNA modification-sensitive restriction efficiency (MSRE) 
 
This protocol was used to detect 5fC and 5caC levels at single CpGs by quantification 
of the cutting-efficiency of a modification-sensitive enzyme. 100 ng of iDC DNA was 
digested overnight with 20 U MspI and 20 U HhaI or HhaI alone (control) at 37°C. MspI 
is sensitive to 5fC and 5caC (Ito et al., 2011) whereas HhaI digests both modifications. 
After digestion, the samples were diluted 1:10 with ddH2O and digested fragments 
were quantified using qPCR. The digested and control-digested sample amplification 
values were normalized against the GAPDH region, which lacks a MspI restriction site. 
The cutting efficiency was calculated by subtracting the normalized values for MspI-
digested and HhaI-digested (control) samples from 100%. 
 
5.2.2.7.3.2 fCAB-epi 
 
This chemical modification assisted BS-seq protocol is adapted from the original fCAB-
seq method developed by Song and colleagues (Song et al., 2013). In principle, 5fC is 
modified by O-ethylhydroxylamine (EtONH2) in a chemical reaction to protect it from 
bisulfite-conversion. The subtraction of standard BS-converted sample values from 
fCAB-seq samples allows detection of 5fC at single-base resolution. 
 
Design of control oligos 
To test the adapted protocol (fCAB-epi) four DNA oligos (61 bp) of non-human origin, 
containing only two CpG sites, were designed. The sequence was adapted from the 
pGEM®-3Z vector (Promega). Each oligo contains one of the following modifications at 
both CpGs: 5mC, 5hmC, 5fC, 5caC, or unmodified cytosines. The oligos were ordered 
and synthesized at Eurofins MWG (Ebersberg, Germany). 
 
Table 5.4: Control oligos for fCAB-epi 
Name Sequence (5'->3') 
ctrl_5fC GGGAGGGCTTACCATCTGGCCCCAGGZGGATGCZGGGTAAGATGCTTTTCTGTGACTGGTG 
ctrl_5hmC GGGAGGGCTTACCATCTGGCCCCAGGZGGATGCZGGGTAAGATGCTTTTCTGTGACTGGTG 
ctrl_5mC GGGAGGGCTTACCATCTGGCCCCAGGZGGATGCZGGGTAAGATGCTTTTCTGTGACTGGTG 
ctrl_C GGGAGGGCTTACCATCTGGCCCCAGGCGGATGCCGGGTAAGATGCTTTTCTGTGACTGGTG 
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Protocol 
Instructions of the published protocol were followed with slight alterations (Song et al., 
2013). 1 µg of DNA was treated for 2 h at 37°C in the following reaction setup to 
protect 5fC or in a control setup without EtONH2: 
 
  1 µg DNA 
  2 µl MES buffer (1 M) 
  2 µl O-ethylhydroxylamine (EtONH2, 0.1 M) 
 Fill up with ddH2O to a final volume of 20 µl 
 
In the next step the DNA was purified using the QIAquick Nucleotide Removal Kit 
(Qiagen) and eluted in 30 µl EB (37°C). DNA concentrations were measured using the 
Nanodrop device and 200 ng of sample and control-sample DNA were subjected to 
bisulfite-conversion using the EpiTect Bisulfite Kit according to the manufacturer’s 
manual (Qiagen). The samples were further processed in the MassARRAY EPITYPER 
protocol and measured using mass spectrometry as was described in chapter 
5.2.2.7.1.1. 
 
5.2.2.8 ChIP (Chromatin Immunoprecipitation) 
 
The ChIP (Chromatin immunoprecipitation) is a method to study protein interactions 
with DNA. The majority of regulatory proteins interact directly with their DNA target 
regions. With this method they are crosslinked to their specific genomic location, using 
formaldehyde. This chemical substance directly targets amino groups on amino acids 
and nucleotides forming a Schiff’s base. The resulting DNA fragments can be detected 
and quantified after immuno-based pull-down. Depending on the aim of the experiment 
ChIP samples can be quantified using qPCR for site specific analysis of the regions of 
interest or by whole genome sequencing to study the protein of interest on a genome-
wide level. 
 
Principle 
In the first step formaldehyde was used to cross-link DNA-protein-interactions 
according to a protocol published earlier (Metivier et al., 2003). The cells were 
incubated in media with all supplements and 1% formaldehyde for 10 min at room 
temperature. By adding 0,125 M glycine the reaction was stopped and the cells were 
further washed in 1 x PBS including 1 mM PMSF and 10 mM NaBut twice. The pellet 
was stored immediately at -80°C or further processed.  
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In the next step the pellets were resuspended in L1A lysis buffer (250 µl/10 x 106 cells) 
and lysed in L1B lysis buffer (250 µl/10 x 106 cells) for 10 min on ice. After 
centrifugation the pellets were resuspended in Nuclear Lysis Buffer L2 (400 µl/10 x 106 
cells) and sonicated using the Covaris device with the following settings. 
 
Covaris settings  
Duty cycle 20% 
Intensity 8 
Cycles per burst 200 
Duration 1800 s 
Water level 15 
Tube Chromatin  
Cells 20 x 10
6
 
Volume 800 µl 
 
After centrifugation to clear the lysate, fragment size was checked on an agarose gel 
and 5% of IP volume was separately stored on 4°C and used as input DNA. 2 x 106 
cells were pre-cleared with 50 µl of Sepharose CL-4B beads (blocked in DB 
supplemented with 0,5% BSA and 20 µg/ml glycogen, 2 h, RT) per sample in DB 
(including protease inhibitors) for 2 h at 4°C and after centrifugation incubated with 
2,5 µg appropriate antibody over night at 4°C. Chromatin samples were precipitated 
using 50 µl of blocked ProteinA Sepharose beads (in DB including protease inhibitors, 
supplemented with 0,5% BSA and 20 µg/ml glycogen, overnight, RT) per IP for 3 h at 
4°C. In the next step the bead-complexes were washed according to the following 
conditions. After incubation of wash buffer (5 min, rotating, room temperature) the 
samples were centrifuged for 5 min at 500 g and 4°C and the wash buffer was 
discarded. This step was repeated with all wash buffers listed in the following table. 
 
Buffer Wash steps Volume 
WB I 2 x 400 µl 
WB II 2 x 400 µl 
WB III 2 x 400 µl 
TE, pH 8.0 3 x 400 µl 
 
The antibody-DNA-complexes were now eluted from the beads by incubation with 
freshly prepared 110 µl EB twice (20 and 10 min, RT, shaking at 850 rpm in a 
Thermomixer). After centrifugation (500 g, 3 min, 4°C) 2 x 100 µl supernatant were 
recovered and together with the input DNA (filled up to 200 µl with EB) incubated with 
0,5 µg/µl of Proteinase K over night at 65°C. After reverse cross-linking the samples 
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were digested with 0.33 µg/µl RNAse for 2 h at 37°C and then purified using the 
Qiaquick PCR purification kit with extended incubation of PB (30 min) and elution in 
52 µl pre-warmed EB (55°C) after 2 min incubation at RT. 10 µl of the eluate were 
diluted 1:3 in H2O and quantified using qPCR and the remaining 40 µl were subjected 
to library preparation. 
 
Required buffers and solutions:  
 
Glycine 9 .85g (2.625 M)  Glycine   
  Add ddH2O to 50 ml     
          
Cell Buffer Mix  1 ml (10 mM)  HEPES / KOH (1 M), pH 7.9 
  4.25 ml (85 mM) KCL (2 M)   
  200 µl  (1 mM) EDTA (0.5 M), pH 8.0 
  Add ddH2O to 97 ml *     
          
Nuclear Lysis Buffer (L2) 5 ml (50 mM) Tris/HCl (1 M), pH 7.4  
  5 ml (1%) SDS (20%)   
  1,43 ml (0.5%) Empigen BB (35%)  
  2 ml (10 mM)  EDTA (0.5 M), pH 8.0 
  Add ddH2O to 97 ml *     
          
Dilution Buffer (DB) 2 ml (20 mM) Tris/HCl (1 M), pH 7.4  
  2 ml (100 mM) NaCl (5 M)   
  400 µl (2 mM) EDTA (0.5 M), pH 8.0 
  5 ml (0.5%) Triton X-100 (10%) 
  Add ddH2O to 97 ml *     
          
Wash Buffer I (WB I) 2 ml (20 mM) Tris/HCl (1 M), pH 7.4  
  3 ml (150 mM) NaCl (5 M)   
  500 µl (0.1%) SDS (20%)   
  10 ml (1%) Triton X-100 (10%) 
  400 µl (2 mM) EDTA (0.5 M), pH 8.0 
  Add ddH2O to 100 ml     
          
Wash Buffer II (WB II) 2 ml (20 mM) Tris/HCl (1 M), pH 7.4 
  10 ml (500 mM) NaCl (5 M)   
  10 ml (1%) Triton X-100 (10%) 
  400 µl (2 mM) EDTA (0.5 M, pH 8.0) 
  Add ddH2O to 100 ml     
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Wash Buffer III (WB III) 1 ml (10 mM) Tris/HCl (1 M), pH 7.4 
  10 ml (250 mM) LiCl (2.5 M)   
  10 ml (1%) NP-40 (10%) 
  10 ml (1%) Deoxycholate (10%) 
  200 µl (1 mM) EDTA (0.5 M), pH 8.0 
  Add ddH2O to 100 ml     
          
Elution Buffer (EB) 500 µl  (0.1 M) NaHCO3 (1M) 
  250 µl (1%) SDS (20%)   
  Add ddH2O to 5 ml     
 
         
  *add immediately before use (per ml of buffer): 
  10 µl (1 mM) PMSF (100 mM) 
  20 µl   50x Roche Inhibitor Cocktail 
  10 µl (10 mM) NaBut (100 mM) 
 
5.2.2.9 Library preparation 
 
Principle 
In order to perform next generation sequencing, DNA libraries of each DNA source 
have to be generated. Therefore the DNAs are fragmented to ~200 bp to ensure a 
good coverage and mapping, respectively. To limit DNA input and therefore sample 
preparation costs the DNA is enriched for the mark of interest by antibody pull-down or 
other affinity purification methods before library preparation. The first step of the library 
protocol performs a repair of 3’ and 5’ ends to form blunt ended, phosphorylated DNA 
molecules which serve as anchors for a poly-A tails. Next one adenosine is added to 
the forward and reverse strand. This enables adapter ligation at both ends in order to 
ensure specific bar coding of all DNA fragments of one source. In the next step DNAs 
are purified from adapter dimers and non-ligated fragments by size selection; this can 
be done using agarose gel electrophoresis followed by gel extraction or using 
automated nucleic acid fractionation devices. After PCR amplification and quality check 
the DNAs are ready for sequencing. 
 
Protocol 
Library preparation was performed according to the following two library protocols. 
During this work the size selection of the original protocol was adapted to the Caliper 
LabChIP XT to enhance the yield of DNA. Both protocols are listed on the following 
pages. For the whole procedure DNA low bind consumables were used. All enzymes 
were purchased from Enzymatics (via NEB, Frankfurt, Germany) unless otherwise 
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stated. All components were thawed on ice and all samples were thoroughly mixed on 
a vortexer (speed 6) and spun down before incubation. Incubation steps were carried 
out in a thermal cycler with heated lid if block was heated > 20°C.  
 
First part 
In the first step 40 µl of DNA was polished to generate blunt ended fragments. For 
each donor one fragmented, non-enriched input sample from the identical DNA source 
was diluted (10 ng into 40 µl) and included in the library preparation procedure. All 
samples were mixed with 10 µl of the following mastermix and incubated 30 min at 
20°C. 
 
Table 5.5: Mastermix for DNA end-repair 
Component Volume  Final concentration 
H2O 3,34 µl n.a. 
10x T4 ligase buffer 5,0 µl 1x 
dNTP mix (10 mM) 1,0 µl 2 mM 
T4 DNA polymerase 0,30 µl n.a. 
Klenow fragment 0,06 µl n.a. 
T4 Polynucleotide kinase 0,30 µl n.a. 
Total volume 10 µl 
 
Next the DNAs were purified using the MinElute PCR Purification kit from Qiagen 
according to manufacturer’s instructions with slight alterations to improve DNA yield. All 
centrifugation steps were carried out at 13000 x rpm except for the binding on column 
and the elution step (11000 x rpm). Samples were washed with PE twice and the 
membrane was dried 2 min at full speed. Remaining wash buffer on the purple rim 
inside the column was removed and air dried one minute. The DNA was eluted twice in 
10.2 µl and 10.3 µl of pre-warmed elution buffer (50°C) and incubated 5 min each at 
RT before elution.  
In the next step A-tailing was performed. Sample volume was measured, 2.6 µl of 
mastermix added to 18 µl of sample, mixed and incubated 30 min at 37°C. 
 
Table 5.6: 3’-dA addition by Exo-Klenow 
Component Volume Final concentration 
10 x Blue buffer 2,0 µl 1x 
dATP (10mM) 0,40 µl 195 µM 
Klenow (3’-5’ exo-) 0,20 µl n.a. 
Total volume 2,6 µl 
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Next the Sample volume was calculated and mixed with (sample volume + 2 µl) of 2 x 
Rapid ligation buffer. NEXTflex DNA Barcodes (HiSS Diagnostics, Freiburg, Germany) 
were diluted 1:2 in 1 x T4 DNA ligase buffer, mixed well and 1 µl of adapter mix (1:2) 
was added to the corresponding DNA sample. Finally 1 µl of T4 Rapid DNA ligase was 
added to the mixture and ligated 10 min at 30°C. 
Before the next step, the sample volume was measured and adjusted to 50 µl. 
 
In this clean up step the samples were pre-size-selected according to a ratio of sample 
volume to bead volume of 1:1.1 (Agencourt AMPure XP, Beckman Coulter). 
The tubes were vortexed two times, flicked and vortexed again before incubation for 
5 min at RT followed by precipitation of the beads to the vessel wall on a magnetic rack 
for 2 min at RT. The supernatant was discarded and the beads were carefully washed 
two times with 70% ethanol for 30 seconds. After removal of the ethanol the tubes 
were air dried at 37°C for 2-5 min to evaporate remaining liquid. The dry pellet was 
resuspended in 50 µl ddH2O, incubated 5 min at RT and spun down for one second at 
13,000 x rpm. To separate the beads from the liquid the tubes were placed on a 
magnetic holder for 2 min at RT and the supernatant was transferred to a new tube. 
 
Next the previous clean up step was repeated with the same sample to beads ratio and 
eluted in 37.5 µl for ChIP samples and 25 µl for 5hmC-enriched samples. 
 
From this step the two library preparation protocols differ. 
 
Second part (using agarose gels for size selection) 
The samples were now amplified by performing 18 cycles of PCR according to the 
following mastermix. 
 
Table 5.7: PCR mix (18 cycles) for ChIP-seq 
Component Volume Final concentration 
Phusion HF buffer (5x) 10 µl 1x 
BiooPrimer Mix (100 µM) 2.0 µl 0.5 µM 
dNTP mix (10 mM each) 1.5 µl 300 µM 
Phusion polymerase 0.5 µl n.a. 
Total Volume 50 µl  
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Table 5.8: Parameters for PCR cycling (18 cycles) 
  98°C 30 sec 
18x 
98°C 10 sec 
65°C 30 sec 
72°C 30 sec 
  72°C 5 min 
  4°C forever 
 
After PCR the samples were purified according to the cleanup step described above 
using AMPure XP beads at a sample to beads ratio of 1:1.1 and the DNA was eluted in 
50 µl for a second clean up. 
 
The previous step was repeated with a sample to beads ratio of 1:1.1 and the DNA 
was eluted in 12 µl for size selection on an agarose gel. 
2 µl of 5 x DNA loading dye was added to the samples before loading them on a 2% 
low melting agarose gel (50 ml) together with 1 µg of DNA ladder (NEB) and running it 
at 60 V for 100 min in pre-cooled running buffer (1 x TAE). 
The gel was then placed on an UV screen and 200-350 bp fragments were excised 
with a scalpel. 
 
DNA was purified from the gel pieces using the QIAquick Gel Extraction kit with slight 
alterations to the protocol. 
First the weight of the gel pieces was determined and 6 volumes of QG per volume of 
gel were added. In a 5 min incubation step the slices were dissolved at RT in a rotator 
(speed F1, 6 rpm). After adding 2 volumes of isopropanol per volume of gel the tubes 
were mixed thoroughly and applied on a MinElute column, spun for 30 seconds at 
11000 x rpm and the flowthrough was transferred back onto the column for another 
centrifugation step. The remaining liquid was discarded and the column was washed 
with 500 µl of Buffer QG and spun at maximum speed. Two more wash steps were 
performed with 750 µl of buffer QG and centrifugation at max speed for 45 seconds. 
After removal of the flowthrough the empty column was centrifuged at maximum speed 
for 2 min and transferred into a fresh 1.5 ml Eppendorf tube. Remaining liquid was 
aspirated from the purple ring inside the column and air dried for 1 min at RT. To elute 
the DNA, 13 µl of EB buffer were heated to 50°C, applied to the membrane and 
incubated for 5 min at RT. The column was centrifuged for 1 min at 11000 rpm. 
DNA quality and fragment size were tested on the Bioanalyzer device (DNA 1000 
assay). 
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This protocol was applied to the PU.1 ChIP-seq samples 7, 8, and 9 (5.2.5.6). 
 
Second part (using the Caliper LabChIP XT for size selection) 
The samples were now amplified by performing 4 cycles of PCR according to the 
following mastermix and cycling protocol. 
 
Table 5.9: PCR mix (12/4 cycles) for 5hmC-seq 
Component Volume Final concentration 
Phusion HF buffer (5x) 10 µl 1x 
Betaine (5 M) 13 µl 1.3 M 
BiooPrimer1 (100 µM) 0.25 µl 0.5 µM 
BiooPrimer2 (100 µM) 0.25 µl 0.5 µM 
dNTP mix (10 mM each) 1 µl 200 µM 
Phusion polymerase 0.5 µl n.a. 
Total Volume 50 µl  
 
Table 5.10: Parameters for PCR cycling (4/12 cycles) 
  98°C 2 min 
4x / 12x 
98°C 30 sec 
65°C 30 sec 
72°C 45 sec 
  72°C 5 min 
  4°C forever 
 
After PCR the samples were purified according to the cleanup step described above 
using AMPure XP beads at a sample to beads ratio of 1:1.8 and the DNA was eluted in 
10 µl for Caliper. Measure recovered sample volume and adjust it to a final volume of 
10 µl with H2O. 
DNA samples were prepared for size selection on the Caliper LabChip XT according to 
the manufacturer’s manual and separated using the LabChip XT DNA 300 assay kit 
including one sizing ladder on each chip. Size selection ranges are depicted in Table 
5.11. 
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Table 5.11: Size range for Caliper size selection 
Enrichment method Sample source Range (in bp) Range (in %) Applied to Lib. Nr. 
ChIP 
Sample 234-316 275 bp +/- 15% 
#7-9, 55-63 
Input sample 213-287 250 bp +/- 15% 
5hmC enrichment 
Sample 234-316 275 bp +/- 15% 
#44-50 
Input sample 213-287 250 bp +/- 15% 
Sample 238-322 280 bp +/- 15% 
#38-43 
Input sample 238-322 280 bp +/- 15% 
 
The DNA was recovered from the chip in 20 µl elution buffer and filled up to 37.5 µl for 
ChIP samples and to 25 µl for 5hmC-enriched samples with ddH2O. 
In a second PCR step the DNA fragments were further amplified in 12 PCR cycles 
according to Table 5.9 and Table 5.10. 
 
After amplification the samples were purified with a 1:1.1 sample to beads ratio and 
eluted in 50 µl H2O as described before. 
The previous clean up step was repeated with a sample to beads ratio of 1:1.1 and the 
DNA was recovered in 11 µl H2O if DNA fragment size and amount was measured 
using the Bioanalyzer DNA 1000 assay or in 16 µl for the DNA Hyper Sensitivity assay. 
In the last step the Bioanalyzer was performed. 
 
This protocol was applied to the PU.1 ChIP-seq, hMeDIP-seq, and Hydroxymethyl 
Collector™ samples #38-50, 55-63 (5.2.5.2, 5.2.5.6). 
 
Samples from both protocols were now ready for whole genome sequencing. 
Sequencing was done by the KFB center (Biopark, Regensburg) on an Illumina HiSeq 
1000 device (see next chapter). 
 
5.2.2.10 Next generation sequencing (NGS) 
 
Next generation sequencing was carried out at the service facility “KFB - Center of 
excellence for Fluorescent Bioanalytics” (Regensburg, Germany; www.kfb-
regensburg.de). The sample libraries were quantified (KAPA SYBR FAST ABI Prism 
Library Quantification Kit, Illumina) and cluster generation was performed on the cBot 
(TruSeq SR Cluster Kit v3, Illumina). Next, the samples were sequenced on an Illumina 
HiSeq 1000 device. The resulting data provided as .fastq-files and further processed as 
outlined in chapter (5.2.5). 
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5.2.3 Working with RNA 
5.2.3.1 RNA preparation and isolation 
 
Whole RNA lysates from human blood cells were obtained using the following protocol. 
Cultured cells were washed and pelleted. Cell pellets were lysed in 350 µl RLT 
buffer/5 x 106 cells containing ß-mercaptoethanol and sheared 10 times using a 1 ml 
syringe. The lysates were kept on ice at all times and immediately frozen to -80°C for 
storage. 
Total RNA was extracted from the thawed samples using the Qiagen RNeasy Midi or 
Mini kit according to manufacturer’s recommendation. Quality and concentration of the 
RNA was then verified using agarose gel electrophoresis and the NanoDrop device or 
the Bioanalyzer. 
 
5.2.3.2 Formaldehyde agarose gel 
 
To check RNA quality, samples were analyzed on a formaldehyde gel. Adding 
formaldehyde to the system prevents intramolecular baseparing and thus secondary 
structures which would interfere with the proper separation of the RNA in the gel. 1% of 
agarose was dissolved in 1 x MOPS buffer by heating in a microwave, cooled down to 
~60°C and mixed with 6.5% of formaldehyde. Meanwhile RNA sample were heated at 
37°C for 30 min and four volumes of RNA loading dye (1:4) were added. After heating 
to 65°C the samples were cooled down on ice and ready for loading. Now the 
polymerized gel was put inside an agarose gel chamber, filled with 1 x MOPS buffer, 
and loaded with the prepared samples. The gel was run 1 hour at 120 V and analyzed 
on an UV screen. The gel was handled under a fume hood at all times. 
 
 
5.2.3.3 qRT-PCR 
 
In the quantitative reverse transcriptase real-time PCR (qRT-PCR) a reverse 
transcriptase is used to transcribe the RNA to cDNA which is further amplified. For this 
purpose two kits were used depending on the amount of starting material of RNA. 
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 M-MLV Reverse Transcriptase kit (Promega):  
    1 µg of RNA 
    1µl Random decamer primer 
    1 µl dNTP’s (10pmol/ml) 
    add H2O 
 Incubate for 5 min at 65°C 
    4 µl of 5 x M-LLV Buffer 
 Mix, centrifuge and incubate 2 min at 42°C 
    1 µl M-LLV Reverse transcriptase 
 Incubate 50 min at 42°C and 15 min at 70°C 
 
 Transcriptor High fidelity cDNA Synthesis kit (Roche): 
    100 ng to 1 µg of RNA 
    2 µl Random hexamer primer 
    add H2O 
 Incubate for 10 min at 65°C, put on ice 
    4 µl 5 x High fidelity reaction buffer 
    0.5 µl Protector RNase inhibitor (40U/µl) 
    2 µl dNTP mix (10 mM each) 
    1 µl DTT 
    1.1 µl High Fidelity Reverse transcriptase 
 Mix, centrifuge and incubate 30 min at 50°C 
 Inactivate 5 min at 85°C 
 
After a final dilution step (1:5) the samples are now ready for RT-qPCR or storage at 
-20°C. 
5.2.4 Working with Proteins 
5.2.4.1 Sample preparation and isolation 
 
Whole protein lysates from human blood cells were prepared according to the following 
protocol. Isolated cells were washed, counted and all PBS removed from pellets. Fresh 
cell pellets were then lysed in 200 µl 2x SDS lysis buffer à 3 x 106 cells, sheared with a 
1 ml syringe to homogenize the sample and boiled for 10 min at 95°C in a shaking 
Thermomixer (Eppendorf) at 850 rpm. After centrifugation (1min, 13000 rpm, 4°C) the 
supernatant was transferred to a new tube and stored at -80°C. 
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Required buffers and solutions:  
2 x SDS lysis buffer 10 ml   Glycerin 
  6.25 ml (125 mM) Stacking gel buffer (1 M Tris, pH 6.8) 
  2 g (4%) SDS  
  5 ml (10%) 2-Mercaptoethanol (14.4 M) 
  10 mg (0.02%) Bromphenolblue 
  Add ddH2O to 50 ml.   
 
5.2.4.2 SDS Page, Western blotting and Immunostaining 
 
Protein samples were separated in a discontinuous gel system consisting of two layers 
of gel with different salt and polyacrylamide concentrations. The 8% or 10% gels were 
prepared freshly (Table 5.12) and overlaid with isopropanol alcohol until 
polymerization.  
 
 
Table 5.12: SDS-PAGE stock solutions 
Gel stock solutions Separating gel Stacking gel 
Final AA 
concentration 8% 10% 5% 
Stacking gel buffer - - 25 ml 
Separating gel buffer 25 ml 25 ml - 
SDS (10%) 1 ml 1 ml 1 ml 
Acrylamide (30%) 26,4 ml 33 ml 16,7 ml 
Aqua bidest Adjust to 100 ml 
 
Table 5.13: SDS-PAGE gel mix solutions 
 Separating gel Stacking gel 
Separating gel stock solution 6 ml - 
Stacking gel stock solution - 2,5 ml 
TEMED 6 µl 2,5 µl 
APS (10%) 30 µl 20 µl 
 
To denature secondary protein structures samples were boiled (95°C, 10 min, shaking 
850 rpm), loaded on the gel (1,5 x 105 to 5 x 105 cells per lane) together with a protein 
marker (Bio-Rad or Peqlab) and separated for 30-60 min at 100 V and another 1,5-2 h 
at 120 V in 1 x Laemmli buffer.  
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According to their size proteins were further transferred to a nitrocellulose membrane 
using either a semi-dry system (Biometra Fastblot semi-dry blotter) or a wet system 
(Biorad Mini Transblot Cell). 
 
The semi-dry system is a discontinuous Western blotting system consisting of three 
different buffers. While the membrane was equilibrated in anode buffer B three 
Whatman paper soaked with buffer A were stacked into the chamber. Starting on the 
anode, followed by three Whatman paper soaked in buffer B and then the pre-soaked 
membrane was added on top of the stack. Next, the gel was placed on the membrane 
and covered by three Whatman paper soaked in cathode buffer C. With the cathode on 
top, the chamber was closed and blotted at 11 V for one hour at RT. 
 
In the wet blot system there is only one buffer which surrounds the gel and membrane 
stack completely. At first three pre-soaked Whatman paper, membrane and gel were 
pre-soaked in the Wettransfer buffer. Next three Whatman paper were placed on the 
chamber device followed by the membrane and the gel. On top of the stack followed 
another three Whatman paper before the chamber was closed and arranged in the 
right direction in the tank, which was filled up with tank buffer. The proteins were 
blotted onto the membrane at 100 V for 4 hours at 4°C.  
After one hour of blotting the membranes were recovered, marked at standard band 
sizes with a permanent pen and blocked one hour in 5% dry milk in TBS-T (TBS-
(TDG)-T was used for the TDG antibody) at room temperature. The membranes were 
washed three times in TBS-T before Immunostaining was carried out over night at 4°C 
(antibody concentrations listed in table (Table 5.14). Second antibody (coupled with 
horseradish peroxidase (HRP), anti-rabbit, 1:5000) incubation was performed one hour 
at room temperature. After chemical activation of the antibody (Amersham™ ECL™ kit) 
fluorescence signals were detected exposing the blot to autoradiography film 
(Amersham Hyperfilm™ ECL) and developing it in a Fast-Blot machine (Agfa) or by 
using a fluorescence scanner (Chemi Doc XRS+ System, Bio-Rad). 
 
Table 5.14: Antibodies for Western blotting 
Antibody Membrane Dilution Species Source/ Company 
TET2 Nitrocellulose 1:2000 rabbit Dr. Olivier Bernard, Institut  
        Gustave Roussy, Villejuif, France  
MBD4 Nitrocellulose 1:2000 rabbit Diagenode 
TDG Nitrocellulose 1:10000 rabbit Prof. Dr. Primo Schär,  
        University of Basel, Switzerland 
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Required buffers and solutions:  
 
Stacking gel buffer 60.6 g Tris/HCL   
  Add ddH2O to 500 ml 
        
Separating gel buffer 90.93 g Tris/HCL   
  Add ddH2O to 500 ml 
        
APS 1 g Ammonium persulfate 
  Add ddH2O to 10 ml and store in aliquots at -20°C. 
        
5 x Laemmli buffer 216 g (0.95 M) Glycine 
  15 g (40 mM) Tris 
  15 g (0.5%) SDS 
  Add ddH2O to 3 l   
        
Buffer A 36.3 g Tris   
  200 ml Methanol   
  Add ddH2O to 1 l   
        
Buffer B 3.03 g Tris   
  200 ml Methanol   
  Add ddH2O to 1 l and adjust pH to 10.4 
        
Buffer C 5.2 g ε-Amino-n-caproic acid 
  200 ml Methanol   
  Add ddH2O to 1 l   
        
10 x Tank buffer 140 g Glycine   
  30 g Tris   
  5 g SDS   
  Add ddH2O to 1 l   
        
Wettransfer buffer 200 ml Methanol    
  80 ml Tank buffer (10x) 
  Add ddH2O to 1 l   
        
        
10 x TBS 45.8 g (20 mM) Tris 
  175.5 g (150 mM) NaCl 
  Add ddH2O to 2 l and adjust pH to 7.4 
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1 x TBS (TDG) 100 mM  Tris-HCL pH 8.0 
  150 mM  NaCl   
  0.1% Tween 20   
  Add ddH2O to 1 l   
        
1 x TBS-T 1 l   TBS (1x) 
  1 ml (0.1%) Tween 20 
        
Blocking solution 5 g (5%) dry milk 
  Add 100 ml TBS-T   
 
5.2.4.3 Staining of SDS gels 
 
5.2.4.3.1 Ponceau S staining 
 
After Western blotting the membranes were stained 5 to 10 min with Ponceau S 
(AppliChem) to check protein transfer. To remove the staining solution membranes 
were incubated in 5% dry milk in TBS-T on a shaker and further subjected to 
immunodetection. 
 
5.2.4.3.2 Coomassie staining 
 
In order to check complete protein transfer after Western blotting, gels were incubated 
in Bio-Safe™ Coomassie solution (Bio-Rad) on a shaker for 5-10 min. Washing the gel 
in H2O for 15 min removed the staining. 
 
5.2.4.4 FACS 
 
FACS (Flourescence-activated cell sorting) is a flow cytometry based method to detect 
intra- and extracellular proteins on/in cells and to sort them accordingly. Therefore cells 
are washed and labeled with different antibodies at the same time. The LSRII (BD) 
detects and separates the fluorescence and light scattering signals at single cell 
resolution and sorts the cells into separate tubes for further processing. 
In order to test cell condition after transfection 0,5 x 106 to 1 x 106 cells were washed in 
cold FACS buffer and incubated 20 min at 4°C with 5 µl of CD14-Fitc antibody (My4a, 
Coulter Clone) and 2,5 µl of CD1a-PE antibody (T6-RD1, Coulter Clone) per 500,000 
cells (no light exposure). After another washing step with FACS buffer cells were 
resuspended in 250 µl of fixation buffer. Before subjecting the cells to FACS 
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measurement on the LSRII (BD) 0.2 µg DAPI (Sigma)/mio cells was added to the 
suspension. 
 
5.2.5 Next generation sequencing analysis 
 
Analysis of next generation sequencing data sets was performed on an Apple Mac Pro 
(OS X, v10.9.5, processor 2x2.93 GHz, 6-Core Intel Xeon) as described in the 
following chapters. The raw sequencing data files were provided in the .fastq file format 
from the sequencing facility (KFB, Regensburg, Germany) and further processed 
according to the following scripts. Tools and software used for analysis are given in 
chapter 5.2.6 and additional data sets as well as in-house pearl scripts are further 
described in chapter 5.2.5.9. 
 
5.2.5.1 Comparison of two whole genome 5hmC IP methods 
 
For global analyses of 5hmC we tested and compared two 5hmC-enrichment methods, 
hMeDIP and the Hydroxymethyl CollectorTM kit. Data generation is described in chapter 
5.2.2.7.2.3 and 5.2.2.7.2.4. 
Data processing was done for all hMeDIP-seq and Hydroxymethyl CollectorTM-seq 
samples using the following command line and tools as outlined: 
 
#All files: 
hMeDIP_MO_Lib38.fastq.gz 
hMeDIP_DC18h_Lib39.fastq.gz 
hmCcol_MO_Lib40.fastq.gz 
hmCcol_DC18h_Lib41.fastq.gz 
hmCcol_INPUT_MO_Lib42.fastq.gz 
hmCcol_INPUT_DC18h_Lib43.fastq.gz 
hmCcol_MO_Lib44.fastq.gz 
hmCcol_DCd7_Lib45_GTAGAG.fastq.gz 
hmCcol_MO_Lib46.fastq.gz 
hmCcol_DC18h_Lib47.fastq.gz 
hmCcol_DCd7_Lib48.fastq.gz 
hmCcol_INPUT_MO_Lib49.fastq.gz 
hmCcol_INPUT_DC18h_Lib50.fastq.gz 
 
 
###Mapping to hg19 and creating individual tag directories with Bowtie2: 
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#INPUT: 
$myMap-bowtie2.pl -x hg19 -p 23 -name <target folder for bowtie2> <INPUT path to raw data>  
$makeTagDirectory <target folder for tag directory> <target folder for bowtie2> -genome hg19 -checkGC ; 
#Samples: 
$myMap-bowtie2.pl -x hg19 -p 23 -name <target folder for bowtie2> <experiment path to raw data>  
$makeTagDirectory <target folder for tag directory> <target folder for bowtie2> -genome hg19 -checkGC ; 
# Generate combined tag directory files: 
$makeTagDirectory <path to combined output tag directory file> -d <path to tag directory 1> <path to tag 
directory 2> 
 
###Create UCSC file: 
$makeUCSCfile <path to tag directory> -o auto  
 
Figure 3.25 und Figure 3.27: 
 
####Generation of tag count distribution scatterplots for tag counts of hMeDIP and Hydroxymethyl 
Collector
TM
 kit, to compare the two 5hmC-enrichment methods and method replicates: 
#Find peaks using the INPUT as control tag directory (Homer tools with options -region -s200 -mD200 -
L0): 
$findPeaks <path to tag directory> -i <path to INPUT tag directory> -region -size 200 -minDist 200 -L 0 -o 
<path/filename for output>;  
 
##Remove unmappable regions using Homer tools and BEDtools: 
#Conversion to .bed file: 
$pos2bed.pl <path to peak file> > <path to output .bed file> 
 
#Remove unmappable regions: 
#Set of unmappable regions was produced earlier in the Rehli laboratory. 
$intersectBed -v -a <path to .bed file> -b <path to set of unmappable regions > <path to output .bed> ;  
 
###Generate merged peak file with unique and common peaks, without duplicate peaks: 
#Merging peak file with reference file to obtain all common and unique peaks without duplicates: 
#Find common peaks with minimum overlap of 50%: 
$IntersectBed -a <path to file1> -b <path to file2> -wa -wb -f 0.5 <path to output .bed file> 
 
#Find unique peaks in peak file with maximum overlap of 50%: 
$IntersectBed -a <path to file1> -b <path to file2> -v -f 0.5 <path to output .bed file> 
 
#Exclude duplicates in common peak files and find common peaks missing in the reference file: 
intersectBed -a <path to file1> -b <path to file2> -v -f > <path to output .bed file> 
 
#Merge common peak files of two corresponding files: 
$cat <path to file1> <path to file2> > <path to output .bed file> 
 
#Sorting complete common peak file in Excel: 
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#Sort for minimum start position and maximum stop position, concatenate chromosome-start-stop and 
#remove duplicates. 
 
#Merge unique peak files and complete common peak file to one file: 
$cat <path to file1> <path to file2> > <path to output .bed file> 
 
#Convert .bed file back to peak file .txt: 
$bed2pos.pl <bed file> > <path to output peak file .txt> 
 
#Annotate peak files using Homer (with options -log -size given): 
$annotatePeaks.pl <path to peak file> <genome hg19> -log -size given > <path to output file> 
 
#Save positions and tag counts for R: 
#Generate scatterplots in R: 
$setwd("path to peak file") 
$data <- read.table("peak file name .txt", header=T, sep="\t") 
$Lab.palette <- colorRampPalette(c("blue", "orange", "red"), space = "Lab") 
$attach(data) 
$per <- cor(D1_38_hMeDIP, D1_40_hmCcol) 
$pdf(file="file name .pdf", height=4, width=4) 
$par(mar=c(5,5, 0.5, 0.5),cex.lab=1.4, cex.axis=1.1, pty="s", las=1) 
$smoothScatter(name x-axis,name y-axis,nrpoints = 0,colramp = Lab.palette,ylab="D1_40_hmCcol", 
xlab="D1_38_hMeDIP_log2", cex=0.5) 
$mtext(per,family="Helvetica", col="black", side=1,line=2,cex=1.3,padj=0.2) 
$dev.off() 
 
5.2.5.2 Genome-wide 5hmC analyses 
 
To get a global picture of 5hmC, PU.1 and 5mC dynamics around 5hmC peaks in 
differentiating monocytes, global analysis of 5hmC was performed using the 
Hydroxymethyl CollectorTM kit. Data generation is described in chapter 5.2.2.7.2.4. 
PU.1 ChIP-seq and bisulfite-sequencing is described in chapters 5.2.2.8, 5.2.2.9, 
5.2.2.10, and 5.2.5.9.2. 
Data processing was done for all Hydroxymethyl CollectorTM-seq samples using the 
following command line and tools as outlined: 
 
#All files: 
hmCcol_MO_Lib40.fastq.gz 
hmCcol_DC18h_Lib41.fastq.gz 
hmCcol_INPUT_MO_Lib42.fastq.gz 
hmCcol_INPUT_DC18h_Lib43.fastq.gz 
hmCcol_MO_Lib44.fastq.gz 
hmCcol_DCd7_Lib45_GTAGAG.fastq.gz 
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hmCcol_MO_Lib46.fastq.gz 
hmCcol_DC18h_Lib47.fastq.gz 
hmCcol_DCd7_Lib48.fastq.gz 
hmCcol_INPUT_MO_Lib49.fastq.gz 
hmCcol_INPUT_DC18h_Lib50.fastq.gz 
 
####Mapping to hg19 and creating individual tag directories with Bowtie2: 
#INPUT: 
$myMap-bowtie2.pl -x hg19 -p 23 -name <target folder for bowtie2> <INPUT path to raw data>  
$makeTagDirectory <target folder for tag directory> <target folder for bowtie2> -genome hg19 -checkGC ; 
#Samples: 
$myMap-bowtie2.pl -x hg19 -p 23 -name <target folder for bowtie2> <experiment path to raw data>  
$makeTagDirectory <target folder for tag directory> <target folder for bowtie2> -genome hg19 -checkGC ; 
# Generate combined tag directory files: 
$makeTagDirectory <path to combined output tag directory file> -d <path to tag directory 1> <path to tag 
directory 2> 
 
###Create UCSC file: 
$makeUCSCfile <path to tag directory> -o auto  
 
###To assess 5hmC, PU.1, and 5mC dynamics around 5hmC peaks a complete peak file of unique 5hmC 
peaks of all time points from both donors was generated: 
# Find differential peaks using another time point (TP) as control tag (option -style factor -L 0 -F 2 -s200) 
using Homer tools: 
$findPeaks <path to tag directory> -i <path to control tag directory> -style factor -F 2 -L 0 -size 200 -o 
<path/filename for output>;  
 
##Remove unmappable regions using Homer tools and BEDtools: 
#Conversion to .bed file: 
$pos2bed.pl <path to peak file> > <path to output .bed file> 
 
#Remove unmappable regions with BEDtools: 
#Set of unmappable regions was produced earlier in the Rehli laboratory. 
$intersectBed -v -a <path to .bed file> -b <path to set of unmappable regions > <path to output .bed> 
 
#Convert .bed file back to peak file .txt: 
$bed2pos.pl <bed file> > <path to output peak file .txt> 
 
###Merging all TP into common peak file for cluster analysis with Homer tools:  
#Use option -d = maximum distance between peak centers to merge = average peak size/2 = 100 
$mergePeaks -d 100 <peak file1> <peak file2> [peak file3] ... > <path to newPeakFile.txt> 
 
#Annotating peaks with all tag counts of Hydroxymethyl Collector
TM
-seq tag counts including INPUTs:  
$annotatePeaks.pl <path to merged peak file> hg19 -size given -d <path to tag directories> > <path to 
output file> 
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##Sorting annotated peak file in Excel: 
#Sort set for peak enrichment > 4-fold enriched over INPUT. 
#Sort for replicate time points enriched > 10 tags. 
 
#Annotating positions with all Hydroxymethyl Collector
TM
-seq tag counts including INPUTs (with option -
noadj) for EdgeR: 
$annotatePeaks.pl <path to peak file> hg19 -size 200 -noadj -d <path to tag directories> > <path to output 
file> 
#Save IDs and tag counts for R. 
 
###Normalize data, calculate statistics, and estimate clusters in R: 
#Setting directory and create a new object in R: 
$setwd("path to file") 
$library(edgeR) 
$data <- read.delim("file name", row.names="ID") 
$group <- factor(c(rep("group 1",3), rep("group 2",2), rep("group 3",2))) 
$d <- DGEList(counts=data,group=group) 
$colnames(d) <- c("column 1","column 2", "column 3", "column 4", "column 5","column 6", "column 7") 
 
###Normalization of data: 
$d <- calcNormFactors(d, method=c("upperquartile"))  
###Calculating degree of inter-sample variability: 
$d <- estimateCommonDisp(d, verbose=TRUE) 
#Use normalization with smallest BCV: 
# upperquartille = Disp = 0.05511 , BCV = 0.2348  
#Calculating single values and distribution: 
$d <- estimateTagwiseDisp(d, trend="none") 
#Transformation to log2: 
$y <- cpm(d, prior.count=2, log=TRUE) 
#Printing data: 
$write.table(as.matrix(y),file="log2-transformed data file name",sep="\t", col.names=NA) 
 
###Calculating statistical analysis between MO and DC time points: 
$de.com <- exactTest(d, pair=c("TP 1","TP 2")) 
$results <- topTags(de.com,n = Inf) 
$write.table(as.matrix(results$table),file="output file name",sep="\t", col.names=NA) 
 
##Sorting log2-transformed file in Excel: 
#First the TPs were median-normalized 
#and sorted for FDR. 
#Sort statistical analysis files for FDR <0.05 and 
#delete all peaks in median file that don't have FDR <0.05. 
 
###Performing k-means clustering in R: 
##Estimate cluster-count with k-means: 
$library(gplots) 
$library(RColorBrewer) 
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$s <- read.table("significant data file name", header=TRUE, sep=" ", row.names="ID") 
$data <- as.matrix(s) 
$wss <- (nrow(data)-1)*sum(apply(data,2,var)) 
$for (i in 2:15) wss[i] <- sum(kmeans(data,  
   centers=i)$withinss) 
$plot(1:15, wss, type="b", xlab="Number of Clusters", 
 ylab="Within groups sum of squares") 
$fit <- kmeans(data, estimated cluster-number) 
$aggregate(data,by=list(fit$cluster),FUN=mean) 
 
#Appending cluster assignment: 
$mydata <- data.frame(data, fit$cluster) 
$write.table(as.matrix(mydata),file="cluster file name",sep="\t", col.names=NA) 
 
#The 5hmC cluster file was used for the following analyses. 
 
 
Figure 3.28 A: 
 
####Illustrating the dynamics of 5hmC and PU.1 in distance distribution heatmaps: 
#Sort cluster file for cluster-number in Excel. 
##Sorting clusters for maximum enrichment:  
#Annotating sorted cluster file with Hydroxymethyl Collector
TM
-seq tag and PU.1 ChIP-seq tag counts to 
retrieve tag information using Homer tools: 
$annotatePeaks.pl <path to peak file> hg19 -size given -d <path to tag directories> > <path to output file> 
#Sorting for maximum tag count in averaged replicate time points in Excel, and save position data. 
 
###Generating distance distribution heatmaps of 5hmC and PU.1 around 5hmC peaks using Homer tools 
and R: 
#Annotate position file with combined 5hmC and PU.1 tag counts of replicate TPs: 
$annotatePeaks.pl <path to peak file> hg19 -size 1000 -hist 25 -ghist -d <path to combined tag 
directories> > <path to output file> 
 
#Use generated files for R: 
#For PU.1 heatmaps: 
$setwd("path to ghist file") 
$data <- read.delim("ghist file name", row.names="Gene") 
$d <- data.matrix(data) 
$mycol <- colorRampPalette(c("white","blue"))(199) 
$col_breaks = c(seq(0,3,length=100), seq(3,6,length=100)) 
$png(filename="file name .png", height=24000, width=18000) 
$heatmap.2(d, scale="none", Rowv=NA, Colv=NA, col = mycol, breaks=col_breaks, dendrogram = "none", 
margins=c(0,0), cexRow=0.5, cexCol=1.0, key=FALSE, density.info="none", trace="none", lhei = c(0.05,0.95), lwid = 
$c(0.05,0.95)) 
$dev.off() 
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#For 5hmc heatmaps: 
$setwd("path to ghist file") 
$data <- read.delim("ghist file name", row.names="Gene") 
$d <- data.matrix(data) 
$mycol <- colorRampPalette(c("white","blue"))(199) 
$col_breaks = c(seq(0,5,length=100), seq(5,10,length=100)) 
$png(filename="file name .png", height=24000, width=18000) 
$heatmap.2(d, scale="none", Rowv=NA, Colv=NA, col = mycol, breaks=col_breaks, dendrogram = "none", 
margins=c(0,0), cexRow=0.5, cexCol=1.0, key=FALSE, density.info="none", trace="none", lhei = c(0.05,0.95), lwid = 
$c(0.05,0.95)) 
$dev.off() 
 
Figure 3.28 B: 
 
####Illustrating the dynamics of 5hmC and PU.1 in histograms: 
#Sort file for cluster-number in Excel. 
###Sorting clusters for maximum enrichment:  
#Annotating sorted cluster file with Hydroxymethyl Collector
TM
-seq and PU.1 ChIP-seq tag counts to 
retrieve tag information using Homer tools: 
$annotatePeaks.pl <path to peak file> hg19 -size given -d <path to tag directories> > <path to output file> 
#Sorting for maximum tag count in averaged replicate time points in Excel, and save position data. 
 
###Generating histograms of 5hmC and PU.1 tag counts around 5hmC peaks using Homer tools and R: 
#Split sorted cluster position file into separate clusters. 
#Annotate split cluster files with combined 5hmC and PU.1 tag counts of replicate TPs: 
$annotatePeaks.pl <path to peak file> hg19 -size 1000 -hist 25 -d <path to combined tag directories> > 
<path to output file> 
 
#Split annotated files into 5hmC and PU.1, reduce to coverages, 
#and generate histograms of 5hmC and PU.1 distribution around 5hmC peaks in R: 
$setwd("path to file") 
$data <- read.table("hmC or PU.1 file name", header=T, sep="\t") 
$attach(data) 
$plotcolors <- c("color 1", "color 2", "color 3") 
$pdf(file="file name .pdf", height=4, width=8) 
$par(mar=c(3,3,1,3)) 
$plot(Distance,TP 1,type="l",col=plotcolors[3],xaxt="n",yaxt="n",xlab="",axes=FALSE, ylab="",lwd=1, lty=1,ylim=c(0,16), 
xlim=c(-500,500)) 
$par(mar=c(3,3,1,3), new=TRUE) 
$plot(Distance,TP 2,type="l",col=plotcolors[2],xaxt="n",yaxt="n",xlab="",axes=FALSE, ylab="",lwd=1, lty=1,ylim=c(0,16), 
xlim=c(-500,500)) 
$par(mar=c(3,3,1,3), new=TRUE) 
$plot(Distance,TP 3,type="l",col=plotcolors[1],xaxt="n",yaxt="n",xlab="",axes=FALSE, ylab="",lwd=1, lty=1,ylim=c(0,16), 
xlim=c(-500,500)) 
$axis(1,padj=-1.0,family="Helvetica",cex.axis=1,at=c(-500,-400,-300,-200,-100,0,100,200,300,400,500)) 
$axis(2,padj=0.8,family="Helvetica",cex.axis=1, col="black", col.axis="black") 
$mtext("name y-axis",family="Helvetica", col="black", side=2,line=2,cex=1.3,padj=0.2) 
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$mtext("name x-axis",family="Helvetica",ps=12,side=1,line=2,cex=1.3,padj=-0.6) 
$dev.off() 
 
Figure 3.28 C: 
 
###Plotting heatmaps of 5mC distribution around 5hmC peaks: 
#Use cluster file generated in this chapter, reduce it to positions, and split into separate clusters.  
#Use processed files from chapter 5.2.5.9.2. 
 
#Reformat data and plot graph using R: 
#Command averages methylation level over all valid CpGs at each position: 
$myMethylHist_MODC.pl <path to split cluster peak file> hg19 <path to rescaled MO file> <path to 
rescaled DC file> -scaled -o <path to output file> 
 
$x <- read.table("path to reformatted file", header=T, sep=" ") 
$attach(x) 
$sS1 = smooth.spline(Distance,BG1, spar=0.7) 
$sS2 = smooth.spline(Distance,BG2, spar=0.7) 
$pdf(file="path and file name .pdf", width=3, height=3) 
$par(mar=c(1.4,1.6,0.2,0.2)) 
$plot(Distance,BG1,type="p",col=adjustcolor("brown1",alpha=0.3), xaxt="n",yaxt="n",xlab="", 
ylab="",pch=46,axes=FALSE,lwd=3,ylim=c(0,100)) 
$par(mar=c(1.4,1.6,0.2,0.2), new=TRUE) 
$plot(Distance,BG2,type="p",col=adjustcolor("cyan3",alpha=0.3), xaxt="n",yaxt="n",xlab="", 
ylab="",pch=46,axes=FALSE,lwd=3,ylim=c(0,100)) 
$axis(1,padj=-1.2,family="Helvetica",cex.axis=0.8) 
$axis(2,padj=0.8,family="Helvetica",cex.axis=0.8) 
$lines(sS1, col="color 1", lwd=2) 
$lines(sS2, col="color 2", lwd=2) 
$dev.off() 
 
5.2.5.3 Quality control of 5hmC, PU.1 and 5mC data 
 
To check if the sequencing data produced in different laboratories was comparable and 
thus if the observed dynamics were specific or due to technical variation, we compared 
the sequencing data with a set of random peaks. The random peak set was produced 
by chance using Homer tools (findMotifsGenome.pl). 
 
Figure 3.29 A: 
 
###Generating distance distribution heatmaps of 5hmC and PU.1 around random peaks using Homer 
tools and R: 
#Use random peak file generated with Homer and 
#annotate it with combined 5hmC and PU.1 tag counts of replicate TP: 
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$annotatePeaks.pl <path to random peak file> hg19 -size 1000 -hist 25 -ghist -d <path to combined tag 
directories> > <path to output file> 
 
#Use ghist files for R: 
#For PU.1 heatmaps: 
$setwd("path to ghist file") 
$data <- read.delim("ghist file name", row.names="Gene") 
$d <- data.matrix(data) 
$mycol <- colorRampPalette(c("white","blue"))(199) 
$col_breaks = c(seq(0,3,length=100), seq(3,6,length=100)) 
$png(filename="file name .png", height=24000, width=18000) 
$heatmap.2(d, scale="none", Rowv=NA, Colv=NA, col = mycol, breaks=col_breaks, dendrogram = "none", 
margins=c(0,0), cexRow=0.5, cexCol=1.0, key=FALSE, density.info="none", trace="none", lhei = c(0.05,0.95), lwid = 
$c(0.05,0.95)) 
$dev.off() 
 
#For 5hmC heatmaps: 
$setwd("path to ghist file") 
$data <- read.delim("ghist file name", row.names="Gene") 
$d <- data.matrix(data) 
$mycol <- colorRampPalette(c("white","blue"))(199) 
$col_breaks = c(seq(0,5,length=100), seq(5,10,length=100)) 
$png(filename="file name .png", height=24000, width=18000) 
$heatmap.2(d, scale="none", Rowv=NA, Colv=NA, col = mycol, breaks=col_breaks, dendrogram = "none", 
margins=c(0,0), cexRow=0.5, cexCol=1.0, key=FALSE, density.info="none", trace="none", lhei = c(0.05,0.95), lwid = 
$c(0.05,0.95)) 
$dev.off() 
 
Figure 3.29 B: 
 
###Generating histograms of 5hmC and PU.1 tag counts around random peaks using Homer tools and R: 
#Annotate random peak file with combined 5hmC and PU.1 tag counts of replicate TPs: 
$annotatePeaks.pl <path to random peak file> hg19 -size 1000 -hist 25 -d <path to combined tag 
directories> > <path to output file> 
 
#Split annotated files into 5hmC and PU.1, reduce to coverages, 
#and generate histograms for 5hmC and PU.1 distribution around random peaks in R: 
 
$setwd("path to 5hmC or PU.1 file") 
$data <- read.table("file name", header=T, sep="\t") 
$attach(data) 
$plotcolors <- c("color 1", "color 2", "color 3") 
$pdf(file="file name .pdf", height=4, width=8) 
$par(mar=c(3,3,1,3)) 
$plot(Distance,TP 1,type="l",col=plotcolors[3],xaxt="n",yaxt="n",xlab="",axes=FALSE, ylab="",lwd=1, lty=1,ylim=c(0,16), 
xlim=c(-500,500)) 
$par(mar=c(3,3,1,3), new=TRUE) 
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$plot(Distance,TP 2,type="l",col=plotcolors[2],xaxt="n",yaxt="n",xlab="",axes=FALSE, ylab="",lwd=1, lty=1,ylim=c(0,16), 
xlim=c(-500,500)) 
$par(mar=c(3,3,1,3), new=TRUE) 
$plot(Distance,TP 3,type="l",col=plotcolors[1],xaxt="n",yaxt="n",xlab="",axes=FALSE, ylab="",lwd=1, lty=1,ylim=c(0,16), 
xlim=c(-500,500)) 
$axis(1,padj=-1.0,family="Helvetica",cex.axis=1,at=c(-500,-400,-300,-200,-100,0,100,200,300,400,500)) 
$axis(2,padj=0.8,family="Helvetica",cex.axis=1, col="black", col.axis="black") 
$mtext("name y-axis",family="Helvetica", col="black", side=2,line=2,cex=1.3,padj=0.2) 
$mtext("name x-axis",family="Helvetica",ps=12,side=1,line=2,cex=1.3,padj=-0.6) 
$dev.off() 
 
Figure 3.29 C: 
 
###Generating histograms of 5mC distribution around random peaks in R: 
#Use files generated in this chapter and from chapter 5.2.5.9.2. 
#Reformat data and plot graph using R: 
#Command averages methylation level over all valid CpGs at each position: 
$myMethylHist_MODC.pl <path to random peak file> hg19 <path to rescaled MO file> <path to rescaled 
DC file> -scaled -o <path to output file> 
 
$x <- read.table("path to previous reformatted file", header=T, sep=" ") 
$attach(x) 
$sS1 = smooth.spline(Distance,BG1, spar=0.7) 
$sS2 = smooth.spline(Distance,BG2, spar=0.7) 
$pdf(file="path and file name .pdf", width=3, height=3) 
$par(mar=c(1.4,1.6,0.2,0.2)) 
$plot(Distance,BG1,type="p",col=adjustcolor("brown1", alpha=0.3), xaxt="n",yaxt="n",xlab="", 
ylab="",pch=46,axes=FALSE,lwd=3,ylim=c(0,100)) 
$par(mar=c(1.4,1.6,0.2,0.2), new=TRUE) 
$plot(Distance,BG2,type="p",col=adjustcolor("cyan3", alpha=0.3), xaxt="n",yaxt="n",xlab="", 
ylab="",pch=46,axes=FALSE,lwd=3,ylim=c(0,100)) 
$axis(1,padj=-1.2,family="Helvetica",cex.axis=0.8) 
$axis(2,padj=0.8,family="Helvetica",cex.axis=0.8) 
$lines(sS1, col="brown4", lwd=2) 
$lines(sS2, col="darkcyan", lwd=2) 
$dev.off() 
 
5.2.5.4 Gene ontology (GO) analyses of 5hmC peaks 
 
Gene ontology (GO) analyses were performed in the 5hmC cluster sets generated in 
chapter 5.2.5.2. 
 
####Gene ontology analyses in cluster sets of 5hmC peaks using R: 
#Use 5hmC cluster file generated in 5.2.5.2. 
#Sort file for cluster-number in Excel 
  Material and Methods 
140 
 
###Sorting clusters for maximum enrichment:  
#Annotating sorted cluster file with all 5hmC tag counts using Homer tools: 
$annotatePeaks.pl <path to peak file> hg19 -size given -d <path to tag directories> > <path to output file> 
 
#Sort for maximum enrichment in averaged replicate time points in Excel, save position data, 
#and split into separate cluster files. 
#Annotating sorted cluster file to generate gene ontology information using Homer tools: 
$annotatePeaks.pl <path to split cluster peak file> hg19 -go <path to gene ontology output file> > <path to 
annotated output file> 
 
##Calculating GeneFoldEnrichment of GO terms and transform data into log2: 
#Calculate statistics using the Hypergeomvert test in Excel: 
$hypgeomvert(target genes in term; total target genes; genes in term; total genes) 
#genes in term = all genes with annotation 
#target genes in term = genes in set with annotation 
#total genes = all genes 
#total target genes = all genes in set 
 
#Calculate FDR (= (p-value*N)/rank) and 
#sort for peaks with a significant FDR. 
#Sort for GO terms with > 2-fold enriched GFE. 
 
##Clustering GO terms and generate dendrogram in R: 
$setwd("path to sign. GO term file") 
$library(edgeR) 
$library(gplots) 
$library(RColorBrewer) 
$data <- read.delim("file name of sign. GO term file", row.names="ID") 
#Transform into log2: 
$y <- log2(data) 
$write.table(as.matrix(y),file="log2 file name",sep="\t", col.names=NA) 
#Add random jitter to correct for zeros. 
 
$z <- read.table("corrected log2 file", header=TRUE, sep=" ", row.names="ID") 
$data <- as.matrix(z) 
$hc <- hclust(dist(t(data), method = "manhattan"), method="ward") 
$hr <- hclust(dist(data, method = "manhattan"), method="ward") 
$mycol <- colorRampPalette(c("blue","white","red"))(299) 
$col_breaks = c(seq(-2,-0.33333,length=100), seq(-0.33333,0.33333,length=100), seq(0.33333,2,length=100)) 
$pdf(file="file name .pdf", height=8, width=8) 
$heatmap.2(data, Rowv=as.dendrogram(hr), Colv=as.dendrogram(hc), col = mycol, breaks = col_breaks, na.rm=TRUE, 
scale="none", margins=c(10,10), cexRow=0.5, cexCol=1.0, key=TRUE, density.info="none", trace="none") 
$dev.off() 
#Extract dendrogram info and GFE 
$write.table(t(data[rev(hr$labels[hr$order]), hc$labels[hc$order]]), file = "dendrogram file name", sep = "", 
col.names=NA) 
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##Sort GO terms in Excel: 
#Sort for major GO terms consisting of min. 200 genes. 
#Sort major GO terms for terms enriched exclusively in set #2/#4 in Excel, 
#and print heatmaps in R: 
 
$setwd("path to folder") 
$library(gplots) 
$library(RColorBrewer) 
$z <- read.delim("GOterm file name", row.names="ID") 
$data <- as.matrix(z) 
$mycol <- colorRampPalette(c("blue","white","red"))(299) 
$col_breaks = c(seq(0.65,0.9,length=100), seq(0.9,1.1,length=100), seq(1.1,1.5,length=100)) 
$pdf(file="file name .pdf", height=8, width=8) 
$heatmap.2(data, Rowv=NA, Colv=NA, col = mycol, breaks = col_breaks, dendrogram = "none", na.rm=TRUE, 
scale="none", margins=c(10,10), cexRow=0.5, cexCol=1.0, key=TRUE, density.info="none", trace="none") 
$dev.off() 
 
5.2.5.5 Global gene expression during MO differentiation 
 
To investigate a possible correlation of demethylation events with transcriptional 
changes, the 5hmC cluster peak set (generated in chapter 5.2.5.2) was compared with 
publically available gene expression data obtained from differentiating MO (5 donors) 
and iDC (3 donors) (see chapter 5.2.5.9.1). 
 
####Gene expression analyses in cluster sets of 5hmC peaks using R: 
#Use 5hmC cluster file generated in 5.2.5.2. 
#Sort file for cluster-number in Excel. 
###Sorting clusters for maximum enrichment:  
#Annotating sorted cluster file with all Hydroxymethyl Collector
TM
-seq tag counts using Homer tools: 
$annotatePeaks.pl <path to peak file> hg19 -size given -d <path to tag directories> > <path to output file> 
 
#Sort for maximum enrichment in averaged replicate time points using Excel, save position data, 
#and split into separate cluster files. 
 
###Adjust microarray expression data file of MO and DC [GEO:GSE19236] (see chapter 5.2.5.9.1): 
#Extract and average normalized TP of donors and 
#retrieve genebank accession numbers from Agilent homepage 
(http://www.chem.agilent.com/cag/bsp/gene_lists.asp). 
 
#Annotate split cluster files with expression data file using Homer: 
$annotation.pl <path to split cluster file> hg19 -gene <expression data file> > <path to output file> 
#Sort for annotated peaks and save positions for R. 
 
##Calculate statistics in R: 
  Material and Methods 
142 
 
#Use Man-Whitney-U test to calculate significant changes between MO and DC time points: 
$setwd("path to annotated file") 
$x <- read.table("annotated file name", header=T, sep="\t") 
$attach(x) 
$wilcox.test(TP 1,TP 2,data=x) 
 
#Generate boxplots without outliers to improve visualization of expression changes: 
$setwd("path to expression data file") 
$x <- read.table("expression data file", header=T, sep="\t") 
$logx <- log2(x) 
$pdf(file="boxplot file name .pdf", height=4, width=5) 
$boxplot(logx,what=c(1,1,1,0),axes = FALSE, col = "lightgray", border = "black",overallline = "median", notch=TRUE, 
outline=FALSE, range=2) 
$axis(1,padj=-0.8,family="Helvetica",cex.axis=1,at=1:7,lab=c("MO","6h","18h","27h","42h","51h","66h")) 
$axis(2,padj=0.8,family="Helvetica",cex.axis=1) 
$mtext("name y-axis",family="Helvetica",side=2,line=2,cex=1.2,padj=0.4) 
$mtext("name x-axis",family="Helvetica",ps=12,side=1,line=2,cex=1.2,padj=-0.6) 
$dev.off() 
 
 
5.2.5.6 Genome-wide PU.1 analyses 
 
To get further insights into global PU.1, 5hmC and 5mC dynamics around PU.1 peaks 
a set of all differential, time point-specific PU.1 ChIP-seq peaks was analyzed. The 
ChIP-seq procedure and generation of the data is described in chapter 5.2.2.8, 5.2.2.9, 
and 5.2.2.10. For data generation of 5hmC and 5mC tags see chapter 5.2.2.7.2.4, 
5.2.2.9, 5.2.2.10, and 5.2.5.9.2. 
Data processing was done for all ChIP-seq samples using the following command line 
and tools as outlined: 
 
#All files: 
PU1ChiP_MN_Lib55.fastq.gz 
PU1ChIP_DC18h_Lib56.fastq.gz 
PU1ChIP_INPUT_DC18h_Lib57.fastq.gz 
PU1ChIP_DC18h_Lib58.fastq.gz 
PU1ChIP_DC42h_Lib59.fastq.gz 
PU1ChIP_DCd7_Lib60.fastq.gz 
PU1ChIP_MN_Lib61.fastq.gz 
PU1ChIP_DC27h_Lib62.fastq.gz 
PU1ChIP_DC51h_Lib63.fastq.gz 
PU1ChIP_DC66h_S7.fastq.gz 
PU1ChIP_DCd7_S8.fastq.gz 
PU1ChIP_INPUT_DCd7_S9.fastq.gz 
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###Mapping of .fastq files to hg19 and creating individual tag directories with Bowtie2: 
#INPUT: 
$myMap-bowtie2.pl -x hg19 -p 23 -name <target folder for bowtie2> <INPUT path to raw data>  
$makeTagDirectory <target folder for tag directory> <target folder for bowtie2> -genome hg19 -checkGC ; 
#Samples: 
$myMap-bowtie2.pl -x hg19 -p 23 -name <target folder for bowtie2> <Experiment path to raw data>  
$makeTagDirectory <target folder for tag directory> <target folder for bowtie2> -genome hg19 -checkGC ; 
# Generate combined tag directory files: 
$makeTagDirectory <path to combined output tag directory file> -d <path to tag directory 1> <path to tag 
directory 2> 
 
###Create UCSC file: 
$makeUCSCfile <path to tag directory> -o auto  
 
#####Define transcription factor peaks in ChiP-seq data: 
#Find differential peaks using another time point (TP) as control tag directory (Homer tools with option -
style factor = for TF ChiP-seq analysis, centers peaks on maximum tag overlap): 
$findPeaks <path to tag directory> -i <path to control tag directory> -style factor -o <path to output 
directory>  
 
###Compiling a complete set of all differential peaks for cluster generation: 
#Merging all differential peak sets from all donors with Homer tools: 
#Use option -d = maximum distance between peak centers to merge = average peak size/2 = 104 
$mergePeaks -d 104 <peak file1> <peak file2> [peak file3] ... > <path to output peak file> 
 
#Annotating merged peak file with all PU.1 ChIP-seq tag counts inclusive INPUT: 
#Use option -size = average peak size = 207 
$annotatePeaks.pl <path to peak file> hg19 -size 207 -d <path to PU.1/INPUT tag directories> > <path to 
output file> 
#Sort annotated peak file in Excel: 
#Sort for replicates that are enriched > 4-fold over the INPUT and 
#for replicate-pairs enriched > 10 tags. 
#Annotate position file with option -noadj (= skips tag count normalization based on total tags sequenced) 
for EdgeR: 
$annotatePeaks.pl <path to peak file> hg19 -size 207 -noadj -d <path to PU.1 tag directories> > <path to 
output file> 
 
###Normalize data, calculate statistics, and estimate clusters in R: 
#Setting directory and create a new object in R: 
$setwd("path to file") 
$library(edgeR) 
$data <- read.delim("file name", row.names="ID") 
$group <- factor(c(rep("group 1",3), rep("group 2",2), rep("group 3",2))) 
$d <- DGEList(counts=data,group=group) 
$colnames(d) <- c("column 1","column 2", "column 3", "column 4", "column 5","column 6", "column 7") 
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###Normalization of data: 
$d <- calcNormFactors(d, method=c("upperquartile"))  
###Calculating degree of inter-sample variability: 
$d <- estimateCommonDisp(d, verbose=TRUE) 
#Using normalization with smallest BCV: 
# upperquartille = Disp = 0.11732 , BCV = 0.3425 
#Calculating single values and distribution: 
$d <- estimateTagwiseDisp(d, trend="none") 
#Transformation to log2: 
$y <- cpm(d, prior.count=2, log=TRUE) 
 
###Calculating statistical analysis between MO and DC time points: 
$de.com <- exactTest(d, pair=c("TP 1","TP 2")) 
$results <- topTags(de.com,n = Inf) 
$write.table(as.matrix(results$table),file="output file name",sep="\t", col.names=NA) 
 
##Sorting log2-transformed file in Excel: 
#Calculate medians of all TPs. 
#Sort statistical analysis files for FDR <0.05 and 
#delete all peaks in median file that don't have FDR <0.05. 
 
###Performing k-means clustering in R: 
##Estimate cluster-count with k-means: 
$library(gplots) 
$library(RColorBrewer)  
$s <- read.table("significant data file name", header=TRUE, sep=" ", row.names="ID")  
$data <- as.matrix(s) 
$wss <- (nrow(data)-1)*sum(apply(data,2,var)) 
$for (i in 2:15) wss[i] <- sum(kmeans(data, centers=i) 
$withinss) 
$plot(1:15, wss, type="b", xlab="Number of Clusters", ylab="Within groups sum of squares") 
$fit <- kmeans(data, estimated cluster-number) 
$aggregate(data,by=list(fit$cluster),FUN=mean) 
 
#Appending cluster assignment: 
$mydata <- data.frame(data, fit$cluster) 
$write.table(as.matrix(mydata),file="cluster file name",sep="\t", col.names=NA) 
 
#Sort cluster file for cluster-number in Excel 
#Annotating sorted cluster file with PU.1 ChIP-seq and Hydroxymethyl Collector
TM
-seq tag counts to 
retrieve tag information using Homer tools: 
$annotatePeaks.pl <path to peak file> hg19 -size 207 -d <path to PU.1 tag directories> > <path to output 
file> 
 
#The annotated cluster file was used for the following analyses. 
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Figure 3.32 A: 
 
###Illustrating the dynamics of PU.1 and 5hmC in distance distribution heatmaps: 
##Sorting clusters in cluster file for maximum enrichment: 
#Sort averaged replicates for maximum tag count and reduce to positions. 
 
#Generating distance distribution heatmaps of PU.1 and 5hmC around PU.1 peaks using Homer tools and 
R: 
#Annotate position file with combined PU.1 and 5hmC tag counts of replicate TP: 
$annotatePeaks.pl <path to peak file> hg19 -size 1000 -hist 25 -ghist -d <path to combined tag 
directories> > <path to output file> 
 
#Use generated files for R: 
#For PU.1 heatmaps: 
$setwd("path to ghist file") 
$data <- read.delim("ghist file name", row.names="Gene") 
$d <- data.matrix(data) 
$mycol <- colorRampPalette(c("white","blue"))(199) 
$col_breaks = c(seq(0,3,length=100), seq(3,6,length=100)) 
$png(filename="file name .png", height=24000, width=18000) 
$heatmap.2(d, scale="none", Rowv=NA, Colv=NA, col = mycol, breaks=col_breaks, dendrogram = "none", 
margins=c(0,0), cexRow=0.5, cexCol=1.0, key=FALSE, density.info="none", trace="none", lhei = c(0.05,0.95), lwid = 
$c(0.05,0.95)) 
$dev.off() 
 
#For 5hmc heatmaps: 
$setwd("path to ghist file") 
$data <- read.delim("ghist file name", row.names="Gene") 
$d <- data.matrix(data) 
$mycol <- colorRampPalette(c("white","blue"))(199) 
$col_breaks = c(seq(0,5,length=100), seq(5,10,length=100)) 
$png(filename="file name .png", height=24000, width=18000) 
$heatmap.2(d, scale="none", Rowv=NA, Colv=NA, col = mycol, breaks=col_breaks, dendrogram = "none", 
margins=c(0,0), cexRow=0.5, cexCol=1.0, key=FALSE, density.info="none", trace="none", lhei = c(0.05,0.95), lwid = 
$c(0.05,0.95)) 
$dev.off() 
 
Figure 3.32 B: 
 
###Illustrating the dynamics of PU.1 and 5hmC in histograms: 
###Sorting clusters in cluster file for maximum enrichment: 
#Sort averaged replicates for maximum tag count and reduce to positions. 
 
###Generating histograms of 5hmC and PU.1 tag counts using Homer tools and R: 
#Split cluster position file into 6 separate clusters. 
#Annotate split cluster files with combined PU.1 and 5hmC tag counts of replicate TP: 
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$annotatePeaks.pl <path to peak file> hg19 -size 1000 -hist 25 -d <path to combined tag directories> > 
<path to output file> 
 
#Split annotated files into 5hmC and PU.1, reduce to coverages  
#and generate histograms of 5hmC and PU.1 distribution around 5hmC peaks in R: 
$setwd("path to file") 
$data <- read.table("hmC or PU.1 file name", header=T, sep="\t") 
$attach(data) 
$plotcolors <- c("color 1", "color 2", "color 3") 
$pdf(file="file name .pdf", height=4, width=8) 
$par(mar=c(3,3,1,3)) 
$plot(Distance,TP 1,type="l",col=plotcolors[3],xaxt="n",yaxt="n",xlab="",axes=FALSE, ylab="",lwd=1, lty=1,ylim=c(0,16), 
xlim=c(-500,500)) 
$par(mar=c(3,3,1,3), new=TRUE) 
$plot(Distance,TP 2,type="l",col=plotcolors[2],xaxt="n",yaxt="n",xlab="",axes=FALSE, ylab="",lwd=1, lty=1,ylim=c(0,16), 
xlim=c(-500,500)) 
$par(mar=c(3,3,1,3), new=TRUE) 
$plot(Distance,TP 3,type="l",col=plotcolors[1],xaxt="n",yaxt="n",xlab="",axes=FALSE, ylab="",lwd=1, lty=1,ylim=c(0,16), 
xlim=c(-500,500)) 
$axis(1,padj=-1.0,family="Helvetica",cex.axis=1,at=c(-500,-400,-300,-200,-100,0,100,200,300,400,500)) 
$axis(2,padj=0.8,family="Helvetica",cex.axis=1, col="black", col.axis="black") 
$mtext("name y-axis",family="Helvetica", col="black", side=2,line=2,cex=1.3,padj=0.2) 
$mtext("name x-axis",family="Helvetica",ps=12,side=1,line=2,cex=1.3,padj=-0.6) 
$dev.off() 
 
Figure 3.32 C: 
 
###Plotting heatmaps of 5mC distribution around PU.1 peaks: 
#Use annotated cluster file generated in this chapter, reduce it to positions and split into separate clusters. 
#Use processed files from chapter 5.2.5.9.2. 
 
##Reformat bisulfite-data and plot graph in R: 
#Command averages methylation level over all valid CpGs at each position: 
$myMethylHist_MODC.pl <path to split cluster peak file> hg19 <path to rescaled MO file> <path to 
rescaled DC file> -scaled -o <path to output file> 
 
$x <- read.table("path to reformatted file", header=T, sep=" ") 
$attach(x) 
$sS1 = smooth.spline(Distance,BG1, spar=0.7) 
$sS2 = smooth.spline(Distance,BG2, spar=0.7) 
$pdf(file="path and file name .pdf", width=3, height=3) 
$par(mar=c(1.4,1.6,0.2,0.2)) 
$plot(Distance,BG1,type="p",col=adjustcolor("brown1",alpha=0.3), xaxt="n",yaxt="n",xlab="", 
ylab="",pch=46,axes=FALSE,lwd=3,ylim=c(0,100)) 
$par(mar=c(1.4,1.6,0.2,0.2), new=TRUE) 
$plot(Distance,BG2,type="p",col=adjustcolor("cyan3",alpha=0.3), xaxt="n",yaxt="n",xlab="", 
ylab="",pch=46,axes=FALSE,lwd=3,ylim=c(0,100)) 
$axis(1,padj=-1.2,family="Helvetica",cex.axis=0.8) 
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$axis(2,padj=0.8,family="Helvetica",cex.axis=0.8) 
$lines(sS1, col="color 1", lwd=2) 
$lines(sS2, col="color 2", lwd=2) 
$dev.off() 
 
5.2.5.7 Promoter set analysis 
 
To assess the binding dynamics of PU.1, 5hmC and 5mC around promoters we used 
an openly available promoter set published by the FANTOM consortium (Consortium et 
al., 2014) (see chapter 5.2.5.9.3). As described in (Consortium et al., 2014) the 
promoter set was generated based on transcription, which indicated active usage.  
 
#To obtain cell type-specific sets of actively used promoters, we annotated the promoter set with CAGE 
enhancer expression data from MO (3 donors) and DC (3 donors) (Consortium et al., 2014). 
$annotatePeaks.pl <path to promoter file> hg19 -size given -len 0 -strand + -d <path to CAGE tag 
directories>-noadj -noann -nogene > <path to output file>  
 
#Sort promoter file for at least one TP per row with a minimum tag count of 1 in Excel. 
#Calculate statistics (FDR, logFoldChange, logCPM, p-value) in R: 
$setwd("path to file") 
$library(edgeR) 
$data <- read.delim("annotated file name", row.names="ID") 
$group <- factor(c(rep("TP 1",3), rep("TP 2",4))) 
$lib.size <- c(1000000,1000000,1000000,1000000,1000000,1000000,1000000) 
$d <- DGEList(counts=data,group=group,lib.size=as.numeric(lib.size)) 
$colnames(d) <- c("column name 1", "column name 2","column name 3","column name 4","column name 5","column 
name 6","column name 7") 
$d <- estimateCommonDisp(d, verbose=TRUE) 
#Disp = 0.05591 , BCV = 0.2365  
$d <- estimateTagwiseDisp(d, trend="none") 
$de.com <- exactTest(d, pair=c("MO","mDC")) 
$results <- topTags(de.com,n = Inf) 
$write.table(as.matrix(results$table),file="EdgeR.results.txt",sep="\t", col.names=NA) 
 
##Sorting annotated file in Excel: 
#Sort for FDR<0.05 and >2fold change in log-Fold-Change and 
#sort for cell type-specific expression and divide set into cell type-specific MO or DC sets.  
#Sort for max tag count and reduce to positions. 
#The generated cell type-specific promoter sets are used for the following analyses. 
 
 
Figure 3.33 A: 
 
###Illustrating the dynamics of PU.1 and 5hmC in distance distribution heatmaps: 
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#Annotate the promoter sets with local PU.1 ChIP-seq and Hydroxymethyl Collector
TM
-seq tag counts 
using Homer tools: 
$annotatePeaks.pl <path to promoter file> hg19 -size 207 -d <path to tag directories> > <path to output 
file> 
#Sort for maximum PU.1 tag count in averaged replicate time points (in Excel) and save position data. 
 
###Generating distance distribution heatmaps of PU.1 and 5hmC around promoter TSS using Homer tools 
and R: 
#Annotate cell type-specific promoter sets with tag counts of PU.1 ChIP-seq and Hydroxymethyl 
Collector
TM
-seq samples using Homer tools:  
$annotatePeaks.pl <path to promoter file> hg19 -ghist -hist 25 -s1000 -d <path to tag directories> > <path 
to output file> 
 
#Use generated files for R: 
#For PU.1 heatmaps: 
$setwd("path to ghist file") 
$data <- read.delim("ghist file name", row.names="Gene") 
$d <- data.matrix(data) 
$mycol <- colorRampPalette(c("white","blue"))(199) 
$col_breaks = c(seq(0,3,length=100), seq(3,6,length=100)) 
$png(filename="file name .png", height=24000, width=18000) 
$heatmap.2(d, scale="none", Rowv=NA, Colv=NA, col = mycol, breaks=col_breaks, dendrogram = "none", 
margins=c(0,0), cexRow=0.5, cexCol=1.0, key=FALSE, density.info="none", trace="none", lhei = c(0.05,0.95), lwid = 
$c(0.05,0.95)) 
$dev.off() 
 
#For 5hmc heatmaps: 
$setwd("path to ghist file") 
$data <- read.delim("ghist file name", row.names="Gene") 
$d <- data.matrix(data) 
$mycol <- colorRampPalette(c("white","blue"))(199) 
$col_breaks = c(seq(0,5,length=100), seq(5,10,length=100)) 
$png(filename="file name .png", height=24000, width=18000) 
$heatmap.2(d, scale="none", Rowv=NA, Colv=NA, col = mycol, breaks=col_breaks, dendrogram = "none", 
margins=c(0,0), cexRow=0.5, cexCol=1.0, key=FALSE, density.info="none", trace="none", lhei = c(0.05,0.95), lwid = 
$c(0.05,0.95)) 
$dev.off() 
 
Figure 3.33 A (right panel): 
 
###Investigation of CpG density coverage: 
#Annotate cell type-specific promoter sets with tag counts of PU.1 ChIP-seq and Hydroxymethyl 
Collector
TM
-seq samples to retrieve tag count using Homer tools: 
$annotatePeaks.pl <path to promoter file> hg19 -size 207 -d <path to tag directories> > <path to output 
file> 
#Sort for maximum PU.1 tag count in averaged replicate time points (in Excel) and save position data. 
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###Generating distance distribution heatmaps of CpG-content around cell type-specific promoters using 
Homer tools and R: 
#Use a reference set of all valid CpGs of the genome, containing CpG-locations extended to 100 bp each, 
in order to create a tag directory file. 
#Separate the promoter file into cell type-specific sets of positions and 
#annotate the sets with the reference CpG tag directory using Homer tools:  
$annotatePeaks.pl <path to cell type-specific promoter file> hg19 -size 1000 -hist 25 -ghist -d <path to 
CpG tag directory> > <path to output file> 
 
#Use generated files for R: 
$setwd("path to annotated file") 
$data <- read.delim("annotated file name", row.names="Gene") 
$d <- data.matrix(data) 
$mycol <- colorRampPalette(c("white","blue"))(199) 
$col_breaks = c(seq(0,3,length=100), seq(3,6,length=100)) 
$png(filename="distance distribution heatmap file name .png", height=24000, width=18000) 
$heatmap.2(d, scale="none", Rowv=NA, Colv=NA, col = mycol, breaks=col_breaks, dendrogram = "none", 
margins=c(0,0), cexRow=0.5, cexCol=1.0, key=FALSE, $density.info="none", trace="none", lhei = c(0.05,0.95), lwid = 
c(0.05,0.95)) 
$dev.off() 
 
Figure 3.33 B: 
 
###Illustrating the dynamics of PU.1 and 5hmC in histograms: 
#Annotate cell type-specific promoter sets with tag counts of PU.1 ChIP-seq and Hydroxymethyl 
Collector
TM
-seq samples to retrieve tag count using Homer tools: 
$annotatePeaks.pl <path to promoter file> hg19 -size 207 -d <path to tag directories> > <path to output 
file> 
#Sort for maximum PU.1 tag count in averaged replicate time points (in Excel) and save position data. 
 
##Generating histograms of PU.1and 5hmC tag distribution around cell type-specific promoters using 
Homer tools and R: 
#Separate into cell type-specific sets of positions and 
#annotate cell type-specific promoter sets with tag counts of PU.1 ChIP-seq and Hydroxymethyl 
Collector
TM
-seq samples using Homer tools:  
$annotatePeaks.pl <path to promoter file> hg19 -size 1000 -hist 25 -d <path to tag directories> > <path to 
output file> 
 
#Split annotated file into PU.1 or 5hmC coverages for R. 
##Generate histograms in R: 
$setwd("path to file") 
$data <- read.table("hmC or PU.1 file name", header=T, sep="\t") 
$attach(data) 
$plotcolors <- c("color 1", "color 2", "color 3") 
$pdf(file="file name .pdf", height=4, width=8) 
$par(mar=c(3,3,1,3)) 
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$plot(Distance,TP 1,type="l",col=plotcolors[3],xaxt="n",yaxt="n",xlab="",axes=FALSE, ylab="",lwd=1, lty=1,ylim=c(0,16), 
xlim=c(-500,500)) 
$par(mar=c(3,3,1,3), new=TRUE) 
$plot(Distance,TP 2,type="l",col=plotcolors[2],xaxt="n",yaxt="n",xlab="",axes=FALSE, ylab="",lwd=1, lty=1,ylim=c(0,16), 
xlim=c(-500,500)) 
$par(mar=c(3,3,1,3), new=TRUE) 
$plot(Distance,TP 3,type="l",col=plotcolors[1],xaxt="n",yaxt="n",xlab="",axes=FALSE, ylab="",lwd=1, lty=1,ylim=c(0,16), 
xlim=c(-500,500)) 
$axis(1,padj=-1.0,family="Helvetica",cex.axis=1,at=c(-500,-400,-300,-200,-100,0,100,200,300,400,500)) 
$axis(2,padj=0.8,family="Helvetica",cex.axis=1, col="black", col.axis="black") 
$mtext("name y-axis",family="Helvetica", col="black", side=2,line=2,cex=1.3,padj=0.2) 
$mtext("name x-axis",family="Helvetica",ps=12,side=1,line=2,cex=1.3,padj=-0.6) 
$dev.off() 
 
Figure 3.33 C: 
 
###Plotting heatmaps of 5mC distribution in the vicinity of cell type-specific promoter regions: 
#Use files generated in this chapter and from chapter 5.2.5.9.2. 
 
#Reformat data and plot graph using R: 
#Command averages methylation level over all valid CpGs at each position: 
$myMethylHist_MODC.pl <path to cell type-specific promoter file> hg19 <path to rescaled MO file> <path 
to rescaled DC file> -scaled -o <path to output file> 
 
$x <- read.table("path to reformatted file", header=T, sep=" ") 
$attach(x) 
$sS1 = smooth.spline(Distance,BG1, spar=0.7) 
$sS2 = smooth.spline(Distance,BG2, spar=0.7) 
$pdf(file="path and file name .pdf", width=3, height=3) 
$par(mar=c(1.4,1.6,0.2,0.2)) 
$plot(Distance,BG1,type="p",col=adjustcolor("brown1",alpha=0.3), xaxt="n",yaxt="n",xlab="", 
ylab="",pch=46,axes=FALSE,lwd=3,ylim=c(0,100)) 
$par(mar=c(1.4,1.6,0.2,0.2), new=TRUE) 
$plot(Distance,BG2,type="p",col=adjustcolor("cyan3",alpha=0.3), xaxt="n",yaxt="n",xlab="", 
ylab="",pch=46,axes=FALSE,lwd=3,ylim=c(0,100)) 
$axis(1,padj=-1.2,family="Helvetica",cex.axis=0.8) 
$axis(2,padj=0.8,family="Helvetica",cex.axis=0.8) 
$lines(sS1, col="color 1", lwd=2) 
$lines(sS2, col="color 2", lwd=2) 
$dev.off() 
 
5.2.5.8 Enhancer set analysis 
 
To investigate the PU.1 binding dynamics around active, cell type-specific enhancers 
during monocyte differentiation a publically available set of enhancer elements 
produced by the FANTOM consortium (Andersson et al., 2014) was utilized (see 
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chapter 5.2.5.9.3). As described in (Andersson et al., 2014) the FANTOM5 CAGE 
expression atlas (available from Consortium et al., 2014) was used to identify 
transcribed and thus active enhancer elements in several cell types. Enhancers were 
identified due to their bidirectional transcription and centered between the bidirectional 
transcripts. 
 
#To obtain cell type-specific sets of actively used enhancers, we annotated the enhancer set with CAGE 
enhancer expression data from MO (3 donors) and DC (2 donors, one was left out due to insufficient tag 
coverage) (available from Consortium et al., 2014). 
$annotatePeaks.pl <path to enhancer file> hg19 -size given -len 0 -strand + -d <path to CAGE tag 
directories>-noadj -noann -nogene > <path to output file>  
 
#Sort annotated file for TPs with a minimum tag count of 1 in Excel.  
#Calculation of statistics in R was too stringent. Instead t.test (unpaired, two-sided, <0.05) was used 
(Excel) to calculate statistics: 
#Sorting annotated file in Excel for p<0.05 and separate into two cell type-specific sets. 
#Sort for maximum tag count in MO and DC sets and reduce to positions. 
#The cell type-specific enhancer files were used for the following analyses. 
 
 
Figure 3.34 A: 
 
###Illustrating the dynamics of PU.1 and 5hmC in distance distribution heatmaps: 
#Annotate cell type-specific enhancer sets with tag counts of PU.1 ChIP-seq and Hydroxymethyl 
Collector
TM
-seq samples to retrieve tag count using Homer tools: 
$annotatePeaks.pl <path to enhancer file> hg19 -size 207 -d <path to tag directories> > <path to output 
file> 
#Sort for maximum PU.1 tag count in averaged replicate time points (in Excel) and save position data. 
#Generating distance distribution heatmaps of PU.1 and 5hmC around MO- and DC-specific enhancers 
using Homer tools and R: 
#Annotate cell type-specific enhancer sets with tag counts of PU.1 ChIP-seq and Hydroxymethyl 
Collector
TM
-seq samples using Homer tools:  
$annotatePeaks.pl <path to cell type-specific enhancer file> hg19 -ghist -hist 25 -s1000 -d <path to tag 
directories> > <path to output file> 
 
#Use generated files for R: 
#For PU.1 heatmaps: 
$library(gplots) 
$library(RColorBrewer) 
$setwd("path to ghist file") 
$data <- read.delim("ghist file name", row.names="Gene") 
$d <- data.matrix(data) 
$mycol <- colorRampPalette(c("white","blue"))(199) 
$col_breaks = c(seq(0,3,length=100), seq(3,6,length=100)) 
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$png(filename="file name .png", height=24000, width=18000) 
$heatmap.2(d, scale="none", Rowv=NA, Colv=NA, col = mycol, breaks=col_breaks, dendrogram = "none", 
margins=c(0,0), cexRow=0.5, cexCol=1.0, key=FALSE, density.info="none", trace="none", lhei = c(0.05,0.95), lwid = 
$c(0.05,0.95)) 
$dev.off() 
 
#For 5hmc heatmaps: 
$library(gplots) 
$library(RColorBrewer) 
$setwd("path to ghist file") 
$data <- read.delim("ghist file name", row.names="Gene") 
$d <- data.matrix(data) 
$mycol <- colorRampPalette(c("white","blue"))(199) 
$col_breaks = c(seq(0,5,length=100), seq(5,10,length=100)) 
$png(filename="file name .png", height=24000, width=18000) 
$heatmap.2(d, scale="none", Rowv=NA, Colv=NA, col = mycol, breaks=col_breaks, dendrogram = "none", 
margins=c(0,0), cexRow=0.5, cexCol=1.0, key=FALSE, density.info="none", trace="none", lhei = c(0.05,0.95), lwid = 
$c(0.05,0.95)) 
$dev.off() 
 
Figure 3.34 A (right panel): 
 
###Investigation of CpG density coverage: 
#Annotate cell type-specific enhancer sets with tag counts of PU.1 ChIP-seq and Hydroxymethyl 
Collector
TM
-seq samples to retrieve tag count using Homer tools: 
$annotatePeaks.pl <path to cell type-specific enhancer file> hg19 -size 207 -d <path to tag directories> > 
<path to output file> 
#Sort for maximum PU.1 tag count in averaged replicate time points (in Excel) and save position data. 
 
###Generating distance distribution heatmaps of CpG-content around cell type-specific enhancers using 
Homer tools and R: 
#Use a reference set of all valid CpGs of the genome, containing CpG-locations extended to 100 bp each, 
in order to create a tag directory file. 
#Annotate cell type-specific enhancer sets with the reference CpG tag directory using Homer tools:  
$annotatePeaks.pl <path to cell type-specific enhancer file> hg19 -size 1000 -hist 25 -ghist -d <path to 
CpG tag directory> > <path to output file> 
 
#Use generated files for R: 
$setwd("path to annotated file") 
$data <- read.delim("annotated file name", row.names="Gene") 
$d <- data.matrix(data) 
$mycol <- colorRampPalette(c("white","blue"))(199) 
$col_breaks = c(seq(0,3,length=100), seq(3,6,length=100)) 
$png(filename="distance distribution heatmap file name .png", height=24000, width=18000) 
$heatmap.2(d, scale="none", Rowv=NA, Colv=NA, col = mycol, breaks=col_breaks, dendrogram = "none", 
margins=c(0,0), cexRow=0.5, cexCol=1.0, key=FALSE, $density.info="none", trace="none", lhei = c(0.05,0.95), lwid = 
c(0.05,0.95)) 
$dev.off() 
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Figure 3.34 B: 
 
###Illustrating the dynamics of PU.1 and 5hmC in histograms: 
#Annotate cell type-specific enhancer sets with tag counts of PU.1 ChIP-seq and Hydroxymethyl 
Collector
TM
-seq samples to retrieve tag count using Homer tools: 
$annotatePeaks.pl <path to cell type-specific enhancer file> hg19 -size 207 -d <path to tag directories> > 
<path to output file> 
#Sort for maximum PU.1 tag count in averaged replicate time points (in Excel) and save position data. 
 
##Generating histograms of PU.1 and 5hmC tag distribution around cell type-specific enhancers using 
Homer tools and R: 
#Annotate cell type-specific enhancer sets with tag counts of PU.1 ChIP-seq and Hydroxymethyl 
Collector
TM
-seq samples using Homer tools:  
$annotatePeaks.pl <path to enhancer file> hg19 -size 1000 -hist 25 -d <path to tag directories> > <path to 
output file> 
 
#Split annotated file into PU.1 or 5hmC coverages for R. 
##Generate histograms in R: 
$setwd("path to file") 
$data <- read.table("hmC or PU.1 file name", header=T, sep="\t") 
$attach(data) 
$plotcolors <- c("color 1", "color 2", "color 3") 
$pdf(file="file name .pdf", height=4, width=8) 
$par(mar=c(3,3,1,3)) 
$plot(Distance,TP 1,type="l",col=plotcolors[3],xaxt="n",yaxt="n",xlab="",axes=FALSE, ylab="",lwd=1, lty=1,ylim=c(0,16), 
xlim=c(-500,500)) 
$par(mar=c(3,3,1,3), new=TRUE) 
$plot(Distance,TP 2,type="l",col=plotcolors[2],xaxt="n",yaxt="n",xlab="",axes=FALSE, ylab="",lwd=1, lty=1,ylim=c(0,16), 
xlim=c(-500,500)) 
$par(mar=c(3,3,1,3), new=TRUE) 
$plot(Distance,TP 3,type="l",col=plotcolors[1],xaxt="n",yaxt="n",xlab="",axes=FALSE, ylab="",lwd=1, lty=1,ylim=c(0,16), 
xlim=c(-500,500)) 
$axis(1,padj=-1.0,family="Helvetica",cex.axis=1,at=c(-500,-400,-300,-200,-100,0,100,200,300,400,500)) 
$axis(2,padj=0.8,family="Helvetica",cex.axis=1, col="black", col.axis="black") 
$mtext("name y-axis",family="Helvetica", col="black", side=2,line=2,cex=1.3,padj=0.2) 
$mtext("name x-axis",family="Helvetica",ps=12,side=1,line=2,cex=1.3,padj=-0.6) 
$dev.off() 
 
 
Figure 3.34 C: 
 
###Plotting heatmaps of 5mC distribution in the vicinity of cell type-specific enhancer regions: 
#Use files generated in this chapter and from chapter 5.2.5.9.2. 
#Reformat data and plot graph using R: 
#Command averages methylation level over all valid CpGs at each position: 
$myMethylHist_MODC.pl <path to divided cell type-specific enhancer file> hg19 <path to rescaled MO 
file> <path to rescaled DC file> -scaled -o <path to output file> 
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$x <- read.table("path to reformatted file", header=T, sep=" ") 
$attach(x) 
$sS1 = smooth.spline(Distance,BG1, spar=0.7) 
$sS2 = smooth.spline(Distance,BG2, spar=0.7) 
$pdf(file="path and file name .pdf", width=3, height=3) 
$par(mar=c(1.4,1.6,0.2,0.2)) 
$plot(Distance,BG1,type="p",col=adjustcolor("brown1",alpha=0.3), xaxt="n",yaxt="n",xlab="", 
ylab="",pch=46,axes=FALSE,lwd=3,ylim=c(0,100)) 
$par(mar=c(1.4,1.6,0.2,0.2), new=TRUE) 
$plot(Distance,BG2,type="p",col=adjustcolor("cyan3",alpha=0.3), xaxt="n",yaxt="n",xlab="", 
ylab="",pch=46,axes=FALSE,lwd=3,ylim=c(0,100)) 
$axis(1,padj=-1.2,family="Helvetica",cex.axis=0.8) 
$axis(2,padj=0.8,family="Helvetica",cex.axis=0.8) 
$lines(sS1, col="color 1", lwd=2) 
$lines(sS2, col="color 2", lwd=2) 
$dev.off() 
 
5.2.5.9 Additional data sets (NGS, Microarray) 
 
In addition to NGS data sets generated in this work, other data sets from public 
sources or from scientific cooperation partners were used to compare with our data. 
When this is the case, the data source is stated in the command line instructions or 
referenced to the corresponding publication. 
 
5.2.5.9.1 Whole genome expression data of MO and DC 
 
The expression data set of differentiating MO and DC was previously produced in our 
laboratory (Klug et al., 2010) and is publicly available from the National Center for 
Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) repository 
(accession number [GEO:GSE19236].  
In brief, mRNAs of time courses from differentiating monocytes were quantified on 
Whole Human Genome Expressionarrays (4×44 K Agilent). The normalized (according 
to Klug 2010) expression data of 7 time points of differentiating monocytes from 3-5 
donors were averaged and used in our analyses. 
 
5.2.5.9.2 Bisulfite-sequencing data of MO and DC  
 
MethylC-seq data of DC (Barreiro laboratory, Canada) 
 
Unpublished bisulfite-sequencing data obtained from dendritic cells of 6 donors were 
kindly provided from Dr. Luis Barreiro (CHU Sainte-Justine, Montreal, Canada). In 
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brief, peripheral blood monocytes were isolated from healthy blood donors as 
described in Barreiro et al. (Barreiro et al., 2012). The cells were cultivated in RPMI 
1640 (Invitrogen) in the presence of 10% FCS (Dutscher), L-glutamine (Invitrogen), 
GM-CSF (20 ng/ml, Immunotools), and IL-4 (20 ng/ml, Immunotools) to differentiate 
them into dendritic cells in vitro. After approximately 7 days the cells were harvested, 
and the MethylC-seq protocol (Lister et al., 2009) was performed. DNAs were 
subjected to library preparation (TruSeq RNA Sample Preparation kit v2, Illumina) and 
bisulfite-conversion (MethylCode™ Bisulfite Conversion Kit, Invitrogen). The 
sequencing was performed on an Illumina HiSeq 2000 according to the manufacturer’s 
manual. The sequencing reads were aligned to the human reference genome 
(GRCh37/hg19) and lambda phage genome (Bismark tools) using a bisulfite-converted 
reference genome. The data were quality-checked and methylation levels of each CpG 
were estimated using the number of C (methylated) and T (unmethylated) reads 
(C/C+T) (Lister et al., 2009).  
 
Bisulfite-seq data for CD14+CD16- classical monocyte samples (BLUEPRINT 
Epigenome Project) 
 
Within the framework of the BLUEPRINT Epigenome Project Whole Genome Bisulfite 
Sequencing was applied to several peripheral, CD14+CD16- classical monocyte 
samples as described on the homepage (http://www.blueprint-epigenome.eu/). BS-seq 
data sets from 4 donors were downloaded from the homepage for data analysis 
(http://ftp.ebi.ac.uk/pub/databases/blueprint). 
 
Bisulfite data (MO and DC) from both sources (see above) was processed according to 
the following command line using the indicated tools:  
 
###Adjust bisulfite-sequencing data sets of MO and DC before comparison with our data using Homer 
tools: 
 
#Conversion of BigWig to bedGraph format:   
$bigWigToBedGraph <path to BigWig file> <path to output bedGraph file> 
 
#Merging MO data files: 
$unionBedGraphs -i <path to MO file 1> < path to MO file 2>... -filler NA > <path to output .bedGraph file> 
$myCombine3BedGraph.pl <path to previous output .bedGraph file> > <path to output .bedGraph file> 
 
#Rescale data for uniformity: 
$myScaleBedGraph.pl <path to merged MO or DC file> -S 1 > <path to output file> 
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The resulting files (MO and DC) were used for NGS analyses in chapter 5.2.5. 
 
5.2.5.9.3 Sets of active enhancers and promoters and CAGE expression data of 
MO and DC 
 
For the analyses of PU.1 dynamics in MO and DC we utilized a publically available 
promoter set, enhancer set and CAGE expression data generated by the FANTOM 
consortium. The data sets are published in the following publications (Andersson et al., 
2014; Consortium et al., 2014) and can be downloaded from the homepage 
(http://fantom.gsc.riken.jp/data/).  
We downloaded a promoter set, an enhancer set, and CAGE expression data of 
monocytes (3 donors) and immature dendritic cells (3 donors) and processed them 
according to the instructions in chapters 5.2.5.7 and 5.2.5.8. 
 
5.2.5.9.4 Additional pearl scripts (AG Rehli) 
 
In chapter 5.2.5 several in-house pearl scripts were used to analyze the indicated data 
sets. These pearl scripts were designed by Prof. Dr. Michael Rehli and are listed on the 
following pages. 
 
myMap-Bowtie2.pl 
#!/usr/bin/perl -w 
sub printCMD() { 
 print STDERR "\n\tUsage: map-bowtie2.pl [options] <FASTQ file1> [FASTQ file2]...\n"; 
 print STDERR "\n\t\t\tpaired end: <FASTQ end1>,<FASTQ end2> [FASTQ file2 end1],[end2]...\n"; 
 print STDERR "\n\tRequired Options:\n"; 
 print STDERR "\t\t-index <path-to-bt2 index> (path to bowtie2 index to use for mapping)\n"; 
 print STDERR "\t\t-x <path...> (also works same as -index)\n"; 
 print STDERR "\t\t\ti.e. -index /bioinf/bowtie2/bowtie2-2.0.0-beta6/indexes/hg19\n"; 
 print STDERR "\n\tAlignment Type:\n"; 
 print STDERR "\t\t-bowtie2 (map with bowtie2,default)\n"; 
 print STDERR "\t\t-tophat2 (map with tophat2)\n"; 
 print STDERR "\t\t\t-path <path-to-program-file> (executable file to run if not in path/diff name)\n"; 
 print STDERR "\n\tCPU options:\n"; 
 print STDERR "\t\t-cpu <#> (Number of instances to run at once, default:1)\n"; 
 print STDERR "\t\t-p <#> (Number of cpus per instance, default: 1)\n"; 
 print STDERR "\t\t-un (will output unaligned reads)\n"; 
 print STDERR "\t\tRecommended examples (for 8 cores):\n"; 
 print STDERR "\t\t\tFor bowtie2: -cpu 1 -p 8 (align each file quickly 1 at a time)\n"; 
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 print STDERR "\t\t\tFor tophat2: -cpu 8 -p 1 (because tophat has several non-parallel steps...)\n"; 
 print STDERR "\n\tBowtie options:\n"; 
 print STDERR "\t\t--local (local alignment, default: global/end-to-end)\n"; 
 print STDERR "\t\t-bam (convert output file to sorted bam file, default: sam)\n"; 
 print STDERR "\n\tTophat options:\n"; 
 print STDERR "\t\t--library-type <type> (library type for tophat, default: fr-firststrand\n"; 
 print STDERR "\t\t\t\tOther optoins: fr-unstranded, fr-secondstrand)\n"; 
 print STDERR "\t\t-G <GTF file> (Use as guide for splice mapping)\n"; 
 #print STDERR "\t\t-mis <#> (Max number of mismatches, default: 2)\n"; 
 print STDERR "\n\tGeneral Options to pass along to alignment program:\n"; 
 print STDERR "\t\t-f (Input is FASTA files, default expects FASTQ)\n"; 
 print STDERR "\t\t-pass \"...\" (need to include quotes)\n"; 
 #print STDERR "\t\t-remap (remap unaligned reads with bowtie afterwards, returning random 
position)\n"; 
 print STDERR "\t\t-name (path/outputfile name w/o extension)\n"; 
 print STDERR "\n"; 
 exit; 
} 
if (@ARGV < 2) { 
 printCMD(); 
} 
my $bt2Index = ""; 
my $maxCPUs = 1; 
my $pCPUs = 1; 
my $remapFlag = 0; 
my @files = (); 
my $libraryType = "fr-firststrand"; 
my $maxMultihits = 20; 
my $guideGTF = ""; 
my $program = 'bowtie2'; 
my $exe = ''; 
my $local = ''; 
my $pass = ""; 
my $unFlag = 0; 
my $n = 3; 
my $maxMisMatches = " -n $n --genome-read-mismatches $n --read-mismatches $n "; 
my $bamFlag = 0; 
my $outputFile = ''; 
my $outputFileName = ''; 
my $bamFile = ''; 
my $sortedBamFile = ''; 
 
for (my $i=0;$i<@ARGV;$i++) { 
 #print STDERR "$ARGV[$i] $i\n"; 
 if ($ARGV[$i] eq '-index' || $ARGV[$i] eq '-x') { 
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  $bt2Index = $ARGV[++$i]; 
 } elsif ($ARGV[$i] eq '-bam') { 
  $bamFlag= 1; 
 } elsif ($ARGV[$i] eq '-mis') { 
  my $n = $ARGV[++$i]; 
  $maxMisMatches = " -n $n --genome-read-mismatches $n --read-mismatches $n "; 
 } elsif ($ARGV[$i] eq '-bowtie2') { 
  $program = 'bowtie2'; 
 } elsif ($ARGV[$i] eq '-tophat2') { 
  $program = 'tophat2'; 
 } elsif ($ARGV[$i] eq '-f') { 
  $pass .= " -f "; 
 } elsif ($ARGV[$i] eq '--local') { 
  $local = '--local'; 
 } elsif ($ARGV[$i] eq '-path') { 
  $exe = $ARGV[++$i]; 
 } elsif ($ARGV[$i] eq '-cpu') { 
  $maxCPUs = $ARGV[++$i]; 
 } elsif ($ARGV[$i] eq '-name') { 
  $outputFileName = $ARGV[++$i]; 
 } elsif ($ARGV[$i] eq '-un') { 
  $unFlag = 1; 
 } elsif ($ARGV[$i] eq '-p') { 
  $pCPUs = $ARGV[++$i]; 
 } elsif ($ARGV[$i] eq '-remap') { 
  $remapFlag = 1; 
 } elsif ($ARGV[$i] eq '--library-type') { 
  $libraryType = $ARGV[++$i]; 
 } elsif ($ARGV[$i] eq '-pass') { 
  $pass = $ARGV[++$i]; 
 } elsif ($ARGV[$i] eq '-G') { 
  $guideGTF = " -G $ARGV[++$i]"; 
 } elsif ($ARGV[$i] =~ /^\-/) { 
  print STDERR "\n!!! \"$ARGV[$i]\" not recognized...\n"; 
  printCMD(); 
 } else { 
  push(@files, $ARGV[$i]); 
 } 
} 
#$program .= " -f "; 
if ($exe eq '') { 
 $exe = $program; 
 print STDERR "\tWill run $exe...\n"; 
} 
if ($bt2Index eq '') { 
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 print STDERR "!!! Need to specify bowtie2 index and/or CPUs !!!\n"; 
 printCMD();  
} 
my $genomeName = $bt2Index; 
$genomeName =~ s/^.+\///; 
print STDERR "\tbt2Index = $bt2Index ($genomeName)\n"; 
print STDERR "\tNumber of instances at once: $maxCPUs\n"; 
print STDERR "\tNumber of cpus per instance: $pCPUs\n"; 
if ($program eq 'bowtie2') { 
 print STDERR "\n\tbowtie2 will be used to align the following files:\n"; 
} elsif ($program eq 'tophat2') { 
 print STDERR "\tlibrary type: $libraryType\n"; 
 print STDERR "\n\tTophat2 will be used to align the following files:\n"; 
 $maxMisMatches = ''; 
} 
foreach(@files) { 
 print STDERR "\t\t$_\n"; 
} 
print STDERR "\t\n"; 
my @pids = (); 
my $cpus = 0; 
for (my $j=0;$j<@files;$j++) { 
 my $file = $files[$j]; 
 my $pid = fork(); 
 $cpus++; 
 if ($pid == 0) { 
  #child process 
  my $peflag = 0; 
  my %delete = (); 
  my $file1 = ""; 
  my $file2 = ""; 
  if ($file =~ /\,/) { 
   my @f = split /\,/, $file; 
   $file1 = $f[0]; 
   $file2 = $f[1]; 
   print STDERR "\t\tPaired end files: $file1 and $file2\n"; 
   $peflag = 1; 
   if ($file1 =~ /\.gz$/) { 
    my $newfile = $file1; 
    $newfile  =~ s/\.gz$//; 
    `gunzip -c "$file1" > "$newfile"`; 
    $delete{$newfile} = 1; 
    $file1 = $newfile; 
   } 
   if ($file2 =~ /\.gz$/) { 
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    my $newfile = $file2; 
    $newfile  =~ s/\.gz$//; 
    `gunzip -c "$file2" > "$newfile"`; 
    $delete{$newfile} = 1; 
    $file2 = $newfile; 
   } 
   if ($program eq 'tophat2') { 
    $file = "\"$file1\" \"$file2\""; 
   } elsif ($program eq 'bowtie2') { 
    $file = "-1 \"$file1\" -2 \"$file2\""; 
   } 
  } else { 
   if ($file =~ /\.gz$/) { 
    my $newfile = $file; 
    $newfile  =~ s/\.gz$//; 
    `gunzip -c "$file" > $newfile`; 
    $delete{$newfile} = 1; 
    $file = $newfile; 
   } 
   $file1 = $file; 
   $file = "\"$file\""; 
  } 
  if ($program eq 'tophat2') { 
   my $outputDir = "$file1.$genomeName.tophat2"; 
   my $outputFile = "$file1.$genomeName.tophat2.bam"; 
   my $outputJunc = "$file1.$genomeName.tophat2.junc"; 
   my $logFile = "$file1.$genomeName.tophat2.log"; 
   `$exe --library-type $libraryType -p $pCPUs -g $maxMultihits $guideGTF -o 
$outputDir $pass $maxMisMatches "$bt2Index" $file 2> $logFile`; 
   `mv "$outputDir/accepted_hits.bam" "$outputFile"`; 
  `parseTophatJunctions.pl "$outputDir/junctions.bed" > "$outputJunc"`; 
   `rm -r "$outputDir"`; 
  if ($unFlag) { 
   my $samFile = "$file1.$genomeName.tophat2.sam"; 
   `samtools view -h "$outputFile" > "$samFile" 2>> $logFile`; 
   my $unalignedFile = "$file1.$genomeName.tophat2.unaligned.fq"; 
   my $unalignedFile2 = "$file2.$genomeName.tophat2.unaligned.fq"; 
   `getUnalignedReadsSam.pl $samFile $file1 > $unalignedFile 2>> $logFile`; 
    if ($peflag) { 
   `getUnalignedReadsSam.pl $samFile $file2 > $unalignedFile2 2>> $logFile`; 
    } 
    `rm "$samFile"`; 
   } 
  } else { 
   my $logFile = "$file1.$genomeName.bowtie2.log"; 
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   my $unFile = " --no-unal"; 
   if ($outputFileName eq '') { 
    $outputFile = "$file1.$genomeName.bowtie2.sam"; 
   } else { 
    $outputFile = "$outputFileName.sam"; 
   }  
   if ($unFlag) { 
    $unFile = "--un $file1.$genomeName.bowtie2.unaligned.fq"; 
   } 
  `$exe $local $unFile -p $pCPUs $pass -x "$bt2Index" $file > "$outputFile" 2> "$logFile"`; 
   if ($bamFlag) { 
    if ($outputFileName eq '') { 
     $bamFile = "$file1.$genomeName.bowtie2.tmp.bam"; 
     $sortedBamFile = "$file1.$genomeName.bowtie2"; 
    } else { 
     $bamFile = "$outputFileName.tmp.bam"; 
     $sortedBamFile = "$outputFileName.bowtie2"; 
    }  
  `samtools view -S -b -@ $pCPUs "$outputFile" > "$bamFile" 2>> "$logFile"`; 
  `samtools sort -m 5000000000 -@ $pCPUs "$bamFile" "$sortedBamFile" 2>> $logFile`; 
    `rm "$outputFile" "$bamFile"`; 
   } 
  } 
  foreach(keys %delete) { 
   `rm "$_"`; 
  } 
  exit(0); 
 } 
 push(@pids, $pid); 
 if ($cpus >= $maxCPUs) { 
  my $id = wait(); 
  $cpus--; 
 } 
} 
my $id = 0; 
while ($id >= 0) { 
 $id = wait(); 
 if ($id == -1) { 
 } else { 
 } 
} 
print STDERR "\n"; 
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myMethylHist_MODC.pl 
#my $directory = "path to directory"; 
 
if (@ARGV < 1) { 
 print STDERR "<input file> <genome> <MO DNA methylation bedGraph file> <DC DNA 
methylation bedGraph file> <options>  -o <outputfile>\n"; 
 print STDERR "\toptions:\n"; 
 print STDERR "\t\t-size <#> histogram size (default 1000)\n"; 
 print STDERR "\t\t-scaled <#> bedgraph is already transformed\n"; 
 exit; 
} 
my $size = 1002; 
my $scaled = 0; 
for (my $i=1;$i<@ARGV;$i++) { 
 if ($ARGV[$i] eq '-size') { 
  $size = $ARGV[++$i] + 2; 
  } 
  elsif ($ARGV[$i] eq '-scaled') { 
  $scaled = 1; 
  } 
  elsif ($ARGV[$i] eq '-o') { 
  $outputfile = $ARGV[++$i]; 
  } 
} 
my $posFile = $ARGV[0]; 
my $genome = $ARGV[1]; 
my $bedGraph = $ARGV[2]; 
my $bedGraph2 = $ARGV[3]; 
my $uppersize = $size / 2; 
my $lowersize = $size / -2; 
my $shift = 1; 
my $sum = 0; 
my $count = 0; 
$rand = rand(); 
my $tmpFile = "$directory/" . $rand . ".bedGraph.tmp"; 
my $tmpFile1 = "$directory/" . $rand . ".hist.tmp"; 
my $tmpFile2 = "$directory/" . $rand . ".TP.tmp"; 
my $tmpFile3 = "$directory/" . $rand . ".out.tmp"; 
my $tmpScript = $rand . ".R"; 
my $tmpOut1 = "$directory/" . $rand . ".out1.tmp"; 
my $tmpOut2 = "$directory/" . $rand . ".out2.tmp"; 
 
 print STDERR "\tprocessing first sample\n"; 
 if ($scaled == 1) { 
 print STDERR "\t...using scaled bedGraph file1\n"; 
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 $tmpFile = $bedGraph 
 } else { 
 print STDERR "\t...converting bedGraph file\n"; 
 `myScaleBedGraph.pl "$bedGraph" -S 1 >"$tmpFile"`; 
 } 
 print STDERR "\t...creating ghist file\n"; 
`annotatePeaks.pl "$posFile" "$genome" -size "$size" -hist 1 -ghist -bedGraph "$tmpFile" >"$tmpFile1"`; 
 
 print STDERR "\t...transposing ghist file\n"; 
 `myTP.pl "$tmpFile1" > "$tmpFile2"`; 
 
#open OUT, ">$outputfile"; 
open OUT, ">$tmpOut1"; 
open IN, $tmpFile2 ; 
 
while (<IN>) { 
 chomp; 
 s/\r//g; 
 my @line= split /\t/; 
 if ($line[0] eq 'Gene') { 
 print STDERR "\t...printing table\n"; 
 print OUT "Distance\tBG1\n"; 
 } elsif ($line[0] eq $uppersize || $line[0] eq $lowersize) { 
 } else { 
 print OUT "$line[0]"; 
 $columns = @line ; 
for (my $i=1;$i<$columns;$i++) { 
 if ($line[$i] == 0) { 
 } 
 else { 
 $sum = $sum + $line[$i]; 
 $count = $count +1; 
 } 
} 
 if ($count == 0) { 
 print OUT "\t\n"; 
 } 
 else { 
 $mean = $sum / $count - 1; 
 print OUT "\t$mean\n"; 
 } 
} 
$sum = 0; 
$count = 0; 
} 
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close IN; 
close OUT; 
 print STDERR "\tprocessing second sample\n"; 
 if ($scaled == 1) { 
 print STDERR "\t...using scaled bedGraph file2\n"; 
 $tmpFile = $bedGraph2 
 } else { 
 print STDERR "\t...converting bedGraph file\n"; 
 `myScaleBedGraph.pl "$bedGraph2" -S 1 >"$tmpFile"`; 
 } 
 print STDERR "\t...creating ghist file\n"; 
`annotatePeaks.pl "$posFile" "$genome" -size "$size" -hist 1 -ghist -bedGraph "$tmpFile" >"$tmpFile1"`; 
 print STDERR "\t...transposing ghist file\n"; 
 `myTP.pl "$tmpFile1" > "$tmpFile2"`; 
 
open OUT2, ">$tmpOut2"; 
open IN2, $tmpFile2 ; 
while (<IN2>) { 
 chomp; 
 s/\r//g; 
 my @line= split /\t/; 
 if ($line[0] eq 'Gene') { 
 print STDERR "\t...printing table\n"; 
 print OUT2 "Distance\tBG2\n"; 
 } elsif ($line[0] eq $uppersize || $line[0] eq $lowersize) { 
 } else { 
 print OUT2 "$line[0]"; 
 $columns = @line ; 
 
for (my $i=1;$i<$columns;$i++) { 
 if ($line[$i] == 0) { 
 } 
 else { 
 $sum = $sum + $line[$i]; 
 $count = $count +1; 
 } 
} 
 if ($count == 0) { 
 print OUT2 "\t\n"; 
 } 
 else { 
 $mean = $sum / $count - 1; 
 print OUT2 "\t$mean\n"; 
 } 
} 
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$sum = 0; 
$count = 0; 
} 
close IN2; 
close OUT2; 
 `paste \"$tmpOut1\" \"$tmpOut2\" | cut -f1,2,4 > $outputfile`; 
 
# `rm -f \"$tmpFile1\" \"$tmpFile2\"`; 
 if ($scaled == 0) { 
 `rm -f \"$tmpFile\"`; 
 }  
 print STDERR "\t...printing pdf\n"; 
 
open OUT, ">$tmpScript"; 
print OUT "x <- read.table(\"$outputfile\", header=T, sep=\"\t\")\n"; 
print OUT "attach(x)\n"; 
print OUT "sS1 = smooth.spline(Distance,BG1, spar=0.5)\n"; 
print OUT "sS2 = smooth.spline(Distance,BG2, spar=0.5)\n"; 
print OUT "pdf(file=\"$outputfile.pdf\", width=3, height=3)\n"; 
print OUT "par(mar=c(1.4,1.6,0.2,0.2))\n"; 
print OUT "plot(Distance,BG1,type=\"p\",col=adjustcolor(\"brown1\", 
alpha=0.3),xaxt=\"n\",yaxt=\"n\",xlab=\"\", ylab=\"\",pch=46,axes=FALSE,lwd=3,ylim=c(0,100))\n"; 
print OUT "par(mar=c(1.4,1.6,0.2,0.2), new=TRUE)\n"; 
print OUT "plot(Distance,BG2,type=\"p\",col=adjustcolor(\"cyan3\", 
alpha=0.3),xaxt=\"n\",yaxt=\"n\",xlab=\"\", ylab=\"\",pch=46,axes=FALSE,lwd=3,ylim=c(0,100))\n"; 
print OUT "axis(1,padj=-1.2,family=\"Helvetica\",cex.axis=0.8)\n"; 
print OUT "axis(2,padj=0.8,family=\"Helvetica\",cex.axis=0.8)\n"; 
print OUT "lines(sS1, col=\"color 1\", lwd=2)\n"; 
print OUT "lines(sS2, col=\"color 2\", lwd=2)\n"; 
print OUT "dev.off()\n"; 
close OUT; 
`R --no-save < "$tmpScript"`; 
#`rm -f \"$tmpScript\" \"$tmpFile\" \"$tmpFile2\" \"$tmpOut1\" \"$tmpOut2\"`; 
exit; 
 
 
myCombine3BedGraph.pl 
if (@ARGV < 1) { 
 print STDERR "<input union.bedGraph file> <options> <outputfile>\n"; 
 exit; 
} 
open IN, $ARGV[0] or die "Could not open file $ARGV[0]\n"; 
my $count = 0; 
my $value = 0; 
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my $adjustedcount = 0; 
while (<IN>) { 
 chomp; 
 s/\r//g; 
 my @line= split /\t/; 
 
 for (my $i=3;$i<@line;$i++) { 
  if ($line[$i] eq 'NA') { 
  } else { 
  $count++; 
  $value = $value + $line[$i]; 
  } 
 } 
 $adjustedcount = int( $value *1000 / $count) / 10 ; 
 print $line[0]; 
 print "\t$line[1]\t$line[2]\t$adjustedcount\n"; 
 $count = 0; 
 $value = 0; 
} 
close IN; 
exit; 
 
 
 
myScaleBedGraph.pl 
if (@ARGV < 1) { 
 print STDERR "<input bedGraph file> <options> <outputfile>\n"; 
 print STDERR "\toptions:\n"; 
 print STDERR "\t\t-S <#> add factor\n"; 
 exit; 
} 
open IN, $ARGV[0] or die "Could not open file $ARGV[0]\n"; 
my $scale = 1; 
for (my $i=1;$i<@ARGV;$i++) { 
 if ($ARGV[$i] eq '-S') { 
  $scale = $ARGV[++$i]; 
 } 
} 
while (<IN>) { 
 chomp; 
 s/\r//g; 
 my @line= split /\t/; 
 $adjustedcount = $line[3]+$scale; 
 print $line[0]; 
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 print "\t$line[1]\t$line[2]\t$adjustedcount\n"; 
} 
close IN; 
exit; 
 
5.2.6 Software tools and databases 
 
Software/Database Version Source/Company 
Adobe Illustrator CS3 Adobe Systems, Mountain View, USA 
BEDtools v2.20.1 or later http://bedtools.readthedocs.org/en/latest/ 
BioEdit  v6.4.5 http://www.mbio.ncsu.edu/BioEdit/bioedit.html 
BioGPS - http://www.ncbi.nlm.nih.gov/geo/ 
Bowtie2 v2.2.1 http://bowtie-bio.sourceforge.net/bowtie2/index.shtml 
ControlMate v1.4.0 Life Technologies, Carlsbad, USA 
EpiDesigner - http://www.epidesigner.com/ 
Epityper   v1.2 Sequenom, Hamburg, Germany 
GeneRunner  v3.0.5 http://www.generunner.com 
Homer v4.5 or later http://homer.salk.edu/homer/ 
ImageLab  v4.0.1 Bio-Rad, Munich, Germany 
MethPrimer - http://www.urogene.org/methprimer 
Microsoft Excel  2010 Microsoft, Redmond, USA 
PerlPrimer  v1.1.19 http://perlprimer.sourceforge.net/ 
PubMed  - www.ncbi.nlm.nih.gov/entrez 
R 3.0.2 http://www.r-project.org/ 
USCS Genome Browser - www.genome.ucsc.edu 
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6 Publications 
Neumeier, M., Krautbauer, S., Schmidhofer, S., Hader, Y., Eisinger, K., Eggenhofer, 
E., Froehner, S.C., Adams, M.E., Mages, W., and Buechler, C. (2013). Adiponectin 
receptor 1 C-terminus interacts with PDZ-domain proteins such as syntrophins. 
Experimental and molecular pathology 95, 180-186. 
 
Klug, M.*, Schmidhofer, S.*, Gebhard, C., Andreesen, R., and Rehli, M. (2013). 5-
Hydroxymethylcytosine is an essential intermediate of active DNA demethylation 
processes in primary human monocytes. Genome biology 14, R46. 
 
Pham, T.H., Minderjahn, J., Schmidl, C., Hoffmeister, H., Schmidhofer, S., Chen, W., 
Langst, G., Benner, C., and Rehli, M. (2013). Mechanisms of in vivo binding site 
selection of the hematopoietic master transcription factor PU.1. Nucleic acids research 
41, 6391-6402. 
 
Bauer, S., Wanninger, J., Schmidhofer, S., Weigert, J., Neumeier, M., Dorn, C., 
Hellerbrand, C., Zimara, N., Schaffler, A., Aslanidis, C., et al. (2011). Sterol regulatory 
element-binding protein 2 (SREBP2) activation after excess triglyceride storage 
induces chemerin in hypertrophic adipocytes. Endocrinology 152, 26-35. 
 
Wiest, R., Weigert, J., Wanninger, J., Neumeier, M., Bauer, S., Schmidhofer, S., 
Farkas, S., Scherer, M.N., Schaffler, A., Scholmerich, J., et al. (2011). Impaired hepatic 
removal of interleukin-6 in patients with liver cirrhosis. Cytokine 53, 178-183. 
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